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Abstract 
Alzheimer’s disease (AD) is accompanied by increased brain levels of soluble 
amyloid-β (Aβ) oligomers (McLean et al., 1999). It has been suggested that Aβ 
oligomers directly impair synaptic function (Haass and Selkoe, 2007) and modulate 
high voltage-activated calcium channels (Sberna et al., 1997; Bobich et al., 2004; 
Nimmrich et al., 2008a). State-dependent drugs are hypothesized to target 
pathologically overactivated channels without altering physiological activity, which 
may reduce adverse side effects (Winquist et al., 2005). Here, the effect of 
Aβ globulomer, a synthetic, stable, and pathologically relevant oligomeric Aβ 
preparation (Barghorn et al., 2005; Gellermann et al., 2008), on high voltage-
activated calcium channels was further elucidated. Furthermore, it was tested 
whether novel state-dependent calcium channel blockers can ameliorate oligomeric 
Aβ-induced deficits in synaptic transmission. 
First, the effect of oligomeric Aβ on excitatory synaptic transmission was investigated 
in rat organotypic hippocampal slice cultures. Specific block of P/Q-type and N-type 
calcium channels by ω-agatoxin IVA and ω-conotoxin MVIIA, respectively, 
completely reversed Aβ oligomer-induced deficits. By contrast, (additional) L-type 
calcium channel block by nimodipine (Diochot et al., 1995; Furakawa et al., 1999), a 
potential antidementia medicine (Birks and López-Arrieta, 2002), was ineffective. As 
assessed by whole cell patch clamp analysis, oligomeric Aβ
 
shifted the activation of 
P/Q-type and N-type calcium channels, recombinantly expressed in HEK293 cells, to 
more hyperpolarized values. Application of non-aggregated Aβ
 
peptide had no effect. 
These findings suggest that overactivation of presynaptic calcium channels by 
oligomeric Aβ may lead to functional synaptic deficits, which can be prevented with 
presynaptic calcium channel blockers.  
In a second part of this work, novel state-dependent calcium channel blockers were 
identified (published in Mezler et al., 2012a) and their potential to protect from 
Aβ-induced functional deficits investigated. Compounds were initially detected by a 
fluorescence imaging plate reader-based primary high throughput screen (previously 
performed at Abbott) using HEK293 cells recombinantly expressing P/Q-type calcium 
channels. For subsequent compound validation using a more direct measure of 
channel function, an automated patch clamp secondary screening assay was 
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established and incorporated into the hit-to-lead cycle of a drug discovery process. 
Representative compounds out of this screen were characterized for state-dependent 
P/Q-type calcium channel block by manual patch clamp recordings. Finally, these 
blockers were able to protect from Aβ-induced functional decline in synaptic 
transmission similarly as the state-independent peptide toxins.  
Findings from this work hint towards the therapeutic potential of state-dependent 
presynaptic calcium channel block, which needs to be further elucidated in an in vivo 
model of AD. As P/Q-type calcium channel gain-of-function is also associated with 
migraine and epilepsy, novel specific channel blockers may also alleviate symptoms 
of other neurological diseases, beyond AD. 
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Zusammenfassung 
Die Alzheimer-Krankheit geht im Gehirn mit einem erhöhten Spiegel von löslichen 
Amyloid-ß (Aβ) Oligomeren einher (McLean et al., 1999). Es wird vermutet, dass Aβ 
Oligomere unmittelbar synaptische Funktion schädigen (Haass and Selkoe, 2007) 
und spannungsaktivierte Kalziumkänale beeinflussen (Sberna et al., 1997; Bobich et 
al., 2004; Nimmrich et al., 2008a). Für zustandsabhängige Wirkstoffe wird 
angenommen, dass diese auf pathologisch überaktivierte Kanäle wirken ohne deren 
physiologische Aktivität zu beeinflussen, was unerwünschte Nebenwirkungen 
reduzieren würde (Winquist et al., 2005). In der vorliegenden Arbeit wird der Effekt 
von Aβ Globulomer, einer synthetischen, stabilen und pathologisch relevanten 
oligomeren Aβ Präparation (Barghorn et al., 2005; Gellermann et al., 2008), auf 
spannungsaktivierte Kalziumkanäle weiter aufgeklärt. Darüber hinaus wurde 
getestet, ob neuartige zustandsabhängige Kalziumkanalblocker Aβ Oligomer-
induzierte Defizite der synaptischen Übertragung lindern können. 
Zuerst wurde der Effekt von oligomerem Aβ auf exzitatorisch synaptische 
Übertragung organotypischer hippocampaler Schnittkulturen der Ratte untersucht. 
Spezifischer P/Q-Typ und N-Typ Kalziumkanalblock, jeweils durch ω-agatoxin IVA 
beziehungsweise ω-conotoxin MVIIA, kehrte die Aβ Oligomer-induzierten Defizite 
vollständig um. Im Gegensatz dazu war (zusätzlicher) L-Typ Kalziumkanalblock 
durch nimodipine (Diochot et al., 1995; Furakawa et al., 1999), ein potenzielles 
Antidementivum (Birks and López-Arrieta, 2002), unwirksam. Durch Whole Cell 
Patch Clamp Untersuchungen wurde ermittelt, dass oligomeres Aβ die Aktivierung 
von – in HEK293 Zellen rekombinant exprimierten – P/Q-Typ und N-Typ 
Kalziumkanälen zu hyperpolarisierenden Spannungswerten verschoben wurde. 
Applikation von nicht aggregiertem Aβ Peptid hatte keinen Effekt. Diese Befunde 
lassen vermuten, dass Überaktivierung präsynaptischer Kalziumkanäle durch 
oligomeres Aβ zu funktionellen synaptischen Defiziten führen kann, die durch 
präsynaptische Kalziumkanalblocker verhindert werden können. 
Im zweiten Teil dieser Arbeit wurden neuartige zustandsabhängige 
Kalziumkanalblocker identifiziert (publiziert in Mezler et al., 2012a) und deren 
Potenzial untersucht Aβ-induzierte funktionelle Defizite zu verhindern. Substanzen 
wurden zunächst durch ein Fluorescence Imaging Plate Reader-basiertes primäres 
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Hochdurchsatz-Screening (im Vorfeld bei AbbVie durchgeführt) mittels HEK293 
Zellen identifiziert, die rekombinant P/Q-Typ Kalziumkanäle exprimieren. Für 
anschließende Substanzvalidierung wurde eine direktere Messung der Kanalfunktion 
etabliert, ein automatischer Patch Clamp Sekundärscreen, der in den Hit-To-Lead 
Zyklus eines Wirkstoffentwicklungsprogramms eingebettet wurde. Die 
Zustandsabhängigkeit des P/Q-Typ Kalziumkanalblocks repräsentativer Substanzen 
dieses Screenings wurde durch manuelle Patch Clamp Messungen charakterisiert. 
Letztlich waren diese Blocker in der Lage vor den Aβ-induzierten Defiziten in 
synaptischer Übertragung, ebenso wie die zustandsunabhängigen Peptidtoxine, zu 
schützen. 
Die Ergebnisse dieser Arbeit deuten auf das therapeutische Potential eines 
zustandsabhängigen präsynaptischen Kalziumkanalblocks hin, was durch ein in vivo 
Model der Alzheimer-Krankheit weiterer Aufklärung benötigt. Da erhöhte P/Q-Typ 
Kalziumkanalfunktion auch mit Migräne und Epilepsie in Verbindung gebracht wird, 
könnten neuartige spezifische Kalziumkanalblocker auch die Symptome anderer 
neurologischer Erkrankungen, neben der Alzheimer-Krankheit, lindern. 
  
 1 
1 Introduction 
1.1 Alzheimer’s Disease (AD) 
The most common form of dementia, AD, which ultimately ends fatally, was initially 
described by Alois Alzheimer more than a century ago. Due to the worldwide 
increasing life expectancy, AD has been increasingly receiving attention by the 
scientific community and the public since the 1960s. The following chapter will 
provide an insight into the current and predicted number of demented patients, the 
detrimental effects of private caregiving to family members and the economical 
burden dementia imposes on governments around the world. Moreover, a brief 
overview is given about the clinical manifestations and disease progression of AD as 
well as the currently available pharmacological treatment options. The subsequent 
section will review the histopathological hallmarks of AD. As the hippocampal region 
is one of the primarily affected regions and is also utilized in experimental studies 
within this PhD work, a short introduction of its anatomical structure and function is 
included. In the last sections, the rationales and proposed mechanisms of action of 
the currently marketed drugs is elaborated in more detail. Finally, several currently 
proposed molecular mechanisms are reviewed focusing on ion channel-related 
synaptic pathophysiology of AD. 
 
1.1.1 Clinical and Socioeconomic Facts 
For 2010, worldwide 35.6 million people were estimated to be suffering from 
dementia, a serious loss of cognitive ability (Ferri et al., 2009). Usually this decline in 
brain function manifests progressively and affects memory, learning, orientation, 
language, comprehension, judgment and personality. Wimo and Prince (2010) 
predict the number of demented people to rise to 65.7 and 115.5 million in the years 
2030 and 2050, respectively. This report also estimated the current worldwide 
socioeconomic costs caused by dementia at 604 billion US dollars, with 70% of costs 
occurring in Western Europe and North America. Dementia has a tremendous impact 
on the ability to live independently and cognitive impairment was identified as one of 
the main predictors for institutionalization in the USA (Gaugler et al., 2007). 
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Moreover, the burden and emotional stress of private care, which is usually carried 
out by family members or friends of the demented patient, causes very high levels of 
psychological morbidity among the caregivers, increasing their rate of major 
depression by 2.8 to 38.7 times (Cuijpers, 2005). This report also emphasizes that by 
far the strongest factor correlated with dementia is age. The overall prevalence at 
age 60 and over was estimated at 5-7% in most regions of the world, and starting 
from age 65 the likelihood of developing dementia roughly doubles every 5 years. 
Based on a study about early onset dementia within the United Kingdom, Harvey et 
al. (2003) estimated that this doubling every 5 years already starts at age 35. 
Dementia can be caused by a single disease or a mixture of several underlying 
diseases including AD, vascular dementia, dementia with Lewy-Bodies, and others. 
AD is the leading cause for dementia, as it has been illustrated by post-mortem 
analysis of demented people, which identified AD-related pathology in 86% and pure 
(exclusive) AD pathology in 43% of the cohort (Jellinger, 2006). This is in line with a 
previous review by Nussbaum and Ellis (2003) stating that about two thirds of all 
dementias are caused by AD. 
Upon diagnosis of AD before age 90, Dodge et al. (2003) found that the remaining 
life years individuals from an American cohort decreased by about one third to one 
half. They also report that diagnosed AD patients are burdened with a significantly 
higher level of disability for the rest of their shortened life. Early phases of AD are 
marked by a subtle impairment of learning and memory including forgetfulness, 
whereas at the same time older episodic, semantic and implicit memory remains 
mostly intact. As cognitive impairments increase, everyday life activities become 
more and more challenging and the patient requires assistance by another person. 
As motor impairments manifest and cognitive impairments continue to worsen (e.g., 
not being able to recognize family members anymore), caregiving becomes 
increasingly demanding until the patient has to be institutionalized. Late stage AD is 
accompanied by loss of speech and the inability of patients to feed themselves. The 
ultimate cause of death often occurs by respiratory system diseases like an acquired 
inflammation of the lung (Förstl and Kurz, 1999; Brunnstrom and Englund, 2009). 
When comparing death rates in the USA from the year 2008 with 2000, deaths 
caused by AD increased by 66% whereas the number of other common causes of 
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death decreased including stroke, human immunodeficiency virus, prostate cancer, 
breast cancer, and heart disease (Thies and Bleiter, 2012).  
Unfortunately, as of today there is no causative treatment available for AD. First and 
second line medical treatment is obtained by acetylcholinesterase inhibitors 
(donepezil, rivastigmine, galantamine and tacrine) and the N-methyl-D-aspartate 
(NMDA) receptor antagonist memantine, respectively. As these drugs are only 
effective in about half of the patients slowing down cognitive decline by a mere 6-12 
months, they are only considered as symptomatic treatment which does not stop or 
even reverse the progression of the disease. Despite major investments into basic 
research and drug development have led to numerous clinical trials (Mangialasche et 
al., 2010), no new medication for AD has gained approval from regulatory authorities 
of the United States since 2003. 
Considering all of these factors, it is evident that AD is a detrimental disease for both 
the patient and their relatives. Due to the complete lack of effective therapeutic 
intervention, those affected have to inevitably face a terminal disease, which 
gradually diminishes cognitive functions and impacts the personality of the diseased, 
as well as intensive long-term caretaking, which is physically and emotionally 
extraordinarily demanding. Moreover, the associated high socioeconomic costs are 
increasingly becoming an issue for governments and institutions around the world. 
 
1.1.2 Histopathology of AD and Function of the Hippocampal Formation 
The diagnosis of AD today is defined by two histopathological hallmarks, which were 
already described by Alois Alzheimer (1907), after whom this disease was named. 
These hallmarks are senile plaques, mostly composed out of amyloid (Aβ) peptide, 
and neurofibrillary tangles, comprising hyperphosphorylated forms of the microtubule 
associated protein tau found especially in the cortex and hippocampus (Bouras et al., 
1994). In addition, neuronal cell death has been reported (Neary et al., 1986). 
However, a decrease in the number of neurons has also been observed for normal 
aging and AD may rather facilitate cell shrinkage within the hippocampus (Simic et 
al., 1997; Gosche et al., 2002). Even today AD can only be unambiguously confirmed 
post-mortem based on the demonstration of these Aβ plaques and neurofibrillary 
tangles along with amyloid deposits in the cerebral blood-vessels, reactive gliosis, 
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and neuronal atrophy. Prior to death medical history, mental tests, and exclusion of 
other diseases allow clinical diagnosis of AD (McKhann et al., 1984; McKhann et al., 
2011) with an averaged sensitivity of 81% and specificity of 70% (Knopman et al., 
2001). Current clinical diagnosis can, however, only be obtained if the disease has 
already progressed to a state where cognitive deficits have already manifested. In 
the future, earlier diagnosis of AD may be feasible with surrogate markers including 
immunoassays detecting Aβ and tau phosphorylated at specific epitopes in 
cerebrospinal fluid. These biomarkers may also serve as diagnostic markers for AD 
trials (reviewed by Hampel et al., 2010). 
The entorhinal cortex, appears be the first structure with histopathological changes in 
AD (Hyman et al., 1984; Braak et al., 1993; Gómez-Isla et al., 1996). This structure 
constitutes the main input to the hippocampal formation, which comprises the 
hallmarks of AD and is also already affected during early stages of the disease 
(Blennow et al., 1996). The role of the hippocampal region in AD was further 
supported by animal models of AD (reviewed by Fitzjohn et al., 2008).  
The function of the hippocampus in learning and memory was unambiguously 
demonstrated by Scoville and Milner (1957). After bilateral removal of the 
hippocampus for treatment of epilepsy, the patient H.M. suffered from permanent 
anterograde memory impairment hindering encoding of any new long-term 
memories. Interestingly, although H.M. could not encode new memories, he was still 
able to recall some retrograde memories especially ones from long ago. It has 
subsequently been observed in many patients that bilateral hippocampal damage 
induces severe loss of (at least) anterograde episodic memory (reviewed by Spiers et 
al., 2001). On a molecular level, learning and memory is associated with synaptic 
plasticity (Hebb, 1949). Within the hippocampus several forms of plasticity can be 
observed including long-term potentiation (LTP; Bliss and Lomo, 1973). Initial support 
for the theory of LTP as neurophysiological correlate of learning and memory has 
been collected by Morris et al. (1986), providing experimental evidence that 
hippocampal LTP measured in vitro is required for formation of memories in vivo. As 
a consequence, disturbances in LTP may contribute to the clinical symptoms in AD 
(Rowan et al., 2003). In addition to its function in memory, is noteworthy that the 
hippocampus is also involved in other tasks like spatial navigation, as initially 
described by O'Keefe and Dostrovsky (1971). 
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Another, more technical, reason why this region has been intensively studied is 
because of its relatively simple, three-layered anatomical structure and well-defined 
cytoarchitecture. Hippocampal circuitry is organized in a highly ordered manner with 
lamina-specific connections of afferent fibers. This also holds true for isolated 
hippocampal slice cultures, where termination of hippocampal afferents does not lead 
to significant translaminar sprouting of the remaining intrinsic fibers (Frotscher et al., 
1995; Frotscher et al., 1997). Furthermore, synaptic field potentials have symmetry 
along the septotemporal axis. Thus, slices taken from different transversal parts of 
the hippocampus show similar electrophysiological patterns increasing the 
reproducibility of the respective electrophysiological field recordings.  
In the following, the anatomy of the hippocampus is briefly reviewed (Amaral and 
Witter, 1989), focusing on its trisynaptic pathway. Anatomically, the hippocampus is 
located within the medial temporal lobe, is part of the limbic system and consists of 
the entorhinal cortex, dentate gyrus, cornu ammonis (CA1-3) fields, and subiculum. 
The major input afferent to the hippocampal formation arises from the perforant path 
fibers originating from the adjacent entorhinal cortex. They synapse in the outer 
molecular layer of the granule cells in the dentate gyrus and in the stratum 
lacunosum-moleculare at distal apical dendrites. Signals from the granule cells are 
conveyed via their axonal projections called mossy fibers to the pyramidal cell layer 
of the CA3 region. The signal is then further transduced via the Schaffer collateral, 
which innervate proximal apical dendrites in the stratum radiatum of pyramidal CA1 
cells by releasing the excitatory neurotransmitter glutamate. The stratum pyramidale 
comprises the cell bodies of the pyramidal neurons and synapses from a variety of 
interneurons. Recurrent connections of pyramidal cells within the CA1 region mainly 
synapse on the basal dendrites in the stratum oriens. In contrast, dendrites from 
different types of interneurons receive input from both stratum radiatum and stratum 
oriens (Buhl et al., 1996; Halasy et al., 1996). The CA1 region projects to the 
adjacent subiculum and the entorhinal cortex, thereby closing the loop between the 
entorhinal cortex and hippocampus. Most sensory input to the hippocampus is 
received through the entorhinal cortex, which after the loop in the hippocampus 
conveys the signal back to the same cortical area that it originally received the input 
from. Furthermore, a smaller fraction of subcortical afferents terminate diffusely on 
different kinds of target cells (Wyss et al., 1979). As a consequence, isolated studies 
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of transverse hippocampal sections still inherit a large portion of the hippocampal 
circuitry. 
Stimulation of the Schaffer collateral results in a negative shift in the extracellular 
field potential measured in the stratum radium (reflecting the current sink of the 
postsynapse) and a positive potential measured in the pyramidal layer (representing 
the corresponding current source close to the soma). The initial change in potential is 
solely due to excitatory transmission, since the Schaffer collateral fibers release the 
neurotransmitter glutamate. After a few milliseconds the excitatory potential is 
superimposed by feed forward and feed backward inhibitory currents of bistratified 
cells, innervating stratum radiatum, or basket cells which synapse perisomatically at 
the pyramidal cell layer (Buzsáki, 1984; Buhl et al., 1996; Halasy et al., 1996). 
 
1.1.3 Molecular Mechanisms 
Despite extensive studies especially within the last three decades, the precise 
molecular causes leading to AD have not been understood. Several competing 
mechanisms of actions have been proposed and (partially) evaluated in the clinic. 
This chapter will first review the scientific rationale which led to the drugs currently in 
clinical use for treatment of AD. Then, the amyloid hypothesis of AD will be 
introduced and discussed, also referring to findings from related clinical trials. Finally, 
based on this hypothesis, findings regarding ion channel-dependent synaptic 
pathophysiology will be reviewed. 
 
1.1.3.1 The Cholenergic and Glutamte Hypotheses: Rationale for Current 
Drug Treatment 
As of today, several competing hypotheses for mechanisms of action exist for AD; 
the first one was termed the cholinergic hypothesis and introduced by Bartus et al. 
(1982), who based this theory mainly on two sets of findings. On the one hand, the 
neurotransmitter acetylcholine plays an important role in learning and memory 
(Drachman and Leavitt, 1974). On the other hand, AD studies exhibited central 
nervous system (CNS) deficits in synthesis and release of acetylcholine, choline 
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uptake, and loss of cholinergic neurons from the nucleus basalis pointing towards a 
substantial cholinergic deficit in AD (Bowen et al., 1976; Davies and Maloney, 1976; 
Perry et al., 1977; Whitehouse et al., 1982). These changes were observed by post-
mortem biopsy, correlated with the cognitive impairment of AD patients (Perry et al., 
1978) ,and were found within a year of the onset of symptoms of dementia (Bowen et 
al., 1982), suggesting that the deficit might be causative for AD.  
The therapeutic strategy of increasing acetylcholine levels in patients, through 
inhibition of acetylcholinesterase, has resulted in four of currently five approved drugs 
for the treatment of AD. However, cholinergic treatment is only considered to be 
symptomatic. In addition, the therapeutic benefit is limited as progression of AD is 
only postponed in a fraction of patients by several months after treatment of 
donepezil (Steele and Glazier, 1999). Although, there have been reports that positive 
long-term effects compared to placebo control are not detectable (Courtney et al., 
2004; Petersen et al., 2005), meta-analyses by Lanctot et al. (2003) and Birks (2006) 
concluded that increasing cholinergic levels through acetylcholinesterase inhibitors 
lead to a significant therapeutic effect. Recently, EVP-6124 (EnVivo 
Pharmaceuticals), a novel α7 nicotinic acetylcholine receptor partial agonist 
(Prickaerts et al., 2012), has recently shown efficacy in a phase 2b trial for 
symptomatic treatment of AD (Hilt et al., 2012). It remains to be seen in a larger 
cohort, if this positive modulation of acetylcholine-mediated transmission may be 
superior compared to acetylcholinesterase inhibitors for the treatment of AD or 
whether cholinergic-dependent treatment can be additive.  
Also, glutamatergic neurotransmission in the neocortex and hippocampus was found 
to be disrupted in AD patients (Maragos et al., 1987; Palmer and Gershon, 1990; 
Myhrer, 1998). In the hippocampus, glutamate levels as well as NMDA binding are 
decreased especially for pyramidal CA1 neurons (Greenamyre et al., 1987; Ulas et 
al., 1992). As glutamate is crucial for learning and memory (Bliss and Collingridge, 
1993; Riedel et al., 2003), alterations in the glutamatergic system has also been 
implicated as a contributor to the clinical symptoms of AD. Glutamate may be a 
secondary cause of neuronal damage in AD via excitotoxicity, which appears to be 
primarily NMDA receptor-mediated (reviewed by Greenamyre and Young, 1989; 
Harkany et al., 2000). NMDA receptor activation was also found to stimulate Aβ 
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production, which in turn affects synaptic transmission (reviewed by Butterfield and 
Pocernich, 2003). 
Several NMDA antagonists have failed in the clinic as neuroprotective agents for the 
treatment of AD due to side effects, including hallucinations, agitation, or anesthesia 
(Olney et al., 1991; Krystal et al., 1994). This was partly associated with high NMDA 
binding affinity also altering physiological channel function (Kornhuber and Weller, 
1997). Memantine, an uncompetitive low to moderate affinity NMDA blocker, showed 
neuroprotective potential in preclinical AD models in vivo (Barnes et al., 1996; 
Danysz and Parsons, 2003) and in vitro (Nimmrich et al., 2010). In the clinic, 
memantine has shown modest effects in moderate-to-severe AD (Reisberg et al., 
2003) and has exhibited no severe psychotomimetic adverse effects (Orgogozo et 
al., 1991; Winblad and Poritis, 1999). It was approved by regulatory authorities in 
Europe and the U.S. for the treatment of moderate to severe AD, respectively, and 
also exhibits beneficial effects in patients receiving donepezil (Tariot et al., 2004). 
Based on a recent meta-analysis by Schneider et al. (2011) there is no evidence that 
memantine is beneficial during earlier stages of AD and cognitive benefits during 
moderate AD are smaller than for acetylcholinesterase inhibitors. 
Moreover, other therapeutic approaches are being pursued for AD. For example, 
block of the serotonin 5-HT6 receptor enhances (e.g., cholinergic) neurotransmission 
(Upton et al., 2008; Rossé and Schaffhauser, 2010) and led to successful clinical 
phase 2 trials. For SB-742457 (GlaxoSmithKline) efficacy and tolerability was shown 
in mild-to-moderate AD patients (Maher-Edwards et al., 2010). Upon additive 
treatment with donepezil, this compound (Maher-Edwards et al., 2011) and the 
5HT-6 antagonist Lu-AE58054 (Press release, Lundbeck, 2012) also slowed 
cognitive decline of moderate AD patients. Other approaches include antioxidants 
like vitamin E (Petersen et al., 2005; Galasko et al., 2012), anti-inflammatory drugs 
like ibuprofen (Tabet and Feldmand, 2003), and acetylsalicylic acid (Jaturapatporn et 
al., 2012), which however have not resulted into new drug approvals. For example, 
dimebon, an antihistamine drug used in Russia with several additional mechanisms 
of action including neuroprotective effects on mitochondria and block of multiple ion 
channels (Bachurin et al., 2001; Bachurin et al., 2003), revealed very promising 
potential in a phase 2 study (Doody et al., 2008). Unfortunately, dimebon failed to 
show efficacy in the subsequent phase 3 trial (Jones, 2010). 
1.1  Alzheimer’s Disease (AD) 
9 
1.1.3.2 The Amyloid Hypothesis 
Identification of the amino acid sequence of the main constituent of amyloid plaques 
by Glenner and Wong (1984) and Masters et al. (1985) set the stage for the amyloid 
hypothesis. It proposes that accumulation of Aβ constitutes the primary cause for AD 
pathology and suggests that tau pathology is a downstream event induced by an 
imbalance of Aβ production and clearance (Hardy and Allsop, 1991). In the following, 
the genetic evidence and results from animal models supporting this hypothesis are 
described. Subsequently, some clinical trials will briefly be summarized, which aimed 
at reducing Aβ plaque levels but have not so far resulted in any drug approval. 
Finally, converging evidence is presented, which suggests that AD pathology is only 
mediated by certain forms and epitopes of Aβ and not, as originally believed, by 
insoluble Aβ plaques - one hallmark of AD.  
Table 1.1  Genetic factors predisposing to AD (adapted from Selkoe, 1996) 
Gene defect Age of AD onset Aβ phenotype 
APP Early ↑ production of total Aβ or Aβ1-42 peptides 
Apolipoprotein E4 
polymorphism Late ↑ density of Aβ plaques and vascular deposits 
Presenilin-1 Early ↑ production of Aβ1-42 peptides 
Presenilin-2 Early ↑ production of Aβ1-42 peptides 
 
The Aβ hypothesis is strongly supported by genetic evidence (Table 1.1). As stated 
previously, AD is a predominately disease of the elderly, but there is also early-onset 
AD (before age 60 or 65), which makes up about 1-5% of all cases. Although only 
about 13% of these can be attributed to familiar forms in a dominant autosomal 
manner (Campion et al., 1999), these cases have been crucial in depicting 
pathogenic pathways of AD. Associated with early-onset are mutations in the genes 
encoding the amyloid precursor protein (APP), presenilin-1, and presenilin-2. Aβ 
generation occurs via cleavage of APP, an integral membrane protein involved in 
synaptogenesis (Wang et al., 2009), by the enzyme β-secretase and the protease 
complex γ-secretase. Mutations of the APP gene cause early onset AD (Chartier-
Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991) and lead to 
overexpression of total Aβ levels (Citron et al., 1992) or an increase in the 
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Aβ42-to-Aβ40 ratio (Suzuki et al., 1994). Mutations of the presenilin-1 and presenilin-2 
genes increase the production of Aβ42 by altering APP metabolism via interaction with 
γ-secretase and their mutations (Scheuner et al., 1996; Citron et al., 1997; De 
Strooper et al., 1998; Wolfe et al., 1999). Furthermore, the E4 allele of 
apolipoprotein, a cholesterol transport protein capable of binding to Aβ (Strittmatter et 
al., 1993), confers a higher likelihood especially for late-onset (after 60 or 65 of age) 
of AD (Corder et al., 1993). Creation of several transgenic mice models, which in part 
resemble AD-like pathology, has further supported the significance of these genetic 
alterations (reviewed by McGowan et al., 2006).  
It should be noted, however, that alterations of tau protein and Aβ levels in human 
cerebrospinal fluid (CSF) are not exclusively linked to AD, but also to other forms of 
dementia (Spillantini et al., 1998; Gloeckner et al., 2008). Moreover, it has not been 
unambiguously proven that Aβ induces tau pathology. For example, one conflicting 
finding is that tau pathology seems to correlate more closely with neuronal loss than 
Aβ plaques (Schmitz et al., 2004). However, experimental data from transgenic mice 
models of AD showed that clearance of Aβ also decreases levels of neurofibrillary 
tangles (Oddo et al., 2004), but not vice versa. In addition, application of Aβ in turn 
induced neurofibrillary tangles and thereby neuronal loss (Lewis et al., 2001). So it 
has been postulated that the pathological assembly of Aβ induces tau-related 
pathology and may lead to the development of AD (Oddo et al., 2006). Moreover, 
APP is located on chromosome 21 and patients with Down syndrome (trisomy 21) 
develop amyloid deposits and early onset AD until age 40 (Olson and Shaw, 1969; 
Glenner and Wong, 1984; Wisniewski et al., 1985; Teller et al., 1996; Lott and Head, 
2005). This is supportive of the hypothesis by Hardy and Allsop (1991) that Aβ 
deposition may be major events and precede tau pathology in AD. 
Aβ aggregation into insoluble plaques has long been associated with neurotoxicity 
(Lashuel et al., 2002). In turn, one therapeutic approach has been to lower the 
plaque load, which was supported by studies in APP-overexpressing transgenic mice 
(Schenk et al., 1999). However, this approach has not (yet) led to a successful drug 
approval. In 2002, active immunization with AN-1792 (Elan Pharmaceuticals) against 
Aβ in a phase 2b study successfully lowered Aβ plaque load. Unfortunately, the 
treated individuals still developed dementia as found in a follow-up study (Gilman et 
al., 2005; Holmes et al., 2008). Furthermore, this study had to be aborted due to the 
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severe side effect of meningitis in 6% of patients. Therefore, antibodies for passive 
immunization have been developed, which are less likely to induce an inflammatory 
response (McLaurin et al., 2002; Dodel et al., 2010). The follow-on project of 
AN-1792 is Bapineuzumab (also termed AAB-001 or ELN115727: Pfizer, Johnson & 
Johnson, and Elan) a monoclonal antibody, which was also designed to bind to and 
clear Aβ plaques in patients with mild to moderate AD. After promising results 
obtained in a 6 month long phase 2b study (ClinicalTrials.gov identifier 
NCT00663026, no significant effects were observed in the following 1.5 year long 
phase 3 studies on a total of 2,452 patients (NCT00574132, NCT00575055), leading 
to recent discontinuation of bapineuzumab (Press release Johnson&Johnson, 2012). 
Another monoclonal antibody directed against plaques, called Solanezumab 
(LY2062430, Lilly), has also failed its primary endpoints in a recent 1.5 year long 
phase 3 study on 2,050 patients with mild to moderate AD (Press release Lilly, 2012). 
However, significant effects of slowed cognitive decline were reported in a secondary 
subgroup analysis comprising only patients with mild AD. As a consequence, this 
implies that plaque load reduction may be efficacious only for mild AD. This in line 
with a hypothesis from Golde et al. (2011) trying to explain the observed failures in 
clinical development of candidate drugs for AD. This may be caused by the fact that 
candidates are optimized on preclinical models which represent prestages or milder 
forms of AD-like pathology compared to the enrolled patients with more advanced 
disease progression. Another promising drug candidate currently tested in multiple 
phase 3 studies is Gammagard (an immunoglobulin for intravenous administration, 
Baxter), containing antibodies extracted from human plasma which may lower Aβ 
plaque burden. A three year follow-up study on a previous, small scale phase 2 study 
revealed that AD patients, who have previously received the highest dose of 
gammagard, did not exhibit any progression of cognitive decline (Relkin et al., 2012).  
In parallel to efforts to facilitate Aβ clearance, other drug candidates aimed at 
decreasing Aβ production. For example, semagacestat (LY450139, Eli Lilly), a 
γ-secretase and β-secretase inhibitor, proceeded into two clinical phase 3 studies. 
However, studies had to be aborted as this candidate actually worsened disease 
progression (press release Eli Lilly, 2010). Unfortunately, these negative results 
concerning facilitated cognitive decline were again observed in a phase 2 study with 
avagcestat (BMS-708136, Brystol-Myers Squibb), a γ-secretase inhibitor which is 
effective in lowering Aβ concentrations (Coric et al., 2012). Other trials have also 
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failed to show efficacy (Green et al., 2009). These results question the therapeutic 
benefit of γ- and β-secretase inhibitors for AD and suggest that lowering overall 
levels of Aβ might even be malignant. This would imply that, under certain 
circumstances, Aβ may actually support neuronal function. In fact, a dual mechanism 
of action of Aβ as neurotrophic and neurotoxic agent has been described (Yankner et 
al., 1990; Zou et al., 2002; Atwood et al., 2003). 
Within the amyloid hypothesis, it has not been unambiguously elucidated which form, 
epitope, or accumulation of Aβ may lead to the cognitive decline. Aβ monomers 
assemble to form several soluble oligomeric, then fibrillar forms which gradually form 
insoluble plaques (Selkoe, 2002). At first functional deficits were primarily attributed 
to the insoluble Aβ plaques. However, there is now converging evidence that other 
forms or epitopes of soluble Aβ may to some extent or even predominantly affect 
neuronal function. This shift in paradigm was initially supported by findings which 
have shown that the severity of cognitive decline is only poorly correlated with plaque 
load, and some patients, who have many plaque deposits, show only mild cognitive 
impairment (Blennow et al., 1996). This was also observed in mouse models of AD. 
In the absence of Aβ plaques functional synaptic deficits (Hermann et al., 2009) and 
impairment of learning and memory were observed (Westerman et al., 2002) 
suggesting that soluble Aβ forms rather than plaques might be responsible for 
dementia (Hardy and Selkoe, 2002; Mattson, 2004; Haass and Selkoe, 2007; Mc 
Donald et al., 2010). This was supported by numerous studies showing that LTP is 
decreased and long-term depression facilitated by synthetic Aβ (Cullen et al., 1997; 
Barghorn et al., 2005) as well as Aβ derived from natural sources (Walsh et al., 2002; 
Klyubin et al., 2008; Shankar et al., 2008a) in vitro and in vivo. Both physiological 
parameters correlate with morphological alternations in spine density (Engert and 
Bonhoeffer, 1999; Matsuzaki et al., 2004; Zhou et al., 2004) and with deficits in 
learning and memory (Morris et al., 1986). In line with this, it was found that soluble 
Aβ was localized near synapses (Kokubo et al., 2005a; Noguchi et al., 2009) and 
may bind to neurons (Lacor et al., 2007). These findings studies suggest that 
alterations in synaptic transmission via soluble Aβ occur early in the disease 
progress causing synaptic decline, which finally leads to memory dysfunction. This 
refined amyloid hypothesis is supported by the fact that soluble Aβ and synapse loss 
is more strongly correlated with severity of dementia in AD compared to plaque load, 
neurofibrillary tangles, and cholinergic disturbances as reported by numerous studies 
1.1  Alzheimer’s Disease (AD) 
13 
(DeKosky and Scheff, 1990; Masliah et al., 1990; Terry et al., 1991; DeKosky et al., 
1996; Lue et al., 1999; McLean et al., 1999; Wang et al., 1999).  
Of soluble Aβ forms, monomers do neither affect synaptic function in vitro (Nimmrich 
et al., 2008a) nor cognitive function in vivo (Cleary et al., 2005). Moreover, they are 
rather regarded as neurotrophic instead of neurotoxic (Zou et al., 2002; Atwood et al., 
2003; Giuffrida et al., 2009). This may in part explain, why efforts aiming at lowering 
overall Aβ levels, e.g., through modulation of the γ-secretase complex, have so far 
failed to show efficacy in a phase 3 study (see p.11). Consequently, overall reduction 
of the Aβ level might not be therapeutically beneficial. As mentioned above, it is an 
ongoing matter of debate what the toxic species Aβ is. On the one hand, the size of 
aggregated Aβ oligomers may constitute its function, as toxic effects have been 
attributed e.g., to Aβ dimers (Walsh et al., 2002; Klyubin et al., 2008), trimers 
(Townsend et al., 2006), dodecamers (Lesne et al., 2006), and higher molecular 
weight aggregates (Noguchi et al., 2009). However, Aβ may also undergo 
conformational changes (Ono et al., 2009). Such changes can result into different 
aggregation pathways, one of them resulting in a stable Aβ1-42 globulomer epitope 
formed by a loop of the Aβ amino acids 20-31 (Yu et al., 2009b) which distinguishes 
this epitope from other Aβ monomers, oligomers, and fibrils (Gellermann et al., 2008) 
and induces synaptic deficits (Barghorn et al., 2005; Nimmrich et al., 2008a; 
Nimmrich et al., 2010). Therefore, current (preclinical) therapeutic approaches also 
include exclusive clearance of toxic Aβ epitopes via conformation-specific antibodies 
(Hillen et al., 2010). 
 
1.1.3.3 Ion Channel-Related Synaptic Pathophysiology 
Besides lowering Aβ levels, an alternative approach for future AD therapeutics based 
on the amyloid hypothesis would be to antagonize the effects of oligomeric Aβ on its 
(synaptic) targets. Numerous targets for Aβ have been proposed causing synaptic 
alterations. Here, findings about the interaction of different forms of Aβ with ion 
channels, located in the plasma membrane are being described. Finally, a stable 
oligomeric Aβ preparation is introduced, which appears to be pathogenically relevant 
and well suited for studying the effects of oligomeric Aβ on ion channels and 
functional synaptic decline.  
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In recent years it has become apparent that oligomeric forms of Aβ rather than 
monomeric or fibrillar forms are causal to synaptic failure (Walsh and Selkoe, 2007). 
For example, synaptic spine densities decrease after prolonged exposure to toxic Aβ 
(Lacor et al., 2007). Moreover, oligomeric Aβ inhibits hippocampal LTP in vitro 
(Lambert et al., 1998; Barghorn et al., 2005; Townsend et al., 2006) and in vivo 
(Walsh et al., 2002). Recently, it has been shown that Aβ dimers, obtained from 
cerebrospinal fluid samples of AD patients, inhibit LTP, enhance long-term 
depression, and reduce dendritic spine density in the hippocampus of normal rodents 
(Klyubin et al., 2008; Shankar et al., 2008b). In addition, Aβ correlates with 
impairment of learning and memory in APP rodent models (Ashe, 2001; Cleary et al., 
2005). Yet, the precise mechanism of action is still being discussed. 
Among others, some ion channels are currently being proposed as synaptic targets. 
APP overexpression in slice cultures, which will also result in elevated Aβ levels, 
exerts both presynaptic and postsynaptic effects. Impaired vesicle recycling and 
silencing of amino-3-hydroxy-5-methyl-4-isoxazol-propionacid (AMPA) currents were 
found in cultured hippocampal neurons by Ting et al. (2007). Snyder et al. (2005) 
have found an Aβ-induced depression of NMDA currents in cortical neurons, which 
was attributed to facilitated endocytosis of the receptor in vitro. Aβ-induced deficits in 
LTP in vivo were also described as being NMDA-dependent (Kim et al., 2001).  
A number of recent studies report disturbances of the presynaptic neurotransmitter 
release machinery by oligomeric Aβ. This is supported by the finding that APP is 
transported to presynaptic terminals, in the hippocampus of transgenic mice, where it 
is subsequently cleaved to Aβ (Lazarov et al., 2002). Furthermore, oligomeric Aβ 
co-localizes to axon terminals in AD patients (Kokubo et al., 2005b; Ishibashi et al., 
2006; Noguchi et al., 2009). Kelly et al. (2005) reported that Aβ oligomers decrease 
dynamin 1 levels, which play a crucial part in endocytosis of synaptic vesicles, 
possibly caused by cleavage of the protein by calpain. This may lead to a depletion 
of the readily releasable vesicle pool, which is mediated by a downregulation of the 
dynamin 1 gene or (presynaptic) NMDA-receptors (Kelly and Ferreira, 2007; Shankar 
et al., 2007; Abramov et al., 2009), possibly leading to the fatal consequences in AD.  
Furthermore, disturbed neuronal intracellular (free) calcium levels were observed in 
models of aging and AD (Disterhoft et al., 1994). Aβ was found to alter calcium 
homeostasis in vitro (Mattson et al., 1992) and changes in calcium-dependent 
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enzymes were reported in AD patients (Green et al., 2007). Intracellular calcium 
overload may be caused by several mechanisms (Yu et al., 2009a), one of them 
being interaction of soluble Aβ with presynaptic voltage-gated calcium channels 
(reviewed by Nimmrich and Ebert, 2009; Demuro et al., 2010). As introduced later, 
these channels play a crucial role in intracellular calcium influx, vesicle release, and 
presynaptic plasticity (reviewed by Catterall and Few, 2008). 
Modification of all types of high voltage-activated (HVA) calcium channels by Aβ has 
been described in several studies, also producing conflicting results. Some studies 
investigated chronic effects of Aβ in rat cortical neurons. MacManus et al. (2000) and 
Ramsden et al. (2002) described an increase in HVA calcium channel currents by full 
length Aβ1-40 which was most likely mediated via N-type and P/Q-type calcium 
channels. By contrast, Ueda et al. (1997) chronically applied truncated Aβ25-35 and 
found decreased cell viability which could be attenuated by nimodipine, an 
unselective L-type calcium channel blocker, but not by specific N-type or P/Q-type 
calcium channel blockers. Moreover, after chronic exposure to Aβ25-35 they also found 
an increase in calcium currents which was also insensitive to specific N-type or 
P/Q-type calcium channel blockers, but could be attenuated by nimodipine. This 
finding was recently confirmed by Kim and Rhim (2011) who also recorded a current 
increase from recombinant L-type calcium channels in HEK293 cells after acute 
treatment with Aβ25-35. The conflicting results that Aβ affects different channels may 
be caused by the use of different preparations. Rovira et al. (2002) found that both 
Aβ25-35 and Aβ1-40 increased calcium currents in acute hippocampal slices, however 
the former preparation via L-type whereas the latter via non-L-type calcium channels. 
Which Aβ form is most relevant for the pathophysiology of AD has not been 
elucidated. The relevance of truncated Aβ25-35 for the pathogenesis of AD has been 
suggested by the fact that this form has been found in vivo (Kaneko et al., 2001) and 
exerts multiple toxic effects in vitro as reviewed by Millucci et al. (2010). Whereas full 
length Aβ1-40 and Aβ1-42 is most abundantly found in AD patients and the alteration of 
the Aβ1-42-to-Aβ1-40 ratio is associated with early onset AD (Suzuki et al., 1994; Duff 
et al., 1996; Scheuner et al., 1996), which strongly suggests the involvement of full 
length Aβ in the pathophysiology of AD. 
Because Aβ spontaneously forms aggregates, it needs to be emphasized that the 
studies cited above used poorly defined Aβ species for studying functional effects. 
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The well known rapid aging of Aß preparations can influence their biological function: 
fresh and aged (aggregated) Aβ1-40 can exert opposite effects by increasing (N-type 
and P/Q-type) and decreasing (only N-type) calcium channel currents, respectively 
(Ramsden et al., 2002). Similarly, the effects of Aβ1-42 can vary depending on the 
aggregation and oligomerization status (Innocent et al., 2010). Aβ species in more 
sophisticated preparations of Aβ1-42, like amyloid-derived diffusible ligands, are also 
poorly defined (Lambert et al., 1998; Hepler et al., 2006). Despite this shortcoming, 
such preparations have proved useful in identification of the pathological nature of 
oligomeric Aβ (Lacor et al., 2007). As of today, many different oligomeric forms of Aβ 
have been discovered. A comprehensive overview from Benilova et al. (2012) 
illustrates that numerous oligomers were found in AD patients, extracted from natural 
sources and synthetically prepared. To further add to this complexity, polymerization 
of Aβ is complex and may occur via metastable intermediates (Lee et al., 2011). 
Therefore, many oligomeric Aβ forms are metastable in aqueous solution (Figure 1.1) 
and may exert different biological effects.  
For the purpose of studying the characteristics of pathological Aβ oligomers in a 
controlled and reproducible manner, stable and well-defined oligomer preparations 
were created including Aβ globulomer, which is formed from synthetic Aβ1-42 
(Barghorn et al., 2005). This study showed that Aβ globulomer predominantly 
consists of 12-mer Aβ1-42 oligomers. Stability of this preparation was attributed to a 
conformational switch leading to an Aβ peptide epitope with a distinct aggregation 
pathway, independent of the pathway forming fibrils (Gellermann et al., 2008; see 
upper left corner of Figure 1.1). The fact that Aβ globulomer inhibits LTP in acute 
hippocampal slices and that Aβ globulomer epitopes are found in AD patients as well 
as in APP overexpressing mouse models, support the pathological relevance of this 
preparation for AD (Barghorn et al., 2005). It has to be noted that several Aβ forms 
have been detected ex vivo (Shankar et al., 2008a; Noguchi et al., 2009) and it 
appears likely that there are several pathologically relevant oligomeric Aβ species 
which induce different toxic effects as suggested by findings on different synthetic 
preparations (reviewed by Benilova et al., 2012). Furthermore, the neurotoxic 
properties of Aβ might depend on the mixtures with other Aβ species (Kuperstein et 
al., 2010). Keeping these considerations/limitations in mind, we focused on 
investigating the effects of Aβ globulomer in order to further elucidate molecular 
mechanisms of a stable, oligomeric, and non-fibrillar Aβ preparation.  
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Figure 1.1  Scheme of different natural and synthetic Aβ assemblies (from Benilova et 
al., 2012). Aβ monomers, oligomers, and fibrils exist in a complex equilibrium, sensitive to 
numerous external factors. Coexistence of several oligomeric populations that do or do not 
propagate into fibrils is possible. Despite the differences in structure, stability, and 
concentration, all oligomers may contribute to Aβ toxicity. ADDL: Aβ-derived diffusible 
ligands; ASPD: amylospheroids; TG2: Transglutaminase 2. 
Aβ globulomer was described to affect the frequency of postsynaptic currents in 
primary hippocampal cell cultures pointing towards a presynaptic target (Nimmrich et 
al., 2008a). This probably led to a decrease in presynaptic vesicle release, which was 
found to be caused by a decrease in P/Q-type calcium channel currents in vitro. 
These effects could be reversed by R-roscovitine, a P/Q-type calcium current 
modulator. In a direct approach of recombinantly expressed P/Q-type calcium 
currents in Xenopus oocytes Mezler et al. (2012a) showed that the α1A subunit of the 
channel was specifically modulated by Aβ globulomer leading to an increased 
calcium influx. It was speculated that this increase might cause excitotoxic synaptic 
degeneration. The reason for the bidirectional modulation of P/Q-type calcium 
channels by Aβ globulomer has not been resolved but might be caused by several 
factors (and will also be addressed in the discussion). For example, Koch et al. 
(2004) showed that a peptidic potassium channel blocker can enhance or reduce the 
potassium current depending on the channel state. Concentration and 
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state-dependent bidirectional effects have also been observed for R-roscovitine 
(Buraei and Elmslie, 2008). EVP-6124, a α7 nicotinic acetylcholine modulator and, as 
described previously, a clinical candidate for the treatment of AD showed 
concentration-dependent bidirectional effects probably due to a partial agonistic 
mechanism (Prickaerts et al., 2012). Moreover, the L-type calcium channel agonist 
Bay K 8644 can also inhibit cardiac calcium channels, which depends on the 
surrounding voltage (Kass, 1987; Schreibmayer et al., 1992). This indicates that 
subtle differences in the interaction of a compound with a channel can lead to 
different functional effects. Therefore, differences between expression systems might 
explain the bidirectional results from the Aβ globulomer studies. In fact, Aβ oligomers 
have been described to increase and decrease the frequency of postsynaptic 
currents (Shankar et al., 2007; Abramov et al., 2009), which may be a downstream 
effect of P/Q-type calcium channel modulation. Furthermore, Aβ can both increase 
and decrease LTP (Puzzo et al., 2008).  
To conclude, the mechanism of action of oligomeric Aβ has not yet been completely 
elucidated partially because many studies used poorly defined preparations (see 
above). So in this PhD work we tested the effect of a stable Aβ oligomer preparation 
on presynaptic calcium channels. In addition to recent findings obtained in Xenopus 
oocytes (Mezler et al., 2012a) and rat primary hippocampal cell cultures (Nimmrich et 
al., 2008a), we here study the effect of oligomeric Aβ on recombinant P/Q-type and 
N-type calcium channels in a human cell line. Moreover, possible state-dependent 
effects of Aβ oligomers are being investigated. On a systemic level, we also 
assessed whether block of P/Q-type, N-type, or L-type calcium channels bears 
therapeutic potential by preventing functional deficits in an in vitro model of Aβ 
oligomer-induced synaptic degeneration described in Nimmrich et al. (2010). 
 
1.2 High Voltage-Activated Calcium Channels 
This chapter covers theoretical considerations, which might support successful drug 
development of compounds influencing high voltage-gated calcium channels. First, a 
brief introduction into the basic properties of the voltage-gated calcium channel family 
including channel structure, physiological function, and pharmacological properties is 
provided. Second, the terminology of ion channel states and transitions is listed. 
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Third, a comprehensive overview is given regarding the mechanisms and kinetics of 
inactivation in HVA calcium channels. Last, the principle of state-dependence is 
introduced, as a drug property which probably increases its tolerability in humans, 
referencing to experimental findings, properties of clinically used substances, and 
current drug development efforts. 
 
1.2.1 Structure and Pharmacological Characterization 
In this subchapter voltage-gated calcium channel structure, ion selectivity, subtype 
classification and nomenclature, pharmacology, localization, and function is 
introduced according to Catterall et al. (2005) and (in part) illustrated in Figure 1.2 
(p.21). 
As determined by studies using channel mutations, ion selectivity in calcium 
channels is obtained through a selectivity filter of a cluster of four glutamate residues 
(Yang et al., 1993), which are thought to project into the pore to sort calcium from 
other ions. The relative permeability sequence has experimentally been determined 
as calcium > barium > lithium > sodium > potassium > caesium (Hess et al., 1986). 
As calcium is favored over sodium by a factor of 1000, the calcium current is hardly 
affected by the extracellular sodium concentration (Polo-Parada and Korn, 1997). In 
many electrophysiological settings calcium is replaced by barium as a charge carrier, 
which diminishes (secondary) calcium-dependent effects and therefore unmasks 
voltage-dependent effects. 
Electrophysiological recordings identified voltage-activated calcium currents with 
distinct characteristics. Depending on the voltage necessary for channel opening, 
major categorization was carried out into low-voltage and HVA channels. The former 
comprises T-type calcium currents (also denoted as the CaV3.x family), which 
mediate cardiac pacemaker activity (Satoh, 2003) and thalamic oscillations (Perez-
Reyes, 2003)  and may be important drug targets for epilepsy and neuropathic pain 
(Nelson et al., 2006). However, these channels have received little attention as a 
potential treatment strategy for AD. In part, this is due to the fact that interaction of Aβ 
or tau with these channels has not been reported. In addition, in vitro data suggests 
that long-term neuroprotection is rather mediated via HVA (L-type) than T-type 
calcium channels (Wildburger et al., 2009). HVA channels activate at strongly 
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depolarized membrane potentials and are multi-subunit complexes. The channels 
have been further subdivided depending on pore forming subunit, channel kinetics, 
pharmacology, and cellular distribution (Tsien et al., 1991) yielding L-type, N-type, 
P/Q-type and R-type calcium channels.  
Unlike all other calcium channels, L-type calcium channels (also denoted as the 
CaV1.x family) are modulated by the agonist (-)-Bay K 8644. In addition, they are 
sensitive to dihydropyridines (e.g., nimodipine), phenylalkamines (verapamil), and 
benzothiazapines (diltiazem). However, these blockers can also act on other HVA 
calcium channels (Diochot et al., 1995; Ishibashi et al., 1995; Hockerman et al., 
2000). L-type calcium channels are expressed in all excitable and many types of 
non-excitable cells and are predominately located on cell bodies and proximal 
dendrites in neuronal cells (Hell et al., 1993). Channels were also found to interact 
with intracellular calcium stores (Dolmetsch et al., 2001; Thibault et al., 2007) and 
may regulate gene expression (Murphy et al., 1991). Upon prolonged membrane 
depolarization, channel inactivation is mostly calcium (Imredy, 1994) and to a lesser 
extent voltage-dependent (Tsien et al., 1991).  
By contrast, most N-type calcium channels (CaV2.2) display significant 
voltage-dependent inactivation (Nowycky et al., 1985). They are less sensitive to 
dihydropyridines, but are inhibited by the peptidic blockers ω-conotoxin extracted 
from predatory marine snails (Olivera et al., 1987). These channels seem to be 
exclusively expressed in neuronal tissue (Plummer et al., 1989), cluster at synaptic 
areas (Jones et al., 1989), are involved in neurotransmitter release (Dutar et al., 
1989), and are physically associated with proteins of the release machinery (Leveque 
et al., 1994; Sheng et al., 1994). However, especially for many synapses in the CNS, 
neurotransmitter release is not primarily controlled by this channel type (Luebke et 
al., 1993; Potier et al., 1993).  
Neurotransmitter release is also mediated via P/Q-type calcium channels (CaV2.1), 
especially in the CNS (Mori et al., 1991; Luebke et al., 1993; Stea et al., 1994). 
These channels are less sensitive to dihydropyridines and some ω-conotoxins, but 
are specifically blocked by the funnel web spider toxin ω-agatoxin IVA and 
ω-agatoxin TK, also termed ω-agatoxin IVB (Adams et al., 1993; Teramoto et al., 
1993; Olivera et al., 1994). Initially, P-type and Q-type currents were distinguished 
due to their different pharmacological affinity to ω-agatoxin-IVA and 
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electrophysiological properties. However, differences are most likely caused by 
different splice variants of the pore forming subunit and different complements of 
auxiliary subunits (Bourinet et al., 1999; Soong et al., 2002). 
A
B
 
Figure 1.2  Voltage-gated calcium channels (from Dolphin, 2012). (A) Voltage-gated 
calcium channel α1 subunits have 24 transmembrane α-helices, organized into four 
homologous repeats (I–IV). The fourth transmembrane segment S4 of each repeat (red) has 
approximately five positively charged amino acids and, together with S1, S2, and S3, 
comprises the voltage-sensing domain of the channel. Yellow segments represent the pore 
loops. β subunits consist of an Src homology (SH3) domain (pink circle) and a guanylate 
kinase domain (purple circle), which binds to the intracellular linker between domains I and II 
of the α1 subunit. The α2δ subunit consists of α2 (red) disulphide-bonded to the δ subunit 
(orange). The site(s) of interaction between the α1 subunit and the α2δ subunit is poorly 
understood. (B) Dendrogram based on an alignment of the membrane-spanning regions and 
pore loops of the α1 subunits. CaV1 and CaV2 comprise the HVA and CaV3 the low-voltage-
activated (LVA) channels. Original names (blue), CaV nomenclature (red) and gene names 
(green) of the α1 subunits are given.  
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Even after application of dihydropyridines, ω-conotoxins, and ω-agatoxins a small 
residual HVA R-type calcium current (CaV2.3) remains (Zhang et al., 1993). Of the all 
HVA calcium currents the R-type has been least studied. Results from transgenic 
mice suggest that rather a family of channels than a single channel mediates this 
current (Wilson et al., 2000). Dietrich et al. (2003) reported that R-type calcium 
currents contribute to LTP induction in hippocampal mossy fibers but not to basal 
transmission or short-term plasticity, which suggests that these channels are 
remotely localized from the release machinery. 
HVA calcium channels are associated with the auxiliary β, α2δ (see Figure 1.2, p.21), 
and in some cases the γ subunit which modulate channel function. The β subunit 
(reviewed by Buraei and Yang, 2010) enhances expression of the HVA pore forming 
α1 subunits by promoting channel insertion into the membrane. The β subunit lacks 
transmembrane segments and binds to the intracellular I-II loop of the α1 protein. 
Four different β subunits have been described, which are encoded by distinct genes. 
Due to alternative splicing in total 15 different β subunit forms have been described; 
the β1b subunit was studied in this PhD thesis. β subunits also shift voltage-
dependence of activation and inactivation as well as channel kinetics (reviewed by 
Buraei and Yang, 2010). For example, the rate of voltage-dependent inactivation is 
increased for β1 and β3, whereas it is often decreased for the β2 subunit.  
Moreover, there are four different α2δ extracellularly located subunits, named α2δ1 
(which was studied in this PhD work), α2δ2, α2δ3, and α2δ4. (reviewed by Dolphin, 
2012). They consist out of two disulfide-linked proteins and might be anchored to the 
membrane by a glycosylphosphatidylinositol anchor (Davies et al., 2010). Recent 
studies by (Kadurin et al., 2012), however, suggest that this anchor is not 
indispensable for the function of α2δ. The main role of this subunit is to increase 
calcium currents by promoting trafficking of α1 to the plasma membrane and 
increasing its turnover time but can also modulate channel function depending on the 
type of the co-expressed α1 subunit. Moreover, α2δ subunits modulate presynaptic 
function by increasing the density of synaptic voltage-gated calcium channels and the 
neurotransmitter release probability (Hoppa et al., 2012). In line with this, the drugs 
gabapentin and pregabalin, used as antiepileptic agents, are supposed to interact 
with α2δ thereby reducing vesicle release and neuronal excitability (Fink et al., 2002; 
Taylor et al., 2007; Bauer et al., 2009). 
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In addition, eight different γ subunit genes have been identified. They often induce a 
slight hyperpolarizing and depolarizing effect of the voltage-dependence of 
inactivation and activation, respectively, thereby reducing calcium currents to some 
extent (Buraei and Yang, 2010). However, unlike the other subunits, the γ subunit is 
not co-expressed in all calcium channel complexes (especially in the CNS), 
predominantly associated with L-type calcium channels (Yang et al., 2011), and 
involved in other functions like regulation of trafficking, localization, and biophysical 
properties of other ionotropic glutamate receptors (reviewed by Milstein and Nicoll, 
2008). 
 
1.2.2 Terminology of Channel States and Transitions 
Characterization of e.g., inactivation kinetics is one prerequisite for the development 
of state-dependent HVA calcium channel blockers. Here, the nomenclature used to 
characterize transitions of channel states, like inactivation induced by conformational 
switches (Stotz et al., 2000; Bezanilla, 2002), is being briefly introduced. 
Ion channels can exist in an open (conducting) state or in non-conducting closed or 
inactivated states. The difference between the non-conducting closed and inactivated 
states is that for the latter the channel is unresponsive to an activating stimulus, 
comparable to the reduced response of a desensitized receptor. The transition from 
closed to open is denoted as activation, open to closed is called deactivation, open or 
closed to inactivated is called open and closed-state inactivation, respectively, and 
inactivated to open or closed is called recovery from inactivation (Figure 1.3). 
Figure 1.3  Nomenclature of channel state 
transitions. HVA calcium channels can be 
present in the non-conducting closed (C) and 
inactivated (I) states or in the conducting open 
(O) state. Kinetics of each state transition depend 
on the surrounding membrane potential. For P/Q-
type and N-type calcium channels recovery from 
inactivation occurs more rapidly to closed (solid 
lines) than to open (dotted lines) states.  
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Ion channels can exist in an open (conducting) state or in non-conducting closed or 
inactivated states. The difference between the non-conducting closed and inactivated 
states is that for the latter the channel is unresponsive to an activating stimulus, 
comparable to the reduced response of a desensitized receptor. The transition from 
closed to open is denoted as activation, open to closed is called deactivation, open or 
closed to inactivated is called open and closed-state inactivation, respectively, and 
inactivated to open or closed is called recovery from inactivation (Figure 1.3). 
For a subgroup of calcium channels, denoted as voltage-dependent, the probability 
of being in a certain state depends on the voltage across the cell membrane. At the 
neuronal resting potential, the HVA calcium channels are mostly present in a closed 
state. The likelihood for activation increases upon membrane depolarization like 
action potential arrival. At the same time the probability of channel inactivation 
increases, which either causes an active decrease in ion conductivity (by open-state 
inactivation) or a decreased availability for subsequent channel opening (by closed-
state inactivation; Patil et al., 1998). For prolonged membrane depolarizations only 
residual P/Q-type and N-type calcium channel currents, if at all, can be detected 
(Hans et al., 1999). This implies that under depolarized conditions recovery from 
inactivation is much slower than inactivation. Thus, for P/Q-type and N-type calcium 
channels recovery from inactivated states predominantly occurs to closed states 
during hyperpolarized potentials. 
 
1.2.3 Function and Mechanisms of Inactivation 
An effective state-dependent screening protocol should induce stable inactivation. 
Moreover, as certain pathologies may induce inactivation in different ways as 
mentioned in the discussion, it might be beneficial for screening protocols to (some 
extent) mimic the disease-like state of interest. To achieve this, thorough 
understanding of physiological HVA calcium channel inactivation is a prerequisite. 
Thus, a comprehensive overview is provided regarding the function, mechanisms, 
and kinetics of inactivation in HVA calcium channels.  
As calcium channel activation occurs at a significantly faster rate than inactivation, 
membrane depolarization induces channel opening, thereby increasing intracellular 
calcium concentration. Calcium acts, for example, as a cytoplasmic messenger 
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activating signaling pathways leading to gene transcription (Dolmetsch et al., 2001) 
or by triggering neurotransmitter release (Wheeler et al., 1994; Sutton et al., 1999). 
At the same time calcium channel inactivation prevents prolonged and excessive rise 
in intracellular calcium concentrations, which may otherwise lead to detrimental 
cytotoxic effects like apoptosis (Choi, 1988; Orrenius et al., 1989; Cerella et al., 
2010). As a functional example, inactivation may contribute to the short-term 
depression of neurosecretion (Branchaw et al., 1997; Forsythe et al., 1998). Some 
naturally occurring mutations of the P/Q-type calcium channel were found in humans 
that modulate its inactivation properties, potentially contributing to respective clinical 
symptoms such as migraine and ataxia (Matsuyama et al., 1999; Kraus et al., 2000; 
Wappl et al., 2002). Inappropriate calcium channel inactivation may thus lead to CNS 
malfunction.  
Channel inactivation can be both calcium and voltage-dependent. Calcium 
dependent modulation is most strongly observed for L-type calcium channels 
(Peterson et al., 1999; Zuhlke et al., 1999), but is also present for presynaptic 
P/Q-type calcium channels (Lee et al., 1999). It is induced by a local rise in 
intracellular calcium concentration and is mediated by the calcium-sensing protein 
calmodulin which binds directly to multiple sequences of the α1 calcium channel 
subunit. This may induce conformational changes of the channel, which modify the 
probability of the channel to be in a conducting or non-conducting state. Calcium 
dependent inactivation and facilitation occurs within several milliseconds, and is 
thereby able to contribute to synaptic short-term plasticity (Forsythe et al., 1998). For 
presynaptic P/Q-type calcium channels, calcium-dependent modulation is absent if 
barium replaces calcium as a charge carrier or after intracellular application of 
BAPTA, a fast calcium chelator (Borst and Sakmann, 1998; Cuttle et al., 1998). This 
type of inactivation is also less pronounced with coexpression of the β1b subunit, 
used in this PhD study, than for other β subunits (Lee et al., 2000). Due to its 
mechanism of action, calcium-dependent inactivation mostly induces open-state 
rather than closed-state inactivation, which can take place without previous calcium 
influx.  
By contrast, voltage-dependent inactivation can also occur during depolarizations 
which are sub-threshold to channel opening (Patil et al., 1998). The onset of this type 
of inactivation can happen at a fast rate (in the range of ms to few s) and at a slow 
1  Introduction 
26 
rate (several s to min). Similar to the ball and chain model applicable to sodium and 
potassium channels (Armstrong and Bezanilla, 1973; Hoshi et al., 1990), fast 
voltage-dependent inactivation of calcium channels is induced by an intracellular 
residue plunging the pore of the channel, which was denoted as a hinged lid 
mechanism (Figure 1.4; Stotz et al., 2000).  
 
Figure 1.4  Hinged-lid model of fast voltage-dependent inactivation of HVA calcium 
channels (from Zamponi, 2005).(A) Possible model for calcium channel inactivation, which 
involves occlusion of the channel pore from the intracellular side by parts of the domain I-II 
linker of the α subunit. (B) Inhibition of inactivation was found to be mediated by: (a) the β2a 
subunit; (b) interaction of β subunits with the N-terminus and/or C-terminus indirectly 
affecting the I-II linker function; (c) In the absence of β subunits, interactions between the I-II 
and II-IV linker.  
Unlike for sodium and potassium channels, the mechanism of fast inactivation for 
calcium channels is hypothesized to underlie the intracellular domain I-II linker 
interacting with the S6 transmembrane regions (Stotz and Zamponi, 2001) thereby 
blocking ion permeability. This interaction can be modulated by other α1 cytoplasmic 
loops. For example, intramolecular interaction of the domain III-IV linker with the 
domain I-II linker was found to slow down inactivation (Geib et al., 2002). In addition, 
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fast inactivation is also strongly modulated by the auxiliary subunits, especially the 
β subunit (Varadi et al., 1991). For example, the β1b subunit, which was investigated 
in this PhD work, tends to increase the rate of inactivation (Isom et al., 1994; Qin et 
al., 1998). Mechanistically, β subunits may interact with the N-terminus or C-terminus 
of the α1 subunit, which in turn may influence the inactivation inducing domain I-II 
linker (Soldatov, 1998; Stephens et al., 2000; Sandoz et al., 2001). The α2δ subunits 
may also regulate inactivation (Klugbauer et al., 1999; Davies et al., 2007). When 
coexpressed with the β1b subunit, as in this PhD study, α2δ1 was found to significantly 
facilitate inactivation N-type calcium channel currents in Xenopus Oocytes (Canti et 
al., 2000).  
In contrast to fast voltage-dependent inactivation, slow inactivation has been 
described and understood in much less detail. A couple of studies have described 
the slow inactivation kinetics in detail. Mostly the inactivation of channels containing 
the β2 subunit is dominated by slow kinetics, but also channels with other β isoforms 
undergo slow inactivation. For example, in a study in Xenopus oocytes by Sokolov et 
al. (2000), on-rates of slow inactivation were calculated to be about a minute, but 
also depended on the auxiliary β subunit. By contrast, recovery from slow inactivation 
seemed to be independent of the length of the conditioning prepulse and the 
β subunit. However, the rate of recovery is slowed for more depolarized membrane 
holding potentials and inactivation was fully reversible at a holding potential of 
-80 mV or below, but not at -60 mV. Due to further point mutation studies, this report 
also suggested that slow inactivation can occur from both open and fast inactivated 
states (the relation to closed-state inactivation was not elucidated). A complete 
mechanism of action for slow inactivation has not yet been proposed, but might be 
similar to the ones of fast inactivation, since also for the slow inactivation point 
mutations within the cytoplasmic end of the S6 transmembrane regions can 
selectively abolish slow inactivation of L-type calcium channels (Shi and Soldatov, 
2002). Moreover, this study found that inhibition of one type of inactivation facilitates 
the other type, so fast and slow inactivation might actually be linked. 
Functionally, slow inactivation may have implications for synaptic short-term 
plasticity. For example, after strong physiological channel activation (after trains of 
action potentials) or pathological membrane depolarization including hypoxic or 
1  Introduction 
28 
ischemic events (Kristian and Siesjö, 1998), more channels are driven into this type 
of slowly recovering inactivation thereby preventing calcium overload.  
The membrane potential in neurons is most of the time too low for opening of HVA 
calcium channels. Hence, especially for these channels closed-state inactivation that 
regulates the availability of channels upon action potential arrival might be an 
important mechanism modulating synaptic transmission. In addition, since 
voltage-dependent channel inactivation, unlike calcium-dependent inactivation, can 
induce both open- as well as closed-state inactivation, it is currently perceived as the 
more relevant type of inactivation within drug development targeting calcium 
channels in the CNS (Winquist et al., 2005). 
 
1.3 Drug Discovery Targeting Ion Channels 
In the following, the general potential as well as possible pitfalls of ion channels as 
potential drug targets are being briefly described. Subsequently, current technical 
advances in patch clamp technology are presented which may overcome a key 
technical bottleneck in rational drug discovery associated with the limited throughput 
of manual electrophysiology. Thereafter, the potential of state-dependent target 
modulation to induce functional selectivity (Urban et al., 2007; Kaczorowski et al., 
2008) and to increase the tolerability of future drugs is discussed and exemplified by 
current N-type calcium channel drug development efforts. In the last subsection, the 
involvement of P/Q-type calcium channels in other diseases beyond their role for AD 
(see section 1.1.3.3 p. 13ff), is shortly reviewed along with unselective P/Q-type 
modulators, which are already in clinical use. Finally, an outlook is given how (more) 
selective and state-dependent P/Q-type calcium channel modulators might be 
identified. 
 
1.3.1 Ion Channels as Drug Targets 
Only about 22% of proteins in the human genome are located on the cell surface, but 
they make up 60% of the current drug targets (Overington et al., 2006). Many ion 
channels are located in the plasma membrane and are typically complex, multimeric, 
transmembrane proteins that consist of separate pore-forming and accessory 
1.3  Drug Discovery Targeting Ion Channels 
29 
subunits (Ashcroft, 2006). They allow passive ion passage along the electrochemical 
gradient across cell membranes and exhibit a high degree of structural diversity. 
They comprise only around 1.3% of the human genome (Venter et al., 2001), but 
constitute about 13.9% of all drugs approved by regulatory authorities in the US 
being the second-most frequent targeted gene-family group after G-protein coupled 
receptors indicating that these channels are attractive drug targets (Overington et al., 
2006).  
Despite their validation as potential drug targets, only a small fraction out of 406 ion 
channels found in the human genome is so far targeted by approved drugs (Venter et 
al., 2001; Imming et al., 2006). The lack of exploitation of this target class is 
complicated by the inability to assess target occupancy in clinical trials, since 
adequate biomarkers are missing, which makes the interpretation of negative clinical 
results difficult (Kaczorowski et al., 2008). Moreover, the modulation of ion channels 
bears the risk of inducing significant side effects, as they are expressed in many cell 
types and play a major role in cellular ion homeostasis (Farrugia, 2008).  
The fact that up to now low molecular weight (LMW) compounds often do not exhibit 
sufficient selectivity between ion channel subtypes is obviously unfavorable in terms 
of drug tolerability (see for instance (reviewed by Yamamoto and Takahara, 2009). In 
contrast, for some HVA calcium channels selective peptide blockers have been 
found, as noted in section 1.2.1 (p.19ff). One of them, conotoxin MVIIA (ziconotide), 
an N-type calcium channel-specific blocker, was successfully approved for treatment 
of neuropathic pain (Schmidtko et al., 2010). However, other peptidic channel toxins 
(e.g., ω-agatoxin IVA and IVB) are not suited for clinical development. Reasons for 
this may include insufficient brain availability (no blood brain barrier penetration), lack 
of bioavailability and irreversible channel blockage (Adams et al., 1993). Although 
modifications of peptide toxins have led to somewhat improved biophysical properties 
(Craik and Adams, 2007), these pitfalls have not yet been overcome. Besides 
improving drug tolerability by molecular selectivity (towards a specific ion channel), 
current drug discovery approaches also focus on inducing functional selectivity by 
identifying state-dependent LMW molecules, as described in section 1.3.3 (p.32ff). 
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1.3.2 High Throughput Methods 
In rational drug discovery, identification and validation of an appropriate (e.g., ion 
channel) target is followed by large-scale compound screening, identification of 
(potential) modulators, and subsequent optimization of one or several promising 
chemical scaffolds (also called lead structures/compounds). Throughout this process 
many compounds are created, so that biological activity needs to be assessed in a 
high-throughput manner. Here, a brief overview is given about several existing 
methods and their respective shortcomings in supporting drug development, which 
may partially be overcome by automated patch clamp techniques. 
Historically, drug development has been hampered by technical constraints, namely 
the lack of adequate high-throughput methods for identification and validation of 
novel compounds (Clare, 2010). For functional channel and compound 
characterization, manual electrophysiology has served as the gold-standard over 
several decades. This is because of its direct readout of ion channel function via 
measurement of the current and voltage across the membrane, excellent temporal 
resolution to resolve fast channel kinetics and high sensitivity due to an exceptional 
signal-to-noise ratio. However, manual patch-clamp experiments have a low 
throughput and are labor-intensive, posing a significant bottleneck for ion channel 
drug development. To this end, there are higher throughput assays available which 
have been incorporated into drug discovery programs. Among these are methods 
using fluorescent dyes which are sensitive to the calcium-level (Benjamin et al., 
2006) or membrane-potential (Epps et al., 1994; Holevinsky et al., 1994). 
Furthermore, assays have been established which are fluorescence resonance 
energy transfer-based (Falconer et al., 2002) or measure ion fluxes (Terstappen, 
1999). Unfortunately, these methods lack fast temporal control of voltage, necessary 
for the precise control of voltage-gated ion channels. In addition, ion-channel activity 
is only indirectly measured making these assays susceptible to false positives (Tang 
et al., 2001). Direct measurements of ion fluxes have also been developed 
(Terstappen, 1999) but lack sufficient sensitivity (Rezazadeh et al., 2004). The 
limitations of the high throughput assays decrease the correlation of such data with 
data obtained from more direct electrophysiological methods (reviewed by Dunlop et 
al., 2008; Terstappen et al., 2010).  
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During the last decade, higher throughput automated, planar patch clamp systems 
became commercially available which attempt to bridge this gap. The development of 
the planar patch clamp technique dates back to early methodological approaches 
which replaced the patch pipette by a planar surface perforated with a hole mimicking 
the pipette opening (Krishtal and Pidoplichko, 1975). As reviewed in Behrends and 
Fertig (2007), this principle has not been further exploited due to technical difficulties 
in the manufacturing process until solid-state microstructuring technologies became 
more accessible in the late 1990s. In addition, ion channels have by then received 
more attention also as a target potentially causing adverse effects, since block of the 
human ether-à-go-go channel became associated with long QT syndrome which 
increases the risk for torsades de pointes, a life-threatening ventricular arrhythmia 
(Curran et al., 1995; Sanguinetti et al., 1995). As a consequence, the planar clamp 
patch technique has been refined and is nowadays utilized in several commercially 
available automated patch clamp systems comprising chips either based on polymer 
substrates (e.g., IonWorks Barracuda from Molecular Devices), silicon (e.g., Qpatch 
from Sophion, Ballerup, Denmark), or glass microstructuring (e.g., Patchliner from 
Nanion GmbH, see p.47). In manual electrophysiology electrical access to the cell is 
obtained through a micropipette, which must first be carefully manipulated by a 
skilled experimenter into direct vicinity of an (usually) adherent cell (Hamill et al., 
1981). By contrast, for automated electrophysiology suspended cells are positioned 
on a perforated planar surface by suction for subsequent gain of electrical access 
(Kiss et al., 2003). As this procedure does not require any interaction with the 
experimenter, several wells can be run in parallel. This, together with shorter 
preparation times between experiments by omitting fabrication, filling, and positioning 
of micropipettes, significantly increases the throughput compared to the manual 
patch clamp technique.  
Today, several automated patch clamp systems with different recording properties 
are available, but generally data quality tends to be higher (due to the direct 
functional recording of ion channels) and throughput lower compared to the 
alternative methods introduced above. Therefore, these different methodological 
approaches are somewhat complementary to each other and will most likely be used 
in parallel for current and future drug development programs (e.g., Mezler et al., 
2012b). Here, we used the Patchliner Platform for automated patch clamping (Farre 
et al., 2007), which enables medium-throughput (by simultaneous recordings from up 
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to four cells) and comprises a borosilicate chip surface enabling giga-seal formation. 
This is a prerequisite for precisely controlling the voltage of the patched cell, which is 
especially important for accurate measurements of voltage-gated channels. 
 
1.3.3 State-Dependent Channel Modulation 
Here, first the concept of tonic and non-tonic, namely use-, state-, and voltage-
dependent, channel inhibition is briefly described. Subsequently, the relevance of 
non-tonic channel block as means of inducing functional selectivity to potentially 
lower adverse side effects is introduced. Then this is discussed on the example of 
ongoing drug development activities to identify use- and state-dependent N-type 
calcium channel blockers for the treatment of neuropathic pain. 
On the one hand, pharmacological inhibition of ion channels can be tonic, i.e. 
irrespective of the channel conformation or factors like membrane potential. On the 
other hand, channels can also be modulated voltage-, state-, and use-dependently, 
so that the affinity for the channel depends on the surrounding conditions. By 
definition, the affinity of a voltage-dependent modulator to its target is sensitive to the 
surrounding membrane potential. A state-dependent modulator has differential 
affinities for certain channel states e.g., inactivated states, which can be 
experimentally assessed by constant (holding potential) or transient (prepulse) 
depolarization of the membrane potential prior to channel activation. A 
use-dependent modulator has different affinities due to several (rapid) transitions 
between states, which can be assessed by repetitive, high frequency channel 
stimulation. So in theory, a use-dependent blocker is also state-dependent, which in 
turn (for voltage-gated calcium channels) implies voltage-dependence, but not vice 
versa. 
Increased potency for inactivated states of ion channels is currently believed to aid 
the therapeutic potential of ion channel blockers by widening the therapeutic window 
through targeting overactive or pathologically depolarized cells while leaving 
physiological activity mostly unaltered (Winquist et al., 2005; Kaczorowski et al., 
2008). For example, tetrodotoxin (TTX) a highly potent marine biotoxin inhibits open 
and closed states from most sodium channels in the low nM range (Boccaccio et al., 
1998), thereby tonically suppressing action potential propagation, potentially leading 
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to pulmonary arrest (Chang et al., 1990). Life-threatening poisoning occurs at plasma 
concentrations which are above the IC50 of TTX to sodium channels, but slight to 
moderate toxicity, including paralysis of extremities, is already observed at 
concentrations similar or even below the IC50 values (Zimmer, 2010). By contrast, 
several clinically used sodium channel blockers were found to be state-dependent. 
For example, lamotrigine, which is effectively used for the treatment of epilepsy, was 
found to stabilize the inactivated state of the sodium channel thereby suppressing 
high frequency repetitive firing rates with little or no effects on basal transmission (Xie 
et al., 1995; Kuo and Lu, 1997). These studies estimated the affinity to inactivated 
sodium channels to be 12 µM and 7 µM, respectively. This is in line with a study of 
Hirsch et al. (2004) stating that that plasma concentrations of about 20 µM are often 
efficacious in epilepsy patients, a concentration well tolerated by most patients. 
These findings support the hypothesis that functional selectivity through 
state-dependent channel block might decrease adverse effects. 
Block of NMDA receptors by memantine was also found to be voltage- and weakly 
use-dependent (Parsons et al., 1993; Bresink et al., 1996). This along with other 
properties like NMDA-subunit specificity and fast (un)binding kinetics may underlie 
the improved tolerability of memantine compared to other NMDA antagonists 
(reviewed by Rogawski and Wenk, 2003; Lipton, 2006). It needs to be noted, that the 
contribution of each property (e.g., voltage- vs. use-dependence) to the improved 
tolerability has not been described. 
Several dihydropyridine HVA L-type calcium channel blockers like verapamil, which 
is used against hypertension and cardiac arrhythmias, have been found to be 
voltage- and state-dependent as well, preferentially binding to inactivated states 
(Nawrath and Wegener, 1997). Notably, this effect was described in retrospective to 
its approval. Another example is the L-type calcium channel antagonist nitrendipine, 
which is also used to treat hypertension, and was found to preferentially bind to and 
block channels during voltage-dependent inactivation (Bean, 1984). Furthermore, 
another dihydropyridine, nimodipine, which is a weakly selective L-type blocker 
clinically used to treat hypertension (Diochot et al., 1995; Furukawa et al., 2003) also 
preferentially binds to inactivated channels. Interestingly, nimodipine exhibited 
antidementive effects in several short-term clinical trials while being well tolerated 
(reviewed by Birks and López-Arrieta, 2002). As many clinically used L-type calcium 
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channel blockers are voltage-dependent (Bean, 1984; Sanguinetti et al., 1986; Kamp 
et al., 1989; Hughes and Wijetunge, 1993; Uneyama et al., 1999) it is tempting to 
speculate that this property contributes to these drugs’ favorable therapeutic window. 
As a consequence, current ion channel drug development efforts focus on the 
discovery of new state-dependent molecules. For example, there is ongoing activity 
to develop N-type calcium channel blockers against neuropathic pain. The N-type 
specific compound conotoxin MVIIA (marketed as Prialt) blocks this channel 
regardless of the channel state, given that there is a physiological membrane 
potential (Stocker et al., 1997; Feng et al., 2003). As mentioned in the previous 
section, it is used for the treatment of severe chronic pain not responding to opioid 
treatment (Miljanich, 2004; Schmidtko et al., 2010). However, despite its efficacy, the 
clinical benefit of Prialt is greatly limited by two factors. First, due to severe 
orthostatic hypotension (McGuire et al., 1997) intrathecal instead of systemic 
application is mandatory. Second, Prialt has a narrow therapeutic window, which is 
defined as the ratio of the dose inducing toxicity compared to the efficacious dose, of 
only a factor of 1.5-2.1 in animals and humans (Brose et al., 1997; Mathur, 2000; 
Staats et al., 2004). Side effects include severe, but reversible CNS impairment, 
including hallucinations, memory impairments, and speech disorder causing 
significant drop-out rates of 49% in clinical long-term study (Wallace et al., 2008). 
The mechanisms of action for these adverse effects are not well understood. 
However, several factors, like site-specific frequency dependence of neurotransmitter 
release and differential probability of N-type calcium channels to inactivate, suggest 
that state-dependent compound properties might ameliorate at least some of the 
adverse effects (reviewed by Snutch, 2005; Winquist et al., 2005). Abbadie et al. 
(2010) reported state-dependent N-type calcium channel block by Trox-1, a novel 
calcium channel blocker in development for treatment of neuropathic pain, which 
supports this hypothesis. CNS and cardiovascular side effects appeared at 20- to 
40-fold higher plasma concentrations compared to the required efficacious plasma 
concentration for reversing inflammatory-induced hyperalgesia and allodynia induced 
by nerve injury, underscoring the potential of this state-dependent blocker for 
systemic tolerability. However, it has to be noted that increasing state-dependent 
properties to enhance tolerability is only a hypothesis which awaits confirmation from 
clinical trials.  
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1.3.4 P/Q-type Calcium Channels as Potential Drug Target 
In the following, the involvement of P/Q-type calcium channels in channelopathies is 
briefly reviewed, which underlines the medical need for development of P/Q-type 
calcium channel modulators. However, up to now no P/Q-type selective calcium 
channel blocker is in clinical use. Therefore, possible approaches are mentioned 
which might aid the development of (selective) compounds.  
Mutations in CACNA1A, the α1A subunit encoding gene, are associated with three 
inherited human diseases: familiar hemiplegic migraine, episodic ataxia type 2 (EA2), 
and autosomal dominant spinocerebellar ataxia type 6 (reviewed by Pietrobon, 2010; 
Rajakulendran et al., 2012). Most mutations found in patients with familiar hemiplegic 
migraine, an autosomal-dominant disorder, lead to changes in the primary structure 
of the pore-forming α1A subunit. In mice these changes facilitate channel function and 
lower the threshold for cortical spreading depression (van den Maagdenberg et al., 
2004; Tottene et al., 2009), which is considered a pathophysiologcial correlate of 
migraine aura in humans (Hadjikhani et al., 2001). Specific block of P/Q-type calcium 
channels might have therapeutic potential in treatment of migraine as this can 
prevent spreading depression (Kunkler and Kraig, 2004; Tottene et al., 2011). On the 
contrary, several channel mutations have been reported causing impaired P/Q-type 
calcium channel function. Some of them lead to a higher susceptibility for absence 
epilepsy in mice (Fletcher et al., 1996; Ophoff et al., 1998) and humans (Jouvenceau 
et al., 2001). In line with this, P/Q-type calcium channel block was described to inhibit 
seizure activity in mice (Jackson and Scheideler, 1996). Other channel mutations, 
which can lead to complete loss of channel function, were identified in episodic ataxia 
type 2 patients (Guida et al., 2001). Moreover, expansion of the polyglutamine repeat 
at the C-terminus was found to facilitate P/Q-type calcium channel inactivation in 
recombinant channels (Toru et al., 2000) and was described to lead to degeneration 
of Purkinje cells and spinocerebellar ataxia 6 in humans (Zhuchenko et al., 1997). As 
there are no or only limited medications available for treatment of these disorders 
and P/Q-type calcium channel might also be involved in AD pathology (see section 
1.1.3.3, p.13), the development of P/Q-type calcium channel agonists and 
antagonists seems promising.  
The generation of specific P/Q-type calcium channel blockers, however, is obviously 
challenging: Only two selective blockers have been identified, ω-agatoxin IVA and 
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IVB, but this class of toxins does not meet the requirements for clinical development 
(see section 1.3.1, p.28ff). Nevertheless, development of peptidomimetics with an 
improved pharmacokinetic profile might overcome these issues, which was at least in 
part achieved for N-type calcium channel peptides (Menzler et al., 2000; Baell et al., 
2004). An alternatively strategy might be to screen LMW compound libraries using a 
selective ω-agatoxin-based radioligand displacement assay (Nimmrich and Gross, 
2012).  
This review also provides a comprehensive overview of drugs, which, to some extent, 
also block P/Q-type calcium channels, but are believed to exert their main 
therapeutic action via other targets. Examples of these drugs are: calcium channel 
antagonists and mood stabilizers (e.g., nimodipine; Diochot et al., 1995; Pazzaglia et 
al., 1998), antipsychotics (e.g., diphenylbutylpiperidines; Sah and Bean, 1994), 
anticonvulsants (e.g., gabapentin; Gee et al., 1996), anesthetics (e.g., isofluran; 
Study, 1994), and herbal medications (e.g., α-eudesmol; Horak et al., 2009). 
Development of novel more selective channel blockers with fewer side effects might 
benefit from an understanding from the precise off-target profile of these unselective 
drugs. 
As the P/Q-type calcium channel might be involved in AD and other disorders, this 
PhD work supported drug discovery efforts aimed at identifying novel P/Q-type 
calcium channel blockers (Mezler et al., 2012b). For this validation of a high 
throughput assay was supported via electrophysiological methods. In the light of the 
unselective profile of ion channel blockers in the clinic (see above) and results from 
previous and current drug discovery efforts on calcium channel blockers (Yamamoto 
and Takahara, 2009) we could not expect to identify compounds with calcium 
channel subtype selectivity. Therefore we focused on identification of functional 
selectivity (here, i.e. state-dependence). This PhD work designed an automated 
electrophysiological secondary screen to identify novel compounds which block 
inactivated P/Q-type calcium channels. Finally, state-dependent effects of two novel 
LMW compounds were quantified by manual electrophysiology.  
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Aims of the Study 
As reviewed in the introduction, AD is accompanied by increased brain levels of 
soluble Aβ, and the toxic effects of some Aß species may ultimately underlie the 
cognitive deficits observed in patients (Cleary et al., 2005). Aβ oligomers have been 
shown to impair hippocampal synaptic function (Cullen et al., 1997; Selkoe, 2002; 
Nimmrich et al., 2010), induce presynaptic deficits (reviewed by Nimmrich and Ebert, 
2009), and modulate presynaptic HVA calcium channels (Bobich et al., 2004; 
Nimmrich et al., 2008a). In drug development state-dependency of ion channel 
modulators is currently believed to improve their tolerability for clinical use. Thus, 
targeting presynaptic calcium channels with state-dependent blockers may be 
considered as a promising therapeutic strategy for AD.  
The overarching goals of the study were to further elucidate the effect of oligomeric 
Aβ on HVA calcium channels, aid the development of novel LMW calcium channel 
blockers, and to evaluate the therapeutic potential of state-dependent calcium 
channel block in a hippocampal in vitro model of AD. Specifically, this study 
comprised the following objectives: 
1. Characterize calcium channel-dependent effects of oligomeric Aβ on synaptic 
transmission. 
2. Elucidate effects of oligomeric Aβ on calcium channel function. 
3. Identify novel calcium channel blockers and characterize state-dependent 
properties. 
4. Test whether state-dependent calcium channel block reverses oligomeric Aβ-
induced synaptic deficits. 
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2 Materials and Methods 
2.1 Chemicals and Biologics 
The calcium channel reference compounds ω-agatoxin IVA (Alomone Labs, 
Jerusalem, Israel) and ω-conotoxin MVIIA (Sigma, St. Louis, MO, USA) were 
dissolved at 0.5 mM and 0.1 mM in water, respectively. Roscovitine (Sigma, St. 
Louis, MO, USA) was dissolved in dimethylsulfoxide (DMSO) at 10 mM. Stock 
solutions were immediately stored at -20°C until fu rther use. The polyclonal P/Q-type 
calcium channel antibody (sc-16228; Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) was dialyzed (HiTrap Desalting Column, GE Healthcare Europe GmbH, 
Freiburg, Germany) against phosphate-buffered saline (PBS; Invitrogen, Darmstadt, 
Germany) and stored at 160 µg/mL in water at 4°C. 
Aβ globulomer was prepared (by the lab of Dr. Stefan Barghorn) as described in 
Barghorn et al. (2005). Synthetic Aβ1-42 peptide was dissolved in HFIP according to 
Stine et al. (2003), which was subsequently evaporated in a vacuum concentrator 
(SA-VC-300H; H. Saur Laborbedarf, Reutlingen, Germany). The peptide was then 
resuspended in DMSO and PBS containing 0.2% SDS. After 6 h incubation at 37°C 
the sample was further diluted with three volumes of water, incubated for 18 h at 
37°C and centrifuged at 3,000 g for 20 min, concent rated by ultrafiltration (30 kDa 
cut-off; Millipore, Billerica, MA, USA) and dialyzed against 0.25x PBS-buffer. This 
was centrifuged at 10,000 g for 10 min and the supernatant containing the 38/48-kDa 
Aβ oligomer, termed Aβ globulomer, aliquoted, and immediately stored at -80°C. The 
ultrafiltrate (5 kDa cut off; Millipore, Billerica, MA, USA) of Aβ globulomer, centrifuged 
at 3,000 g for 1 h, was used as a control for experiments. Synthetic Aβ1-42 peptide 
(H-1368; Bachem, Bubendorf, Switzerland) was dissolved in the respective solutions 
used for patch clamp experiments immediately prior to experiments. The molecular 
mass of the Aβ preparations was characterized through SDS-polyacrylamide gel 
electrophoresis (PAGE) using NuPAGE® 4-12% Bis-Tris gels and NuPAGE® MES 
SDS running buffers (Invitrogen, Darmstadt, Germany). Aβ globulomer 
concentrations are given with respect to the 12-mer complex, e.g., 83 nM of 
Aβ globulomer corresponds to a total concentration of 1 µM of monomeric Aβ1-42.  
 
2  Materials and Methods 
40 
2.2 Generation of Cell Lines and High Throughput Screening 
In the following, the creation of HEK293 (human embryonic kidney 293) cell lines is 
described, which stably express the P/Q-type and N-type calcium channel. HEK293 
cells were initially derived from transformation of cultured human embryonic kidney 
cells with the human adenovirus type 5 (Graham et al., 1977; Louis et al., 1997) and, 
as in this study, have been widely used as a simple heterologous expression 
system. Interestingly, neuron-specific protein expression was found in HEK293 cells 
suggesting they might originate from a neuronal cell lineage (Shaw et al., 2002). 
Stable cell line generation was carried out as described in Mezler et al. (2012b). For 
this, the respective calcium channel gene constructs were cloned into two 
expression vectors, which are plasmids used to introduce genes into cells. One 
vector carries the gene encoding the pore forming subunit of the respective calcium 
channel and controls its transcription level via a tetracycline sensitive promoter. 
Thus, functional calcium channels can only be expressed in tetracycline-induced 
cells. The other vector induces constitutive transcription of the genes encoding the 
calcium channel subunits. Cloning of the channel subunits, generation of stable 
HEK293 cell lines and fluorometric imaging plate reader (FLIPR) measurements 
were carried out by the lab of Dr. Mario Mezler.  
In specific, the human β1.1 subunit hCACNB1 (accession number NM_000723) and 
α2δ1 subunit hCACNA2D1 (accession number NM_000722) were amplified by PCR, 
cloned into the expression vector pBUDCE4.1 (Invitrogen, Darmstadt, Germany), and 
sequence-verified. The human P/Q-type calcium channel α1A subunit CACNA1A 
transcript variant 2 (accession number NM_023035) and human N-type calcium 
channel α1B subunit CACNA1B transcript variant 1 (accession number NM_000718) 
were each cloned into an inducible vector pcDNA5/FRT/TO (Invitrogen, Darmstadt, 
Germany) and sequence-verified.  
Then, HEK 293 T-Rex cells (Invitrogen, Darmstadt, Germany) were transfected in 
two subsequent steps with the prepared expression plasmids in a similar fashion as 
previously described for the rat P/Q channel by Lam et al. (2007). HEK293 T-Rex 
cells were transfected with the PvuI-linearized 
pBudCE4.1/hCACNB1.1/hCACNA2D1 plasmid employing Lipofectamine as 
described by the manufacturer (Invitrogen, Darmstadt, Germany). Briefly, 2.5 x 106 
cells were seeded in 10 cm Petri dishes (Greiner Bio One, Frickenhausen, Germany) 
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with DMEM Glut HG medium (Invitrogen, Darmstadt, Germany) and incubated in a 
humidified incubator at 37°C, 5% CO 2 overnight. On the following day, 2 µg of the 
plasmid was dissolved in 100 µL Optimem Glutamax medium, and 12 µL 
Lipofectamine was dissolved in 100 µL Optimem Glutamax medium. After 5 min 
incubation at room temperature, the two samples were mixed and incubated for 
additional 20-30 min at room temperature. Subsequently 0.8 mL Optimem Glutamax 
medium (Invitrogen Darmstadt, Germany) was added and the mixture used 
immediately for transfection. For this, the cells in the Petri dishes were first washed 
twice with Optimem Glutamax medium, and 2 mL medium was added to each petri 
dish. 1 mL of the Lipofectamine/plasmid mixture was added to each dish and the 
cells incubated for 5 h at 37°C, 5% CO 2. The medium was changed to DMEM Glut 
HG medium, changed twice the following day, the cells split (1:5, 1:10, 1:50, 1:100, 
1:250, 1:500, 1:1000 and undiluted), and transferred to selection medium containing 
DMEM Glutamax HG + charcoal-treated and dextran-treated FBS (Thermo 
Scientific/HyClone, Logan, USA), with 5 µg/mL blasticidin (Invitrogen, Darmstadt, 
Germany) and 200 µg/mL zeocin (Invitrogen, Darmstadt, Germany). After 14-28 
days single cell clones were isolated, expanded, transiently transfected with the 
human CACNA1A.2 subunit in pcDNA3.1 (Invitrogen, Darmstadt, Germany), tested 
in FLIPR (see below) for activity, and the most active single cell clones were 
passaged further. Clone K8 demonstrated the most robust calcium signal after 
transient transfection of the pore forming subunit. Subsequently, the inducible α1A 
subunit - as a MunI linearized pCDNA5/TO/hCACNA1A.2 plasmid – and the 
inducible α1B subunit - as a MunI linearized pCDNA5/TO/hCACNA1B plasmid – were 
transfected into responsive cell clones including K8, as described above. After 
14-28 d in selection medium (DMEM Glutamax HG, 10% charcoal and dextran 
treated FCS, 5 µg/mL blasticidin, 200 µg/mL Zeocin, and 150 µg/mL hygromycin) 
single cell clones were selected and tested in the FLIPR assay (see below) and by 
patch clamp electrophysiology. The best clones were chosen, expanded for batch 
production and cryopreserved with Recovery Cell Culture Freezing (Invitrogen, 
Darmstadt, Germany) as described by the manufacturer. 
For characterization of clones in the FLIPR assay 40,000 cells per well from cell 
culture or 60,000 cells per well from frozen stock were seeded into 96-well plates 
(poly-D-Lysine coated BIOCOAT 96-well plates, Becton Dickinson, Heidelberg, 
Germany) in DMEM Glutamax HG medium, containing charcoal and dextran treated 
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FCS and 1 µg/mL tetracycline (Sigma, St. Louis, USA), and incubated at 37°C. After 
48 h the medium was exchanged for DMEM containing 1 µg/mL tetracycline, but 
without glutamine or serum. Cells were incubated for additional 2-3 h at 37°C, and 
loaded with the Calcium 4 Dye (Molecular Devices, Ismaning, Germany), pre-diluted 
1:2 in HBSS/HEPES with 12 mM Ca2+ and 5 mM Mg2+. Activation of the calcium 
channels was achieved through depolarization of the cells by adding KCl. 
Measurements were performed in a FLIPR384
 
device (Molecular Devices, Ismaning, 
Germany). 
For high throughput screening (carried out by the lab of Dr. Sujatha Gopalakrishnan, 
Abbott Laboratories, Chicago), calcium measurements were performed using 
FLIPRTetra (Molecular Devices) and the use of the Calcium 5 Dye (Molecular 
Devices). Here, cell depolarization and channel activation was obtained by replacing 
the assay buffer (HBSS with 12 mM Ca2+ and 5 mM Mg2+, 20 mM HEPES) with a 
buffer containing a high KCl concentration (final concentration: 5 mM CaCl2, 60 mM 
KCl in HBSS without Ca2+, Mg2+, with 20 mM HEPES). 
 
2.3 Patch Clamp Recordings 
The patch clamp technique, which was first described by Neher and Sakmann 
(1976), enables functional analysis of ion channels (patch clamp technique reviewed 
by Numberger and Draguhn, 1996) and has been considered as the gold-standard 
for investigating direct ion channel modulation (Terstappen et al., 2010). Here, data 
was obtained by whole-cell recordings, which enable electrical access to the entire 
cell and, thus, record the current flow across multiple ion channels. Cells were 
patched at room temperature using a manual and an automated 4-channel Patchliner 
(Nanion GmbH, Munich, Germany) recording setup (see Figure 2.1, p.47).  
At least 7 d prior to the electrophysiological experiments, HEK293 T-Rex cells were 
thawed and cultured in poly-D-Lysine coated flasks (Greiner Bio-One GmbH, 
Frickenhausen, Germany) at 37°C and 7% CO 2. For passaging twice a week, cells 
were washed with PBS without calcium and magnesium (Invitrogen, Darmstadt, 
Germany), incubated with Accutase for 2 min at 37°C  (Sigma, St. Louis, MO, USA), 
lifted of the culture flask by gentle tapping, and diluted in selection medium. Culture 
density and quality was assessed using the electric-field counting system Casy 
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(Schärfe Systeme, Reutlingen, Germany) and cells were discarded if the viability fell 
below 90%. After counting, cells were transferred into new culture flasks containing 
selection medium. Cells were kept in culture for up to 20 splits post-thaw at an 
approximate confluency of 50-80%. Channel expression was induced 1-4 d prior to 
experiments with 1 µg/mL tetracycline, while the selection antibiotics zeocin and 
hygromycin were omitted.  
 
2.3.1 Manual Patch Clamp 
Prior to manual voltage-clamp and current-clamp experiments, cells were plated in 
24-well plates (Costar, Corning, NY, USA) at densities of 2 x 104 cells/well on 
uncoated, 12 mm diameter glass slides (Menzel, Braunschweig, Germany), which 
were previously washed with sterile water (Sigma, St. Louis, MO, USA). Prior to 
recordings, glass slides were washed in the respective external recording solution 
(see below), put into the manual recording chamber, which was situated within a 
faraday cage and mounted on a cushioning table (Science Products, Hofheim, 
Germany). All compounds were applied in a 1:3 fashion to the recording chamber. 
Pipette tips and cells were visualized by an inverted Olympus IMT-2 microscope 
(Olympus Deutschland, Hamburg, Germany). Pipette manipulators were electrically 
controlled by an SM1 control unit (Luigs & Neumann, Ratingen, Germany). Data was 
acquired and low pass filtered (4-pole Bessel) at 3 kHz with an Axonpatch 200B 
amplifier (Molecular Devices, Sunnyvale, CA, USA). Data was digitized by a 
Power1401 analog-digital converter at a sampling rate of 20 kHz, recorded by the 
Signal 3.14 software (both Cambridge Electronic Design, Cambridge, UK), and 
stored on a personal computer.  
 
2.3.1.1  Voltage-clamp 
After the patch pipette was manipulated onto a cell and a high resistance (GΩ) seal 
was formed, voltage-clamp whole-cell recordings were obtained by mechanically 
rupturing the cell surface. This causes the cytosolic solution to be passively replaced 
with the solution in the patch pipette. Moreover, due to a low series resistance (RS) 
(being only about 2-5 times larger than the initial pipette resistance) a good electrical 
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access to the cell is obtained, which supports fast and accurate voltage control of the 
cell. Therefore, whole-cell voltage-clamp recordings were used to study the 
biophysical and pharmacological properties of P/Q-type and N-type calcium 
channels. 
For whole-cell experiments all solutions were filtered with a polyethersulfone 0.22 
µm unit (Millipore, Billerica, MA, USA), aliquoted, and stored at -20°C. Pipettes were 
filled with the following solution (in mM): 110 CsCl, 10 EGTA, 25 HEPES, 4 Mg-ATP, 
0.3 Na-GTP; pH 7.3 adjusted with CsCl; 295 mOsmol adjusted with sucrose. During 
experiments this solution was kept on ice and was again filtered during tip filling by a 
0.2 µM nylon filter unit (ThermoScientific, Rochester, NY, USA). The solution 
surrounding the exterior of the cell (here denoted as extracellular solution) was 
stored at 4°C, used for a maximum of 2 weeks, and c omprised (in mM): 130 NaCl, 
10 BaCl2, 20 glucose, 10 HEPES; pH 7.3 adjusted with NaOH; 305 mOsmol 
adjusted with sucrose.  
Borosilicate pipettes were prepared by a micropipette puller P-97 (Sutter Instrument, 
Novato, CA, USA) and their resistance of 2-4 MΩ was estimated in the recording 
chamber by application of a 5 mV biphasic square pulse and slight positive pressure 
within the pipette. Once the pressure was released and the pipette became cell 
attached the holding potential was switched from 0 to -80 mV which aided giga seal 
formation. Whole-cell conformation was then obtained through suction, which was 
immediately relieved after the square pulse-induced transient currents became 
significantly larger due to the increase in capacitance. Cells were equilibrated for at 
least 5 min before experiments were started to allow for the passive exchange of 
cytosolic with the solution of the pipette. After equilibration, voltage-dependent 
activation was assessed in each cell by generation of a current-voltage (I-V) 
relationship by measuring peak amplitudes during step depolarization at various 
potentials (as described in detail in chapter 2.6).  
Whole-cell recordings were discarded when series resistance (Rs) exceeded 10 MΩ 
during baseline conditions or 20 MΩ anytime during the experiment. Rs was 
compensated online by ~95%. As cells were excluded if seal resistance dropped 
below 200 MΩ anytime during the experiment (in most cases seal resistance 
remained above 1 GΩ throughout the experiment) the resulting ratio 50/ ≥seriesseal RR
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enabled us to neglect the voltage drop caused by the remaining uncompensated Rs. 
In rare cases experiments were discarded because channel activation occurred in a 
step-wise or non-exponential fashion during test pulse depolarizations. As this 
became more pronounced or more frequent when Rs compensation was disabled or 
interconnected cells were patched, this current shape was most likely due to 
technical artifacts like lack of temporal and/or spatial voltage control. Therefore, only 
single, isolated cells were recorded. 
Unless otherwise noted, the holding potential was set to -80 and -90 mV for the 
recombinant P/Q-type and N-type calcium channel, respectively. Different potentials 
were chosen, because at -80 mV slightly increased run-down was observed for N-
type currents and inactivation occurred at more hyperpolarized values for this 
channel. The test pulse was applied close to a potential inducing the maximum 
current response, which constitutes 20 and 10 mV for our recombinant P/Q-type and 
N-type calcium channel, respectively (see results). An intersweep interval of 12 s 
was used. For analysis of LMW compounds a 3 s prepulse was applied. The 
prepulse potential was set for each cell individually to induce about 30-70% of 
current inactivation. 
 
2.3.1.2  Current-clamp 
Current-clamp recordings were carried out in perforated whole-cell mode. In this 
configuration whole-cell access is not obtained by cell rupture but instead by small 
perforations of the membrane. Here this is obtained by the antibiotic gramicidin D 
(Sigma, St. Louis, MO, USA). It is supplemented to the solution of the pipette and 
upon contact with the plasma membrane forms transmembrane channels which are 
permeable for monovalent cations but not anions and larger cell contents (Kyrozis 
and Reichling, 1995; Tajima et al., 1996), which largely reduces cell dialysis. 
Consequently, this technique was applied to estimate the resting membrane 
potential as well as the potassium-induced depolarization of P/Q-type calcium 
channel expressing cells under near physiological conditions. 
Gramicidin D was dissolved in DMSO at 50 mg/mL and stored at -20°C. Pipettes 
were filled with solution containing 150 mM KCl and 10 mM HEPES, which was 
supplemented with 75 µg/mL gramicidin D, thoroughly vortexed, and sonicated for 
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7 min. Pipette tips were first filled with solution lacking and subsequently backfilled 
with solution containing the antibiotic. After seal formation, cells were held at -40 mV 
and Rs was constantly controlled. For Rs < 200 MΩ the patch was considered 
perforated and the experiment was started. After at least 5 min of baseline 
recordings, the KCl concentration was increased to 60 mM in the external HBSS 
solution (containing 10 mM CaCl2 and 20 mM HEPES; Invitrogen, Darmstadt, 
Germany) for 3 min before returning to the baseline KCl concentration in the HBSS 
medium (5.3 mM). After the experiment was finished, cells were excluded if Rs had 
dropped below 40 MΩ, which may be indicative of successful whole-cell formation. 
 
2.3.2 Automated Patch Clamp 
Voltage clamp whole-cell recordings were also obtained from automated patch 
clamp experiments. Unlike manual electrophysiology, where electrical access is 
established through manipulation of a pipette to an adherent cell, the Patchliner 
automated patch clamp system (Nanion GmbH, Munich, Germany) captures 
suspended cells through suction onto a small hole. This hole is situated on a planer 
borosilicate chip surface, which serves as the interface between the extracellular and 
intracellular compartment (i.e. having access to the extracellular and intracellular 
side of the cell, respectively) for whole-cell recordings. 
For preparation of automated planar patch clamp recordings, cells were dissociated 
and isolated with trypsin (Sigma, St. Louis, MO, USA) or Accutase for 2 min, spun 
for 2 min at 100x g and re-suspended in buffer containing (in mM): 140 NaCl, 4 KCl, 
1 MgCl2, 2 CaCl2, 5 glucose, 10 HEPES; pH 7.4 adjusted with NaOH; 298 mOsmol. 
Cells were kept in a storage chamber at an approximate density of 1 x 106 cells/mL 
and were periodically pipetted up and down to maintain viability and dispersion. 
Planar chips with a resistance of approximately 2-3 MΩ were used for recordings. 
The control of suction to obtain GΩ seals and whole-cell configuration between the 
glass chip and the cell membrane as well as the estimation of RS, Cslow, and Cfast 
values was performed using the PatchControlHT software (Nanion Technologies 
GmbH, Munich, Germany).  
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Figure 2.1  The Patchliner – an automated planar patch clamp system (from Nanion 
GmbH, Munich, Germany). Top: Patch clamp platform including the robotic teflon-coated 
pipette arm, here positioned above the headstage. Lower left: Three-dimensional illustration 
of the extracellular (light blue shaded area) and intracellular (dark blue / grey shaded area) 
compartments from one individual chip. Cells are captured in a small hole at the intersection 
of these two compartments. The volumes around the openings of the two compartments 
comprise the respective waste reservoir. Lower right: Two-dimensional scheme of one chip 
including a cell depicted in whole-cell mode.  
Upon start of an experiment, the intracellular compartment of the chip was filled with 
a solution comprising (in mM): 50 CsCl, 10 NaCl, 60 CsF, 2 MgCl2, 20 EGTA, 5 
BAPTA, 5 Mg-ATP, 0.3 Na-GTP, 10 HEPES; pH 7.2 adjusted with CsOH; 290 
mOsmol. The extracellular compartment of the chip was filled with the following 
solution used for recordings (in mM): 105 NaCl, 20 TEA-Cl, 20 BaCl2, 10 mM glucose 
and 10 HEPES; pH 7.35 adjusted with NaOH; 305 mOsmol. Subsequently, cells 
were automatically dispensed into the extracellular compartment and captured to the 
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hole of the planar patch clamp chips by suction. For seal enhancement, the 
extracellular compartment was washed with a solution comprising (in mM): 80 NaCl, 
3 KCl, 35 CaCl2, 10 MgCl2, 10 HEPES; pH 7.4 adjusted with HCl; 298 mOsmol. 
Whole-cell formation is obtained by transient application of -100 mbar negative 
pressure, which is increased by steps of -50 mbar (to a maximum of -350 mbar) until 
Rs < 40 MΩ and Cslow > 2 pF is obtained. After successful whole-cell formation, 
solution of the extracellular compartment was again exchanged with the solution 
used for recordings (see above). Channels with Rseal < 200 MΩ or insufficient whole-
cell formation (Rs > 40 MΩ or Cslow < 2 pF) were excluded from the measurement. Rs 
was compensated online by 70-90%. 
The holding potential was set to -90 mV. Channel opening was elicited by stepping 
the potential to 20 mV for 20 ms each 12 s. I-V relationships were generated by 
measuring peak amplitudes during step depolarization to given potentials. For 
analysis of LMW compounds a 3 s prepulse was applied. The prepulse potential was 
set for each cell individually to induce about 30-70% of current inactivation. 
Compounds were dissolved in the recording solution and applied to the extracellular 
compartment by complete exchange of solution. Data acquisition was performed 
with an EPC10 amplifier and a PatchMaster software package (all HEKA Electronics, 
Lambrecht/Pfalz, Germany). As recordings were obtained from four independent 
chips in parallel a HEKA probe Selector (all HEKA Electronics, Lambrecht/Pfalz, 
Germany) was used to switch the amplifier control between these four independent 
channels. 
 
2.4 Hippocampal Slice Culture Preparation 
As described in the introduction, the hippocampal region has been an intensively 
investigated cortical structure due its well-structured cytoarchitecture and important 
physiological function including memory and learning. Hippocampal slice cultures are 
a well-studied in vitro model of the hippocampal region, which have been used to 
study several aspects of neuronal development or function including synaptic 
properties under non-pathological (Bonhoeffer et al., 1989) and pathological 
conditions (Nimmrich et al., 2010). Preparation of hippocampal slice cultures was 
performed by Tanja Georgi, Siena Kiess, and Michael Bahr. 
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Figure 2.2  The rat hippocampal formation (from Amaral and Witter, 1989). Bottom: 
Schematic drawing of the location and orientation of the rat hippocampus within the cortex. In 
this study, isolated hippocampi were chopped along the (orthogonal) transverse axis 
("TRANS"). "S" and "T" denote the septo-temporal axis. Top: Scheme of axonal projections 
(small letters) and histologically defined regions (capital letters) within a transversal 
hippocampal section. The Schaffer collateral (sc), which was stimulated in this study, 
transfers information from the hippocampal CA3 to the CA1 region. Abbreviations: DG, 
dentate gyrus; CA3, CA1, cornu ammonis fields of the hippocampus; S, subiculum; pp, 
perforant path fibers from entorhinal cortex; mf, mossy fibers from the granule cells. 
Organotypic hippocampal slice cultures were prepared as described by Nimmrich et 
al. (2010) from 9 to 12 day old Wistar rats (Janvier, Genest St.Ile, France), which 
were decapitated with sharp scissors without anesthesia. Hippocampi were isolated 
in Gey’s balanced salt solution (containing in mM: 138 NaCl, 4.9 KCl, 1.5 CaCl2, 
11 MgCl2, 333.3 glucose, 0.3 MgSO4, 0.2 KH2PO4, 0.8 NaH2PO4, 2.7 NaHCO3, and 
25 HEPES; pH 7.2; all chemicals from Invitrogen, Darmstadt, Germany, except 
HEPES from Sigma-Aldrich, Steinheim, Germany), which was previously cooled on 
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ice. Transverse, 400 µm thick hippocampal slices were prepared by using a tissue 
chopper (Mickle Laboratory Engineering, Gomshall, UK). 
Slices were cultured according to Stoppini et al. (1991) on millicell-CM membranes 
(Millipore, Billerica, MA, USA) in 40% basal medium Eagle (BME) with Earle’s salts, 
25% horse serum, 25% Earle’s balanced salt solution, 1 mM Glutamax I, 28 mM 
glucose, and 10% 250 mM HEPES in BME (all chemicals, except HEPES, from 
Invitrogen, Darmstadt, Germany) at 34°C, 5% CO 2. After 3 d media exchange was 
done with Neurobasal A medium (96.4% Neurobasal A medium, 2% B 27 
supplement, 1 mM Glutamax-I; all from Invitrogen Darmstadt, Germany) including 
25 mM D-glucose (Sigma-Aldrich, Steinheim, Germany). Media was previously 
filtered with a 0.2 µM polyethersulfone sterile filter unit (Thermo Scientific, Logan, 
USA). Hippocampal slices were cultured for 15-25 d before recording.  
All animal care and experimental procedures were according to the guidelines of the 
Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC) commission, and were approved by the government of 
Rhineland Platinate (Anzeige 2/92; AZ 889-13). 
 
2.5 Field Potential Recordings 
Within the hippocampal region, the Schaffer collateral - CA1 synapse has been 
widely studied, because of its laminar-organized structure exhibiting functional 
plasticity which correlates with cognitive measures like learning and memory, as 
previously noted in the introduction (Morris et al., 1986; Bonhoeffer et al., 1989). 
After simulation of the Schaffer collateral in organotypic hippocampal slice cultures, 
we used the strength of the resulting field excitatory postsynaptic potential (fEPSP) 
in the CA1 region to assess the functionality of synaptic transmission under several 
pharmacological conditions. 
Specific calcium channel toxins, Aβ globulomer, test compounds with potential 
effects on calcium channels and their respective controls were applied to the culture 
medium of organotypic hippocampal slice cultures 1 d prior recording. As control the 
corresponding vehicle concentration of water, DMSO, or Aβ globulomer ultrafiltrate 
was used. The P/Q antibody was applied 2 h prior to Aβ globulomer. 
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Slices were placed on in a Haas-type interface recording chamber (Harvard 
Apparatus, Hugstetten, Germany), which was supported by a cushioning table 
(Spindler & Hoyer, Göttingen, Germany). They were continuously perfused with 
substance-free artificial cerebrospinal fluid (composition in mM: 118 NaCl, 5 KCl, 
2 MgSO4, 2.5 CaCl2, 1.24 KH2PO4, 25.6 NaHCO3, 10 glucose, pH 7.4; gassed with 
carbogen (95% O2, 5% CO2)) at about 0.7 mL/min driven by a peristaltic Minipuls3 
pump (Gilson, Middelton, WI, USA). Slices were allowed to equilibrate in a 
humidified, carbogen-gassed atmosphere for at least 60 min at 32°C using a TC-10 
temperature control unit (npi electronic, Tamm, Germany). 
fEPSPs were recorded after stimulation of the Schaffer collateral as described by 
Nimmrich et al. (2010). The Schaffer collateral was stimulated with bipolar pulses 
(0.1 ms/phase) using a 0.5 MΩ bipolar tungsten electrode (WPI, Sarasota, FL, USA) 
at an interval of 60 s. Borosilicate glass recording electrodes (Harvard Apparatus, 
Hugstetten, Germany) were pulled by a vertical patch electrode puller (Ochotzki, 
Homburg/Saar, Germany) and filled with artificial cerebrospinal fluid. Their resistance 
was determined at 0.8-1.1 MΩ by a Omega tip-Z MΩ meter (WPI, Sarasota, Fl, USA). 
fEPSPs were recorded from the hippocampal CA1 region (see Figure 2.2 on p.49), 
after electrode placement by mechanical micromanipulators (Harvard Apparatus, 
Hugstetten, Germany). Signals were acquired by an Ext 10-2F amplifier (npi 
electronic, Tamm, Germany), 50 Hz noise reduced by a Hum-Bug (WPI, Sarasota, 
FL, USA), and digitalized at 10 kHz by a Power1401 (Cambridge Electronic Design, 
Cambridge, UK). Data was also visualized in parallel by a DL708E oscilloscope 
(Yokogawa Deutschland, Herrsching, Germany) to control for spontaneous 
discharges. In case of such discharges slices were excluded from analysis. 
 
2.6 Data Analysis 
Data from electrophysiological experiments was exported to Microsoft Excel 2003 
(Microsoft, Redmond, WA, USA) for offline analysis. For slice culture experiments 
input-output curves were created by plotting the fEPSP amplitude over stimulus 
intensity. For patch clamp experiments, command voltages were corrected offline for 
the liquid junction potential (Barry, 1994), which was calculated as 5.8 and 4.0 mV for 
manual and automated patch clamp solutions, respectively. Unless otherwise noted, 
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figures and calculated results were corrected for this offset, in contrast to the denoted 
voltage protocols.  
For I-V relationships, data was fitted with a combination of a first-order Boltzmann 
activation function and the Goldman-Hodgkin-Katz (GHK) current–voltage 
relationship (Kortekaas and Wadman, 1997): 
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with α = F/RT and gmax = αFP0[Ba+]out, where gmax is the maximal membrane 
conductance (which is proportional to the maximal permeability), Vh is the potential 
of half-maximal activation, and Vc is proportional to the slope of the curve at Vh. F 
represents the Faraday constant, R represents the gas constant, P0 is the maximal 
permeability, and T the absolute temperature. For these calculations the intracellular 
concentration of Ba2+ was assumed to be 10 nM. Assuming higher values of up to 
10 µM did not significantly change the results. For some illustrations I-V curves were 
normalized to the maximal response obtained from recordings in drug-free solution. 
Activation curves were calculated from ( )( )ch VVVVIVI /exp1/1)(/)( max −+=  applying 
the GHK constants calculated above. 
Inactivation curves were obtained by plotting the peak amplitude resulting from a test 
pulse against the potential of a proceeding prepulse. Similar to the activation curves, 
the voltage dependence of inactivation of the barium current was well described by a 
first-order Boltzmann function, which normalized the current as follows:  
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where N(V) denotes the level of inactivation determined from the current amplitude 
I(V) normalized to the maximum current Imax, V is the prepulse potential, Vinact is the 
potential of half-maximal inactivation, and Vc is a factor proportional to the slope of 
the curve at Vinact. For very short prepulses (< 1 s), potentials larger than 20 mV were 
not included in the fit. 
For pharmacological patch clamp experiments the last three responses of each 
incubation period were averaged for analysis and normalized to baseline level, which 
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was defined as the average of the last three drug-free responses. Unless otherwise 
noted, test pulses were applied at an interval of 12 s throughout the experiment. The 
equilibration period after obtaining whole-cell configuration was 5 min and baseline 
was recorded for another 2-5 min before pharmacological agents were applied. The 
compound incubation times were chosen to obtain (near) steady-state responses and 
are denoted in the results section for the respective experiment. Run-down correction 
was obtained using time-matched vehicle control cells, which resembled the exact 
application and incubation schemes of compound treated cells. For run-down 
correction, results from compound treated cells were normalized to time-matched 
controls: contolcpdcpd
corrected /= . For example, if a given compound application yields 
20% of the initial baseline current and its time-matched control 80%, the resulting 
run-down corrected value was estimated at 25% of baseline level. As time-matched 
controls also exhibited variation, error propagation needs to be considered, meaning 
that the relative error of a ratio is given by the sum of the squared relative errors of 
the dividend and divisor. Here, this translates into ( ) ( )22 Controlcpdcorrected σσσ += , where 
σcorrected denotes the run-down corrected relative error, σcpd and σcontrol denote the 
relative error of the compound and time-matched control measurements, 
respectively.  
Statistical analysis and data fitting was done using GraphPad Prism 5.03 (GraphPad 
Software, La Jolla, USA) applying a three-parameter sigmoidal fit for concentration 
response curves to estimate the IC50 and exponential fits for rate and decay 
constants. Values are represented as average ± standard error of the mean 
(S.E.M.). Error bars are not visible if they are smaller than the data point symbol. 
 
2.7 Statistics 
For patch clamp experiments, statistical comparisons were made with Student's 
t-test, one-way ANOVA, or one-way repeated-measure (RM) ANOVA. When 
applicable, Dunnett's post hoc analysis was applied to compare against control 
application. Input-output relationships in slice cultures were compared using a 
two-way RM ANOVA with Holm-Sidak post hoc analysis to compare all groups. A 
p value < 0.05 was considered significant. 
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3 Results 
There is converging evidence for the pathological role of Aβ in AD, as indicated in the 
introduction. In this study we have, therefore, investigated the effect of a highly 
stable, oligomeric Aβ1-42 preparation, termed Aβ globulomer. The corresponding 
epitope is found in AD patients and inhibits LTP in vitro, a physiological correlate of 
learning and memory (Barghorn et al., 2005). 
Figure 3.1  Characterization of the Aβ globulomer 
preparation. (A) Applying 4-12% Bis-Tris SDS-
polyacrylamide gel electrophoresis (PAGE) gels, 
Aβ globulomer exhibited strong bands at higher 
molecular weights corresponding to Aβ1-42 12-mers 
(”g”) as described in Barghorn et al. (2005). 
Monomeric and lower order forms were detected at 
considerably lower intensities. Lanes: 1, 
MagicMarkTM XP marker; 2, Aβ globulomer (50 pg); 
3, Aβ globulomer (250 pg). (B) Freshly dissolved Aβ1-42 
peptide exhibits mainly monomeric (“m”) and to a 
lower extent low order oligomeric fractions (“lo”) on the 
SDS-PAGE gel. Lanes: 4, Aβ1-42 peptide (450 pg); 5, 
Aβ1-42 peptide (4,500 pg); 6, SeeBlue® Plus2 marker. 
Before investigating the functional effects of Aβ globulomer (synthesized by Dr. 
Stefan Barghorn), we first validated this preparation by SDS-PAGE (Figure 3.1A). 
Upon qualitative analysis Aβ globulomer solution yielded the strongest bands at 
molecular weights corresponding to the published 38/48 kDa oligomeric complex 
(12-mer). In addition, at the higher Aβ globulomer concentration also low levels of 
~4 kDa (monomeric) and ~16 kDa (small oligomers) were detected. By contrast, the 
~4 kDa fraction was most prominent for the freshly dissolved Aβ1-42 peptide, which 
also exhibited lower levels of protein around ~16 kDa (Figure 3.1B). A smear was 
also detected at higher molecular weight levels in this gel, which appeared to be 
unspecific as it was independent of Aβ1-42 peptide concentration. Fibrillar aggregates, 
which hardly diffuse through the gel and thus remain adjacent to the gel pockets, 
were absent for both Aβ1-42 preparations. These results correspond well to the 
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described Aβ globulomer preparation published in Barghorn et al. (2005). We 
therefore used this preparation in our subsequent studies. 
 
3.1 Effects of Oligomeric Aβ on Synaptic Transmission are 
Calcium Channel-Dependent 
AD leads to progressive worsening of memory formation and retrieval in patients. 
One of the brain regions earliest affected by AD is the hippocampus (Scoville and 
Milner, 1957), a brain region necessary for memory and learning. Within the 
hippocampus, the excitatory, glutamatergic Schaffer collateral-CA1 synapse has 
been extensively studied. It is involved in activity-dependent plasticity such as short-
term and LTP and can be easily studied due to its laminar projections. Because of 
this, this synapse has served as a classical model for elucidating the basics of 
learning and memory (Bliss and Collingridge, 1993). 
Here it was investigated whether Aβ oligomer-induced functional deficits could be 
reversed by blocking calcium channels. To this end we examined extracellular field 
potentials from evoked synaptic responses in the CA1 region of the hippocampus 
after stimulation of the Schaffer collateral synapse in rat hippocampal organotypic 
slice cultures, as previously described by Nimmrich et al. (2010). (Data obtained from 
hippocampal slice cultures was partly generated by Tanja Georgi and Michaela 
Müller). Overnight incubation with 83 nM Aβ globulomer (corresponding to 1 µM 
monomeric Aβ1-42 peptide, see methods) was sufficient to decrease excitatory 
synaptic transmission compared to control application (Figure 3.2). Specific block of 
P/Q-type calcium channels with 500 nM ω-agatoxin IVA, a concentration above its 
IC50 value for P/Q-type calcium channels (Bourinet et al., 1999), successfully 
prevented synaptic decline (Figure 3.2A; p < 0.001, two-way RM ANOVA, Holm-
Sidak post hoc; n = 6-7 slices per group). By contrast application of 500 nM 
ω-agatoxin IVA alone did not change synaptic transmission. Next we collected 
evidence that preventing a direct interaction of Aβ globulomer with the P/Q-type 
calcium channel could ameliorate functional deficits in slice cultures. We saturated 
binding sites at the P/Q-type calcium channels with a polyclonal P/Q antibody for 2 h 
prior to Aβ globulomer treatment, which prevented deficits in synaptic transmission 
(Figure 3.2C; p < 0.05; n = 8-11 per group). Application of the antibody alone had no 
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significant effect on synaptic transmission (Figure 3.2D; p = 0.11; n = 10-11 slices per 
group). These data indicate that a direct interaction of Aβ globulomer with the P/Q-
type calcium channel causes synaptic impairment. 
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Figure 3.2  Effects of P/Q calcium channel modulation on Aβ globulomer-induced 
functional synaptic deficits. Organotypic slice cultures were treated overnight with 
Aβ globulomer and compounds. After washout excitatory synaptic transmission was 
investigated via input-output curves at the Schaffer collateral-CA1 synapse. fEPSP amplitude 
was decreased after application of 83 nM Aβ globulomer in A-C, indicating synaptic 
degeneration. All compounds were applied above their IC50 values. (A) The P/Q-type calcium 
channel specific blocker ω-agatoxin IVA (500 nM, constituting a concentration above the IC50 
value (Bourinet et al., 1999) reverses Aβ globulomer-induced deficits in excitatory synaptic 
transmission. This effect was not due to an intrinsic effect of 500 nM ω-agatoxin IVA. (B) 
Representative current trace examples from A. The stimulation artifact at the beginning of 
each trace is followed by the resulting fEPSP response, which decreases in amplitude after 
Aβ globulomer treatment. (C) Pre-saturation of slice cultures with 2 nM polyclonal P/Q 
antibody (sc-16228) for 2 h prevents Aβ globulomer-induced functional deficits in excitatory 
synaptic transmission. (D) Application of the P/Q antibody alone does not significantly alter 
neurotransmission. *p < 0.05, ***p < 0.001, two-way RM ANOVA; Holm-Sidak post hoc. 
(Adapted from  Hermann et al. (2013a), submitted) 
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Figure 3.3  Effects of N-type and L-type calcium channel blockers on Aβ globulomer-
induced functional deficits in synaptic transmission. (A) Specific N-type calcium channel 
blockade by 100 nM ω-conotoxin MVIIA protected from Aβ globulomer toxicity. (B) This 
concentration of ω-conotoxin MVIIA alone left fEPSP amplitude unaltered. (C) In contrast, 
10µM nimodipine, which preferentially blocks L-type calcium channels, did not reverse 
synaptic deficits induced by 83 nM Aβ globulomer. **p < 0.01, ***p < 0.001, two-way RM 
ANOVA; Holm-Sidak post hoc. (Hermann et al. (2013a), submitted). 
To test the specificity of this effect we also tested the potential of other calcium 
channel blockers on restoring synaptic transmission. Specific block of N-type calcium 
channels with 100 nM ω-conotoxin MVIIA, a concentration above published IC50 
values (Kaneko et al., 2002), also ameliorated Aβ globulomer-induced deficits in 
synaptic transmission (Figure 3.3A; p < 0.001; n = 8 slices per group). This 
concentration of ω-conotoxin MVIIA did not alter synaptic transmission when applied 
alone (Figure 3.3B; n = 8 slices per group). In contrast, 10 µM nimodipine, did not 
restore Aβ globulomer-induced deficits (Figure 3.3C; p = 0.21; n = 8 slices per 
group). This compound blocks L-type calcium channels at IC50s in the low single digit 
µM concentrations or below and possibly also other HVA calcium currents at 
2-10-fold higher concentrations (Diochot et al., 1995; Xu and Lipscombe, 2001). 
3.1  Effects of Oligomeric Aβ on Synaptic Transmission are Calcium Channel-Dependent 
59 
In summary, specific block of P/Q-type and N-type calcium channels reversed 
Aβ globulomer-induced functional deficits in synaptic transmission, whereas block of 
L-type calcium channels was ineffective.  
 
3.2 Oligomeric Aβ Modulates Recombinant Calcium Channels  
From these and previous (Nimmrich et al., 2008a) findings, we attempted to further 
characterize the effect of Aβ globulomer on P/Q-type and N-type calcium channels. 
For this, we studied recombinant channels expressed in HEK293 cells. Before testing 
the effect of acute Aβ oligomers, we first validated functional channel expression by 
analysis of their standard biophysical and pharmacological properties applying patch 
clamp whole-cell analysis.  
 
3.2.1 Biophysical and Pharmacological Validation of Functional Channel 
Expression 
We made use of several cell clones stably transfected with the accessory β1.1 and 
α2δ1 as well as the pore-forming tetracycline-inducible α1A subunit provided by Dr. 
Mario Mezler. Channel expression was previously tested in a FLIPR-based assay, by 
Dr. Mario Mezler, measuring intracellular calcium influx, which is triggered by raising 
the external KCl concentration. The FLIPR assay protocol and inducible channel 
expression was also functionally characterized by electrophysiological patch clamp 
recordings. 
In order to pre-select cell clones which potentially exhibit functional channel 
expression, initial screening of 80 single cell clones (carried out by Dr. Mezler) 
resulted in the identification of cell lines with high and reliable potassium-induced 
calcium signals (60 mM KCl and 10 mM CaCl2). Figure 3.4 shows the response of 
single clones after induction of channel expression with different tetracycline 
concentrations. For 3 selected cell subclones, K8-11, K1-19, and K1-33, Dr. Mezler 
evaluated the concentration/response-relation of KCl. These 3 lines were studied 
under both tetracycline-induced and non-induced conditions (Figure 3.4A; n = 2 per 
group). The EC50 values after tetracycline induction ranged from 35 to 40 mM for all 
three subclones. Notably, clones K8-11 and K1-33 responded only weakly to KCl 
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stimulation under non-induced conditions (maximal signal of 19% and 14% relative to 
induced response). In contrast the response of the clone K1-19 did not differ between 
induced and non-induced state (maximal signal 89% relative to induced response) 
indicating that transfection of the pore forming subunit resulted in loss or a silencing 
of the tetracycline-on promoter in this clone. 
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Figure 3.4  Characterization of selected cell lines with inducible P/Q-type calcium 
channel expression. (A) Concentration-response curve of KCl in three selected cell clones 
from FLIPR measurements. Tetracycline (Tet) induction is indicated by closed symbols, no 
induction (wo Tet) by open symbols. Cells were stimulated with buffer containing high 
potassium (60 mM KCl and 10 mM CaCl2). While cell clone K1-19 responds to KCl 
depolarization with or without tetracycline induction (■; □), clones K1-33 (▲; ∆) and K8-11 
(●; ○) demonstrate tetracycline-dependent responses. (B) Representative example traces 
from manual whole-cell recordings of non-tetracycline induced cells. Similar to the results 
obtained from A, cell clone K1-19 reveals inward currents without previous tetracycline 
induction unlike K1-33 and K8-11. The corresponding voltage protocol is shown in the upper 
panel. (A from Mezler et al. (2012b)) 
As part of this PhD thesis, functional channel expression was further validated by a 
more direct electrophysiological approach, namely by voltage and current clamp 
manual patch clamp recordings (Figure 3.4B). Without tetracycline induction clone 
K1-19 showed significant inward currents, whereas for clone K1-33 and K8-11 (n = 2 
each) no inward currents were detectable and only passive (leak) currents were 
measured. As a consequence, electrophysiological and FLIPR-based recordings 
yielded the similar result that K8-11 and K1-33 were two possible candidate 
subclones. Here, K8-11 was chosen for all further analysis. K1-33 may function as a 
backup cell line. 
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Figure 3.5  Basic biophysical characterization of P/Q-type calcium channels. 
Steady-state activation and open-state inactivation of P/Q-type calcium channels was 
recorded from tetracycline-induced HEK293 cells (clone K8-11), recombinantly expressing 
the full tripartite P/Q-type calcium channel, using manual whole-cell recordings. (A) Voltage 
protocol (upper inset) and corresponding raw traces applying 50 ms test pulses in voltage-
clamp mode. (B) Averaged I-V relationships. The line represents the fit obtained from the 
GHK-equation. (C) Representative current trace during a 1 s test pulse showing rapid 
activation and gradual inactivation. Upper inset: Corresponding voltage protocol. (D) Open-
state inactivation from four cells plotted as current (normalized to the peak amplitude) vs. 
depolarization time (grey = raw data, black = exponential fit). (Hermann et al. (2013b)) 
In order to further validate functional P/Q-type calcium channel expression, we 
analyzed the voltage-dependence of activation as well as the inactivation during 
sustained depolarization (open-state inactivation) applying manual whole-cell 
recordings. The obtained results were subsequently compared to data from previous 
reports on recombinantly expressed channels. Following tetracycline-induction, cells 
(clone K8-11) expressed voltage-dependent currents which qualitatively correspond 
to P/Q-type calcium channel characteristics (Bourinet et al., 1999), including the 
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expected kinetics of activation and open-state inactivation (Figure 3.5A, C). As 
shown in Figure 3.4B (p.60) and Figure 3.12A+B (p.78), without tetracycline-induction 
no inward currents could be recorded serving as negative expression control. 
I-V relationships from tetracycline-induced cells (Figure 3.5B; n = 26) exhibited that 
for each test pulse potential, the resulting peak current amplitude was reached within 
20 ms. The maximum of the I-V relationship was induced at command voltages 
between 10 and 20 mV (corresponding to 4.2 and 14.2 mV, respectively, after 
correction for liquid junction potential). In order to obtain a strong current amplitude 
and, thus, a low signal-to-noise ratio for future recordings, all subsequent 
experiments utilized depolarizing test pulses to 20 mV (14.2 mV if corrected for liquid 
junction potential). Prolonged test pulse potentials to 20 mV revealed strong open-
state inactivation by 93.7 ± 1.0% (Figure 3.5D; n = 4) of the initial peak amplitude 
after a depolarization time of 1 s. Current decay followed a single exponential 
function with an averaged decay time constant λ = 178 ± 19 ms, indicative of P/Q-
type calcium channel-like state transitions (Hans et al., 1999). These activation and 
open-state inactivation properties are comparable to previous reports on recombinant 
P/Q-type calcium channels using a similar splice variant and subunit composition 
(Bourinet et al., 1999; Hans et al., 1999).  
After initial current characterization we carried on with a pharmacological 
investigation of the recombinant P/Q-type calcium channel, in order to estimate the 
sensitivity of our calcium channel currents to reference compounds compared to 
reports from literature. In addition, the specificity of selective calcium channel 
blockers was tested on our recombinant cell lines. Using a test pulse potential to 
20 mV application of the P/Q-type calcium channel specific toxin ω-agatoxin IVA 
decreased currents with an IC50 = 237 nM (Figure 3.7A). In contrast, the N-type 
calcium channel specific blocker ω-conotoxin MVIIA, which blocks N-type currents in 
the low nanomolar range (Kaneko et al., 2002), did not decrease P/Q-type calcium 
channel currents up to a concentration of 30 µM (Figure 3.7A+B). Toxins were 
applied cumulatively with an 8 min incubation period for each concentration to obtain 
steady-state block. Currents were normalized to time-matched controls (Figure 3.7A; 
n = 5 / 4-6 / 7 for ω-agatoxin IVA / ω-conotoxin MVIIA / control per concentration).  
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Figure 3.6  Pharmacological validation of P/Q-type calcium channels. (A) 
Concentration-response curve of ω-agatoxin IVA and ω-conotoxin MVIIA obtained from 
manual whole-cell recordings on HEK293 cells recombinantly expressing the full tripartite 
P/Q-type calcium channel. Channels were activated by step depolarizations from -80 to 
20 mV for 50 ms. Currents were normalized to time-matched controls under buffer 
application. Right inset: Representative current response during depolarization to 20 mV of a 
cell before and after application of cumulative concentrations of ω-agatoxin IVA. (B) Channel 
activation (I-V relationship) of the recombinant P/Q-type calcium channel was suppressed by 
ω-agatoxin IVA, but not by ω-conotoxin MVIIA compared to control. Inset: Corresponding 
voltage protocol. (C) Enhancement of P/Q tail currents by roscovitine is illustrated by 
superimposed tail current traces from a representative cell induced by hyperpolarization from 
20 to -55 mV. Roscovitine was added in a cumulative fashion with the sequence a) control 
(dotted line), b) 5 µM roscovitine, c) 20 µM roscovitine, d) 50 µM roscovitine, e) washout 
(dashed line). (D) Quantitative results obtained from C. While 5 µM roscovitine only tended to 
increase the tail current, the increases at 20 and 50 µM were significant. Washout completely 
reversed the effect. *p < 0.05, ***p < 0.001, one-way ANOVA, Dunnett’s post hoc. (A+B from 
Hermann et al. (2013a, submitted); C+D from Mezler et al. (2012b))  
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The potency of ω-agatoxin IVA was in the expected range for recombinant P/Q-type 
calcium channels containing a –NP–  sequence at domain IV S3-S4 (Bourinet et al., 
1999) indicating that our recombinant cell line exhibits the expected sensitivity to 
pharmacological modulation by peptide channel toxins. Furthermore, 1 µM ω-
agatoxin IVA fully blocked currents across all voltage steps, while ω-conotoxin MVIIA 
treatment did not change the I-V relationship at any voltage applied compared to 
control (Figure 3.6B; n = 5 / 4 / 6 for ω-agatoxin IVA / ω-conotoxin MVIIA / control). 
This strongly indicates that the current recorded is fully mediated by P/Q-type 
calcium channels. 
In order to test if also LMW compounds affect the recombinant calcium channels 
properly we applied roscovitine, which has been described to enhance the tail current 
after quick hyperpolarization from a depolarized potential. This is because channel 
gating is modulated, including a slowing of the deactivation kinetics of the activated 
P/Q channel (Buraei et al., 2005). So this compound can provide hints about whether 
appropriate gating mechanisms are present in our recombinant channels. 
Roscovitine concentration-dependently enhanced the tail current in our P/Q-type 
calcium channel expressing cell line. The increase in tail current was significant at 
20 µM and 50 µM after 2 min of compound application (Figure 3.6D; 159 ± 13%* and 
260 ± 33%***; *p < 0.05, ***p < 0.001, one-way RM ANOVA, Dunnett’s post hoc; 
n = 13). After a washout of 1 min the tail current returned to baseline (102 ± 8%). 
Taken together, we conclude that following tetracycline-induction our P/Q-type 
calcium channel transfected cells express functional P/Q-type calcium channels, 
displaying proper characteristics comparable to published data. We therefore 
considered these cells suitable for investigating the effect of Aβ oligomers on 
P/Q-type calcium channels and to search for novel antagonists in drug screening 
efforts as recently published in Mezler et al. (2012b).  
After validation of the P/Q-type calcium channel expressing cell line, we similarly 
investigated our recombinant N-type calcium channel expressing cell line (Figure 
3.7). From FLIPR experiments cell clone 26 was pre-selected (by Dr. Mario Mezler, 
data not shown), which was used for all subsequent electrophysiological 
experiments. In order to examine functional channel expression, initial patch clamp 
experiments characterized channel activation. Upon depolarization, the shape of the 
raw trace and the resulting I-V relationship appeared qualitatively similar when 
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compared to the recombinant P/Q-type calcium channel (Figure 3.7A; n = 11). 
However, the maximum peak current of the N-type current occurred at slightly less 
depolarized values and was obtained around 10 mV step potential (4.2 mV when 
corrected for liquid junction potential). 
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Figure 3.7  Biophysical and pharmacological validation of N-type calcium channel 
channels. (A) Channel activation of the full tripartite N-type calcium channel recombinantly 
expressed in HEK293 cells was investigated by I-V relationships using manual whole-cell 
recordings. The line represents the fit obtained from the GHK-equation. Inset: Corresponding 
voltage protocol. (B) Concentration-response curve of ω-conotoxin MVIIA on N-type currents. 
These were blocked by cumulative application (4 min per concentration) of ω-conotoxin 
MVIIA with an IC50 = 1.5 nM. N-type currents were evoked by depolarization from -90 to 
10 mV for 50 ms and normalized to time-matched controls under buffer application. Inset: 
Representative peak currents before and after cumulative application of ω-conotoxin MVIIA. 
(B from Hermann et al. (2013a, submitted)) 
We then investigated the pharmacological sensitivity of the cell line. As expected, in 
contrast to the P/Q-type calcium channel expressing cell line, currents in the cell line 
recombinantly expressing the N-type calcium channel were potently blocked after 4 
min application of the N-type specific toxin ω-conotoxin MVIIA with an IC50 = 1.5 nM, 
applying a step potential from -90 to 10 mV. Unlike for recordings on P/Q-type 
calcium channels, a holding potential of -90 mV was applied here, because increased 
run-down was observed at -80 mV for the recombinant N-type calcium channel 
currents. Values were normalized to time-matched controls (Figure 3.7B; n = 3-7 / 4 
for ω-conotoxin MVIIA / control per concentration). These findings compare well to 
previous findings on similar human N-type calcium channel splice variants (Kaneko 
et al., 2002) indicating that our recombinant N-type calcium channels are sensitive to 
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pharmacological modulation and fulfill the main distinguishing feature compared to 
P/Q-type calcium channels (through sensitivity to ω-conotoxin MVIIA, see chapter 
1.2.1). We consequently considered functional channel expression as validated and 
suitable for analyzing the effect of Aβ oligomers on N-type calcium channels. 
 
3.2.2 Aβ Oligomers Facilitate Channel Activation at Intermediate 
Depolarized Potentials 
After validation of functional P/Q-type and N-type calcium channel expression, we 
investigated whether and how Aβ globulomer modulates these channels. We 
revealed that acute, non-cumulative (i.e. one concentration of a pharmacological 
agent per cell) application of Aβ globulomer affected voltage-dependent activation 
but not inactivation of the recombinant P/Q-type calcium channels (Figure 3.8).  
The I-V relationship illustrates that the peak current amplitude was altered at some 
test potentials 10 min after application of 830 nM Aβ globulomer (corresponding to 
10µM Aβ1-42 peptide (see methods); Figure 3.8A; n = 5-7 cells per group). However, 
the maximum of the I/V relationship occurred at similar membrane voltages for all 
Aβ globulomer concentrations. These findings were supported by quantitative 
analysis using activation parameters obtained from the best fit of the GHK-equation. 
The voltage at half activation Vh was shifted to more hyperpolarized values for the 
steady-state activation curve after application of 830 nM Aβ globulomer (Figure 
3.8B+C; for control / 8 nM / 83 nM / 830 nM Aβ globulomer: Vh = 6.9 ± 2.3 mV / 3.0 ± 
1.6 mV / 4.7 ± 2.4 mV / -4.6 ± 2.1 mV**; **p < 0.01, Student's t-test). This indicates 
that Aβ globulomer modulates the voltage-dependence of activation and therefore 
channel gating of recombinant P/Q-type calcium channels. In contrast, both the 
maximum conductance gmax and the slope of the I-V relationship VC remained 
unchanged (Figure 3.8C; for control / 8 nM / 83 nM / 830 nM Aβ globulomer: gmax = 
133 ± 42 nS / 148 ± 26 nS / 229 ± 78 nS / 125 ± 36 nS; VC = -6.1 ± 0.2 mV / -6.4 ± 
0.3 mV / -5.9 ± 0.2 mV / -6,2 ± 0.3 mV). This suggests that the conductance of each 
channel and the voltage range in which channel opening occurs, seen by an 
unchanged slope of the activation curve in Figure 3.8B, remain unaltered. 
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Figure 3.8  Modulation of P/Q-type calcium channels by Aβ globulomer. (A) The 
I-V relationship, obtained from manual patch clamp recordings on our P/Q-type calcium 
channel expressing cell line, was shifted to more hyperpolarized values after 10 min of 
Aβ globulomer application. Upper inset: Representative raw trace depolarized from -80 to 
-10 mV before and after application of 830 nM Aβ globulomer. Lower inset: Voltage protocol 
for I-V relationship. Cells were depolarized to the corresponding test potential for 20 ms. 
Each cell received only a single dose (n = 5-7 per concentration). (B) Steady-state activation 
curve of recombinant P/Q-type calcium channels generated with the parameters derived from 
the GHK-fit. 830 nM Aβ globulomer shifts the activation curve to more hyperpolarized 
potentials. (C) Activation parameters from the GHK-equation yield a difference in the voltage 
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at half activation Vh after application of 830 nM Aβ globulomer, but no differences in the 
maximum conductance gmax and the slope of the I-V relationship Vc for all concentrations 
tested. (D) Steady-state activation curve after 10 min of 10 µM Aβ1-42 monomer application 
(corresponding to 830 nM Aβ globulomer complex). Aβ1-42 monomer does not influence the 
voltage at half-activation Vh. (E) Steady-state inactivation curve after 10 min of 
Aβ globulomer application. Unlike the activation curve, the inactivation curve remained 
unchanged by 830nM Aβ globulomer when compared to control. Both the voltage at half 
inactivation as well as the slope of the inactivation curve was similar between treatments. 
**p < 0.01, one-way ANOVA, Dunnett’s post hoc vs. control. (Hermann et al. (2013a, 
submitted)) 
The corresponding concentration of freshly dissolved monomeric Aβ1-42 peptide 
(10 µM) did not influence the voltage at half activation Vh (Figure 3.8D; for control / 
Aβ1-42 monomer: Vh = 0.4 ± 0.8 mV / 1.1 ± 0.7 mV; n = 4 / 5 per group), the slope of 
the first-order Boltzmann equation Vc as well as the maximal conductance gmax (data 
not shown). This indicates that the previously observed effects on Vh were specific to 
Aβ globulomer and were not caused by the Aβ peptide per se. 
In order to reveal whether Aβ globulomer also modifies voltage-dependent channel 
inactivation, we also examined the inactivation curve after application of 830 nM 
Aβ globulomer. Inactivation was induced by 3 s prepulses, which is a duration 
commonly used to inactivate calcium channels (e.g., Nimmrich et al., 2008a) and 
was, here, sufficient to induce full inactivation (see also Figure 3.11, p.75). Prepulses 
were followed by a short 20 ms test pulse to 20 mV to activate the remaining, 
non-inactivated channels. As illustrated in Figure 3.8A+B, at this test potential no or 
very few effects are observed on channel activation, so that the resulting inactivation 
curve should not be altered due to effects on channel activation. This enabled us to 
exclusively study possible effects on voltage-dependent inactivation. We found that, 
unlike the voltage at half-activation Vh, the voltage at half-inactivation Vinact remained 
similar (Figure 3.8E; for control / 830 nM Aβ globulomer: Vinact = -34.9 ± 1.0 mV / 
-35.7 ± 0.8 mV), suggesting that voltage-dependent inactivation remains unaltered by 
Aβ globulomer.  
Taken together, this indicates that Aβ globulomer increases the probability of 
P/Q-type calcium channel opening at intermediately depolarized potential values 
(between -30 and 20 mV) without affecting channel inactivation. As Aβ globulomer 
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does not uniformly modulate all voltage-dependent properties of these channels 
unspecifically, these results would support a rather distinct mechanism of action. On 
a synaptic level, this modulation of P/Q-type calcium channel function would result in 
facilitated calcium influx upon action potential arrival at the presynapse and may 
increase neurotransmitter release. 
Since block of N-type calcium channels also rescued Aβ-induced functional synaptic 
deficits in hippocampal slice cultures illustrated in Figure 3.3 (p.58), we also tested 
the effect of Aβ globulomer on the closely homologous N-type calcium channel 
(Catterall et al., 2005). As noted previously, to minimize run-down for N-type calcium 
channel recordings a holding potential of -90 instead of -80 mV was applied. After 
10 min application of 830 nM Aβ globulomer, a shift in channel activation was 
observed as visualized by the I-V relationship and the activation curve (Figure 
3.9A+B; n = 5). Quantitative analysis of activation parameters yielded a significant 
shift of Vh (Figure 3.9C; for control / 830 nM Aβ globulomer: Vh = -0.9 ± 1.0 mV / 
-8.4 ± 4.7 mV**; **p < 0.01, Student’s t-test). As for the P/Q-type calcium channel, no 
difference in the slope of the I-V relationship and the maximal conductance was 
observed (Figure 3.9C; for control / 830 nM Aβ globulomer: Vc = -6.1 ± 0.1 mV / 
-6.4 ± 0.4 mV; gmax = 101 ± 25 nS / 106 ± 45 nS). In analogy to the results obtained 
from recombinant P/Q-type calcium channels, this suggests that voltage-dependent 
N-type calcium channel opening occurs at more hyperpolarized values. At the same 
time the relative voltage range in which channel opening can occur and the absolute 
conductivity of the channels is not affected. 
We subsequently investigated inactivation properties of the N-type calcium channel 
after application of 830 nM Aβ globulomer by application of 3 s prepulses. To 
maximize the signal-to-noise ratio a test pulse potential of 10 mV was applied. At this 
potential only minor effects of Aβ globulomer on channel activation are expected 
(Figure 3.9A+B) so that predominately effects of channel inactivation can be 
analyzed. We found no significant shift of the inactivation curve compared to control 
(Figure 3.9D; for control / 830 nM Aβ globulomer: -55.1 ± 0.7 mV / -56.7 ± 0.4 mV; 
n = 3). This suggests that voltage-dependent inactivation of the N-type calcium 
channel is not influenced by Aβ globulomer, as observed for the P/Q-type calcium 
channel.  
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Figure 3.9  Modulation of N-type calcium channels by Aβ globulomer. 
(A) I-V relationship after 10 min of Aβ globulomer application is shifted to more 
hyperpolarized potentials as compared to control application using manual whole-cell 
recordings of our N-type calcium channel expressing cell line. Upper inset: Representative 
raw trace depolarized to a test potential of -10 mV before and after application of 830 nM 
Aβ globulomer. Lower inset: Voltage protocol for I-V relationship. Cells were depolarized to 
the test potential for 20 ms. (B) Steady-state activation curve of N-type calcium channels 
calculated from A illustrates a shift to more hyperpolarized potentials after application of 
830 nM Aβ globulomer. (C) Activation parameters derived from A using the GHK-equation 
yields a left shift in voltage at half activation Vh for 830 nM Aβ globulomer, but no differences 
in the maximum conductance gmax and the slope of the I-V relationship Vc were found. 
(D) The inactivation curve remains unaltered by application of 830 nM Aβ globulomer as 
compared to control. **p < 0.01, Student’s t-test. (Hermann et al. (2013a, submitted)) 
To conclude, Aβ globulomer shifted voltage-dependent activation to hyperpolarized 
values for both the N-type and P/Q-type calcium channel, without altering 
voltage-dependent inactivation. 
3.2  Oligomeric Aβ Modulates Recombinant Calcium Channels  
71 
3.2.3 Effects of Aβ Oligomers Appear to be Independent of Channel 
State 
In order to elucidate the effect of Aβ globulomer on P/Q-type calcium channels in 
further detail, we examined its time-course and tested for possible state-dependent 
effects. For this, we compared the effect of Aβ globulomer application on 
recombinant P/Q-type calcium channels while giving test pulses either directly from 
the holding potential of -80 mV (denoted as resting state) or after a depolarizing 3 s 
prepulse (denoted as inactivated state, Figure 3.10). The prepulse voltage was 
adjusted for each cell so that about 50% of the channels were inactivated. Test 
pulses were given at -10 mV, because at this potential a strong current increase can 
be expected after Aβ globulomer application (see Figure 3.8A, p.67, and Figure 3.9A, 
p.70). Here, Aβ globulomer was applied cumulatively and incubated for only 2 min, 
as the observed current increase already reached a steady state within one or two 
sweeps given at a 12 s interval (Figure 3.10A). This, on the one hand, validates that 
the incubation times for previous patch clamp experiments on Aβ globulomer were 
sufficient. On the other hand, the lack of accumulating current increase after 
subsequent sweeps does not suggest frequency-dependent effects using these 
intersweep intervals. As expected from the previous experiments, 830 nM 
Aβ globulomer significantly increased peak currents. This increase in peak current 
was similar for resting and inactivated states, regardless of whether the different 
protocols were compared directly (data not shown) or data was corrected for 
run-down against the corresponding time-matched control (Figure 3.10A). Likewise, 
statistical analysis of the peak currents 2 min after cumulative application of 
Aβ globulomer resulted in a significant increase at 830 nM, but no significant 
differences between the two protocols (Figure 3.10B). The increase in current 
amplitude was reversible upon wash out. Currents already tended to increase at 
83 nM for both protocols compared to baseline level without reaching statistical 
significance using a two-way RM ANOVA (resting / inactivated state protocol (% to 
control): I8nM = 102 ± 3% / 102 ± 5%; I83nM = 155 ± 12% / 169 ± 16%; I830nM = 379  ± 
82%*** / 451 ± 97%***; Iwash = 127 ± 31% / 154 ± 43%;  ***p < 0.001, two-way RM 
ANOVA, Dunnett’s post hoc vs. control; resting state: n = 7 / 4 for Aβ globulomer / 
control, inactivation protocol: n = 7 / 5 for Aβ globulomer / control). 
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Figure 3.10  Effect of Aβ globulomer on different P/Q-type calcium channel states. 
(A) Time course of the peak current response after stepping from -80 to a test potential of 
-10 mV during increasing doses of Aβ globulomer at time points 0, 2, and 4 min. These 
manual whole-cell recordings were carried out by applying an inactivation protocol (black) 
and resting state protocol (grey). Data was corrected for the corresponding time-matched 
control (n = 5 and n = 4), respectively. Upper inset: Corresponding voltage protocols. 
Inactivation is induced via a 3 s prepulse at a voltage X, which was set individually for each 
cell to induce about 50% inactivation. (B) Quantification of current increase at a test potential 
of -10 mV after Aβ globulomer application derived from A. The last 3 data points were 
averaged for each concentration. 830 nM Aβ globulomer significantly increases P/Q-type 
currents at a test potential of -10 mV compared to control application for both the resting and 
the inactivation protocol. ***p < 0.001; two-way RM ANOVA, Dunnett’s post hoc vs. control. 
(Hermann et al. (2013a, submitted) 
Combining all electrophysiological findings, these data indicate that Aβ globulomer 
leads to a rapid and state-independent increase of P/Q-type and N-type calcium 
channel currents at moderately depolarized potentials. 
 
3.3 Identification of Novel State-Dependent P/Q-type Calcium 
Channel Blockers 
After identification that block of presynaptic calcium channels can be 
synaptoprotective and that oligomeric Aβ augments presynaptic calcium channel 
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currents, a primary (FLIPR, Dr. Mario Mezler) and a secondary compound screen 
(manual and automated patch clamp) was developed to detect, validate, and 
functionally characterize novel channel blockers. As stated in the introduction, 
state-dependence is in many cases considered a desirable drug property because it 
may induce functional selectivity thereby improving the therapeutic window. This may 
in turn increase the tolerability of the drug and overall success for future clinical trials. 
Thus, for the development of novel calcium channel blockers, potential compounds 
should be investigated and ranked by their potency not only on closed and open 
channels, but also on inactivated channels. 
 
3.3.1 Inactivation of Recombinant Channels Accumulates over Time 
As a prerequisite for state-dependent compound evaluation an appropriate screening 
protocol needs to be chosen, which depends on the inactivation properties of the 
channel of interest. Upon action potential arrival the amount of presynaptic calcium 
channels available for opening depends on the fraction of inactivated channels. As 
HVA calcium channels, given physiological conditions, are mostly present in 
non-conducting closed states, inactivation from closed states may be of special 
importance. Therefore, understanding the precise closed-state inactivation properties 
of heterologously expressed P/Q-type channels serves to optimize functional 
screening with the aim to identify compounds targeting the inactivated state of the 
channel. 
In order to determine voltage-dependent closed-state inactivation of P/Q-type 
calcium channels we applied various depolarizing prepulse durations and potentials 
(Figure 3.11). Varying prepulse potentials were utilized to create inactivation curves, 
to qualitatively examine the rate of inactivation from open and closed channel states, 
and to determine the voltage which induces half inactivation, which might be used for 
state-dependent compound characterization. Through the variation in prepulse 
duration we attempted to determine if steady-state inactivation was observed, which 
probably decreases variability between different experiments.  
We found that inactivation was dependent on prepulse voltage in a non-trivial 
manner. Strongest inactivation was reached at intermediate to slightly stronger 
depolarized potentials between 0 mV and 20 mV whereas even more positive 
3  Results 
74 
potentials caused weaker inactivation (Figure 3.11A; n = 4-8 per group). The 
resulting U-shaped inactivation curve suggests preferential inactivation from closed 
channel states as indicated in previous publications (Patil et al., 1998; Gera and 
Byerly, 1999). These studies attributed this phenomenon to complex transition 
kinetics between several closed and inactivated states, which occur at a faster rate 
than inactivation from open states. Physiologically, this mechanism probably 
underlies the faster inactivation of HVA calcium channels during trains of action 
potentials compared to sustained depolarizations; because this mechanism implies 
that (partial) hyperpolarization between action potentials would result in more 
channel inactivation compared to a constant sustained depolarization. Detection of 
this complex and physiologically relevant property indicates that our recombinant 
P/Q-type calcium channels exhibit proper state transitions.  
As Vinact, the voltage at half inactivation, was shifted depending on prepulse length in 
Figure 3.11A, we attempted to find out whether steady-state inactivation could be 
obtained with longer prepulses. For this, 10 s and 100 s prepulses were applied 
using an intersweep interval of 120 and 220 s, respectively, to allow for recovery from 
inactivation between sweeps. Even with these long prepulses, no steady-state 
inactivation was obtained, which is shown in Figure 3.11B by the linear correlation of 
Vinact with the logarithmic prepulse length (r2 = 0.97; slope = -13.9 ± 1.1). The linearity 
implies that a 10-fold increase in prepulse duration shifts Vinact by about -13.9 mV to 
more hyperpolarized values and that no steady-state inactivation can be obtained 
within the range of prepulse durations tested here. 
As elaborated in the discussion, for development of AD-related therapeutics we 
prefer to characterize state-dependent rather than use-dependent compound 
properties. To this end, it was determined whether the hyperpolarizing period to 
-80 mV between sweeps was sufficient for recovery from inactivation. Figure 3.11C 
shows a systematic comparison of inter-sweep intervals of 12 and 120 s in a protocol 
with prepulses of 3 s duration. The resulting inactivation curves were almost identical 
(Vinact = -22.6 ± 0.7 mV / -22.1 ± 0.7 mV for 12 / 120 s intersweep interval; n = 8 / 4). 
Thus, intervals of 12 s between depolarizing steps allow full recovery from 
inactivation at 3 s prepulses. Steady-state inactivation can involve multiple states, 
affecting the dependence of inactivation from prepulse duration. We therefore tested 
the degree of inactivation at different prepulse lengths (prepulse potential -30 mV). 
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Figure 3.11  Inactivation properties of P/Q-type calcium channels. 
(A) Voltage-dependent inactivation of peak currents applying manual whole-cell recordings at 
different prepulse lengths using test pulses from -80 to 20 mV for 20 ms (see inset). 
Inactivation curve dependency on prepulse length (in s: ● 3, ∆ 1, ▼ 0.3, ◊ 0.1, x 0.03). Solid 
lines represent first-order Boltzmann fit of data for prepulses from -80 up to 20 mV. Note 
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incomplete inactivation for short prepulses ≤ 1 sec and decrease of inactivation at highly 
depolarized prepulse potentials. (B) Potential of half-maximal inactivation Vinact’ (calculated 
from A and additional inactivation curves utilizing longer prepulse durations) vs. prepulse 
length (logarithmic scale). The solid line represents the best linear fit and reveals a strong 
correlation (r2 = 0.97). (C) Increasing the interpulse interval from 12 (●, black) to 120 s (○, 
grey) does not shift the inactivation curve at a prepulse length of 3 s. Lines represent the 
first-order Boltzmann fit. Inset: Corresponding voltage protocol. (D) Inactivation vs. prepulse 
duration (prepulse potential -30 mV, see inset). Increasing prepulse length from 1 to 300 s 
induced increasing levels of inactivation (n = 5-7). Data fit with a double exponential (solid 
line; r2 = 0.89) and single exponential (dotted line; r2 = 0.87) calculated from data points at 
prepulse lengths ≤ 10 s. (E) Recovery from inactivation after a 2 min re-polarization phase, 
same experiments as in D. Inactivation was fully reversible after 30 s prepulses, but not 
300 s. Inset: voltage protocol. **p < 0.01, Student’s t-test. (Hermann et al. (2013b)) 
Indeed, inactivation at prepulse length >10 s could only be poorly fit by a first order 
exponential equation (Figure 3.11D, dotted line; n = 5-7 per prepulse duration), in 
contrast to a double exponential equation (solid line). This suggests that inactivation 
might be mediated by two kinetically different processes, i.e. by fast and slow 
inactivation (see chapter 1.2.3, p.24ff). In the same experiment, we tested for 
recovery from prolonged inactivation. P/Q-type currents were inactivated by 
prepulses of 30 or 300 s duration, respectively. We then re-polarized the cell to -80 
mV for 2 min applying test pulses to 20 mV every 12 s (Figure 3.11E). Full recovery 
of the initial current amplitude was obtained for prepulses lasting 30 s, whereas 
prolonged prepulses of 300 s duration caused incomplete recovery (current recovery 
after inactivation: 101.0 ± 3.9% / 63.5 ± 7.3%** for 30 s / 300 s prepulse duration; 
**p < 0.01, Student’s t-test; n = 6 / 5; Figure 3.11E). Thus, prolonged depolarizing 
prepulses cause lasting inactivation of some fraction of the P/Q-type calcium channel 
mediated current indistinguishable from run-down. Although time-matched vehicle 
controls might compensate for that, this decay in current amplitude would 
nevertheless decrease the signal-to-noise ratio and increase cell-to-cell variability, 
which would be unfavorable for assay development.  
Taken together, our recombinant P/Q-type calcium channels resemble complex 
inactivation properties, which are a characteristic feature of functional HVA calcium 
channels (Patil et al., 1998). Moreover, kinetics and recovery of inactivation strongly 
depend on the choice of voltage- and time-parameters. We therefore decided to 
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apply 3 s prepulses for future studies, which is sufficient to induce complete but still 
reversible inactivation, 
 
3.3.2 Channel Activation, but not Inactivation is Similar between Manual 
and Automated Patch Clamp 
On the basis of the previous characterization of the complex inactivation behavior of 
our recombinant cell line, we aimed to develop a protocol for reproducible and 
reversible channel inactivation, suited for pharmacological screening purposes. The 
more pharmacological patch-clamp experiments are carried out the higher the 
chance becomes to successfully identify novel, potent (state-dependent) compounds. 
In order to increase the number of functional pharmacological experiments, 
automated patch clamp is being applied, since manual electrophysiology lacks 
sufficient throughput. For this purpose we aimed to establish and validate a 
state-dependent screening protocol for automated patch clamp which mimics manual 
patch clamp conditions as closely as possible.  
We first implemented and validated measurements on recombinant P/Q-type calcium 
channels on the automated system using voltage clamp analysis. Initially there was a 
strong rundown observed which was alleviated by addition of 5 mM BAPTA to the 
internal solution (data not shown). Without induction of P/Q calcium channel 
expression by tetracycline no appreciable current was obtained at any voltage steps, 
whereas after tetracycline-induction current traces were observed with a similar 
shape compared to previous manual patch clamp experiments on P/Q-type calcium 
channels (Figure 3.12A; middle / lower panel, respectively). This was also true for the 
I-V relationship, which revealed the maximal peak current at depolarization steps 
from -80 to 10 or 20 mV (Figure 3.12B, n = 10 / 22 for non-induced / induced cells, 
respectively).  
After establishing the automated recordings from our P/Q-type calcium channel 
expressing cell line, we compared these measurements with manual patch clamp in 
detail. At first, we analyzed P/Q-type calcium channel activation by application of the 
same voltage protocols between the platforms, which yielded identical results for 
I-V relationships and the resulting activation curves (Figure 3.13A+B; data also 
shown in Figure 3.5B, p.61, and Figure 3.12B, below). Quantitative parameters were 
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not significantly different for the two patch-clamp approaches (Figure 3.13C): voltage 
at half activation (Vh) was 6.1 ± 0.8 mV (manual; n = 26) and 7.2 ± 1.0 mV 
(automatic; p = 0.39, Student’s t-test; n = 22); slope of the I-V relationship (Vc) was 
-5.8 ± 0.1 mV (manual, n = 26) and -6.2 ± 0.2 mV (automatic, n = 22; p = 0.10); and 
maximal conductance (gmax) yielded 230 ± 33 nS (manual) and 301 ± 32 nS 
(automatic; p = 0.14). This shows that automated patch clamp yields identical results 
regarding P/Q-type calcium channel activation compared to manual patch clamp and 
is therefore applicable for investigation of channel activation.  
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Figure 3.12  Automated electrophysiological recordings from P/Q-type calcium 
channels. (A) Superimposed current traces from cells without (middle panel) and 48 h after 
induction with tetracycline (lower panel) obtained from automated whole-cell recordings. 
Upper panel: Corresponding voltage protocol for I-V relationships during automated 
whole-cell recordings. (B) Comparison of I-V relationships from non-induced (∆) and 
tetracycline-induced cells (●). Only for the latter group inward currents were observed at 
potentials typical for HVA P/Q-type calcium channels. (Mezler et al. (2012b)) 
Likewise, inactivation properties were compared between both systems using the 3 s 
prepulse protocol. In contrast to the activation parameters, voltage at half inactivation 
(Vinact) was significantly more negative in the automatic patch clamp system (Figure 
3.13E; manual / automatic: Vinact = -22.5 ± 1.8 mV / -33.6 ± 0.9 mV***, ***p < 0,001, 
Student’s t-test; n = 8 / 5). In order to elucidate the mechanism underlying this 
difference, we also used the same recording solutions for both systems. However, 
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this did not abolish or reduce the difference in inactivation curves (Figure 3.13E; Vinact 
remaining at -23.8 ± 1.1 mV; n = 6). 
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Figure 3.13  Validation of the automated patch clamp recordings for secondary 
screening on P/Q-type calcium channels. (A) Comparison of the I-V relationship of the 
manual (●, solid lines, data from Figure 3.5B) and the automated (Patchliner) system 
(□, dotted lines, data from Figure 3.12B) yield similar results across all voltage-steps applied. 
The lines represent the fit obtained from the GHK-equation. Inset: Corresponding voltage 
protocol. (B) Steady-state activation curves obtained from A. Lines were calculated from a 
first-order Boltzmann equation. No differences were observed between the systems. 
(C + D) Activation parameters Vh, Vc, and gmax obtained from A. Solid bars: manual patch 
clamp experiments; open bars: automatic patch clamp experiments. No significant 
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differences between both systems. (E) Inactivation curves can be different between the 
systems depending on the cell treatment prior to the experiment. Using the standard 
procedures (see methods), voltage at half inactivation (Vinact) occurs at about 10 mV more 
hyperpolarized potentials for automatic (□) as compared to manual (●) patch clamp 
experiments. Use of “Patchliner solutions” (see methods) in manual experiments does not 
eliminate this difference (∆). However, treatment of cells with Accutase (○) or trypsin (■) prior 
to manual recordings shifts Vinact to values similar to automatic patch clamp experiments. 
(F) Comparison of pharmacological modulation between both techniques. After 5 min 
application of the specific P/Q-type calcium channel blocker ω-agatoxin IVA currents were 
similarly blocked in both systems (● manual / □ automated: IC50 = 320 / 411 nM). (Hermann 
et al. (2013b)) 
We next tested for effects of the protease treatment, which was required to suspend 
the cells for automatic patch clamp recordings. When cells were dissociated with 
Accutase prior to manual recordings, Vinact was shifted to more hyperpolarized values 
similar to the results obtained with the automated system (Vinact = -33.6 ± 1.9 mV, n = 
4). A similar treatment of cells with trypsin also shifted inactivation voltage (Vinact = -
35.2 ± 1.5 mV, n = 3) to similar values as observed on the automated patch clamp 
platform. Thus, protease treatment of cells prior to recording causes a 
hyperpolarizing shift of about 10 mV in voltage-dependent inactivation properties of 
recombinant P/Q-type calcium channels. This shows that cell handling is crucial for 
the function of the P/Q-type calcium channel. These results further indicate that 
protocols designed to detect state-dependent compounds via induction of voltage-
dependent inactivation might need to be adjusted for automated patch clamp 
experiments 
In order to test whether protease cell treatment cells might also interfere with 
pharmacological modulation, we compared the potency of ω-agatoxin IVA (which 
binds to an extracellular domain) between manual (non-protease treatment) and 
automatic (protease treatment) recordings. Both approaches yielded similar 
concentration-dependent block of P/Q-type currents after 5 min of single-dose 
application (Figure 3.13F; manual / automated patch: IC50 = 320 ± 25 / 411 ± 111 nM, 
n = 4-7 / 4-6 per concentration). These values are in line with previous studies 
(Bourinet et al., 1999; Hans et al., 1999). This indicates that sensitivity to 
pharmacological modulation might not be altered due to protease cell treatment 
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implying that the automated patch clamp system is suited for pharmacological 
compound investigation. 
 
3.3.3 Compound Screening Reveals Novel Channel Blockers 
For detection of novel P/Q-type calcium channel modulators we established a 
screening cascade published in Mezler et al. (2012b). It comprises a FLIPR-based 
primary high throughput screening which identified 3262 validated hits, which 
inhibited the calcium signal below 10 µM in the respective concentration response 
evaluation. As part of this PhD thesis, depolarization of P/Q-type calcium channels 
under FLIPR assay conditions were validated electrophysiologically and following the 
determination of IC50 values by the FLIPR-based assay, an electrophysiological 
counter screen was established for post-hoc automated patch clamp analysis.  
Figure 3.14  Membrane potential of 
P/Q-type calcium channels during 
FLIPR assay conditions. Investigation of 
the membrane potential under varying 
external KCl concentrations using manual 
perforated patch clamp recordings 
Increasing external KCl concentration of 
the standard HBSS solution to 60 mM led 
to profound membrane depolarization, 
which was reversible upon washout of 
KCl. (Mezler et al. (2012b)) 
The recombinant cell line (clone K8-11) was utilized for a FLIPR-based primary 
screening assay to detect novel LMW P/Q-type calcium channel blockers (performed 
by Dr. Sujatha Gopalakrishnan). To prepare for this assay, we tested if the respective 
cell stimulation with KCl results in a sufficient depolarization of the cell for opening of 
the P/Q-type calcium channels. Thus, we analyzed cells by using the perforated 
patch-technique in current-clamp mode (Figure 3.14). The baseline potential in 
external HBSS medium was recorded for at least 5 min after perforation of the 
membrane was obtained. Increasing the external concentration of KCl from 5.3 mM 
in the normal HBSS buffer to 60 mM resulted in a fast depolarization, which was fully 
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reversible upon KCl washout (Vmem = -30.8 ±1.8 mV / -7.6 ± 1.3 mV*** / -28.77 ± 1.7 
mV for HBSS / HBSS with 60 mM KCl / HBSS; One way ANOVA with Dunnett’s post 
test, ***p < 0.001; n = 6). Taken together with the voltage-dependence of P/Q-type 
calcium channel activation (Figure 3.5B, p.61), this demonstrates that the cells 
sufficiently depolarized for P/Q-type calcium channel opening after KCl-induction 
under FLIPR-assay conditions. Furthermore, these experiments also show that our 
cells have a rather depolarized resting membrane potential, typical for HEK293 cells 
(Thomas and Smart, 2005), before KCl-induction. Considering the voltage-
dependence of closed-state inactivation obtained from electrophysiological patch 
clamp experiments illustrated in Figure 3.11 (p.75), a large fraction of the channels is 
probably inactivated during FLIPR baseline conditions. This implies that compounds 
with high affinity to inactivated P/Q-type calcium channels are likely to be detected in 
the FLIPR assay. 
In order to detect compounds that bind to the inactivated state of the channel in a 
secondary electrophysiological screen, we designed an automated patch assay with 
inactivating prepulses to allow for the detection of both state-independent and state-
dependent compounds. Initial attempts to develop a protocol where inactivation was 
induced with a constant moderate depolarization (e.g., a depolarizing shift in holding 
potential) resulted in unstable currents which ran down over time (similar to manual 
patch clamp recordings; see Figure 3.11D, p.75). A series of experiments determined 
that a depolarizing prepulse length of 3 s caused channel inactivation while 
maintaining stable current induction (data not shown). As described in Figure 3.13E 
(p.79), protease cell treatment, applied to suspend cells prior to automated patch 
clamp recordings, shifts inactivation to hyperpolarized potentials by about -10 mV. 
We therefore decided to shift the holding potential from -80 to -90 mV. As the 
inactivation curve (induced by a single prepulse for each potential) showed no 
significant inactivation at -80 mV this hyperpolarizing shift to -90 mV might not have 
been necessary. However, on the one hand, we wanted to avoid any slow 
accumulating inactivation which would be indistinguishable from run-down as 
illustrated in Figure 3.11D+E (p.75). On the other hand, it can be speculated that 
measurements might become more comparable between the methods if the potential 
difference between holding potential and Vinact remain similar. The resulting final 
screening protocol is depicted in Figure 3.15A. Based on our previous findings 
illustrated in Figure 3.13A (p.79), test pulses were applied at 20 mV in order to yield 
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the maximum current amplitude and signal-to-noise ratio. A 12 s interpulse interval 
was chosen, because at this time no use-dependent inactivation was observed 
(Figure 3.11C, p.75). A prepulse duration of 3 s was chosen, which can be sufficient 
to fully inactivate the channel, but at the same time does not induce (a detectable 
amount of) irreversible slow inactivation or run-down (Figure 3.11A+E, p.75). 
However, it needs to be noted that this duration does not induce steady-state 
inactivation (Figure 3.11B, p.75). Individual inactivation of each cell was estimated 
based on the current amplitudes during the prepulse protocol relative to the currents 
produced during an initial baseline period where no prepulses were applied. If 
necessary, the exact prepulse potential was adjusted for each cell individually so that 
the resulting inactivation was around 50%.  
Three control washing steps applying extracellular bath solution were included: the 
first started 1 min after successful whole-cell formation, the next started 1 min after 
the first washing was finished and the last 1 min after the start of the prepulse 
protocol. These steps were implemented because changes in current amplitude were 
occasionally observed for the first control application (10-20% of cells). In rare cases 
changes were observed after the second or third control application. In this case, 
cells were excluded from the analysis (less than 5% of cells, data not shown). Some 
run-down of current still occurred over time, so time matched control cells were 
recorded for run-down correction. To further minimize artifacts, we chose to perform 
single dose experiments, avoiding a cumulative application protocol that is often used 
for screening purposes. 
The stability of the current under different concentrations of DMSO was also 
examined while continuously applying the prepulse protocol (Figure 3.15B). This was 
necessary because compound aliquots were dissolved at a concentration of 10 mM 
in 100% DMSO. We found that run-down remained unchanged after an application 
of DMSO for 2 min as the current amplitude did not further decrease significantly at 
any concentration, and only a (non-significant) trend was observed for 0.3% DMSO 
(100.3 ± 5.1% / 98.7 ± 3.7% / 86.2 ± 5.4%; for 0.01 / 0.1 / 0.3% DMSO; p = 0.17; 
one-way ANOVA; n = 21 / 51 / 26). Thus, 0.1% DMSO was used as a control for all 
compound applications up to 10 µM. Multiple additions of the same compound on 
the Patchliner did not significantly increase current block, suggesting that unspecific 
adsorption did not occur on the Patchliner chips or pipette. 
3  Results 
84 
No 
prepulse
cpd
wash
1 min
time
A B
C
3s prepulse
-90 mV
X mV
20 mV
1/12 s
0,01% 0,1% 0,3%
0
20
40
60
80
100
[DMSO]
cu
rr
en
t (
%
 
to
 
w
/o
 
DM
SO
)readout
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
0
20
40
60
80
100
120
A
D
B
C
[compounds] @ 10 µM
c
u
rr
e
n
t (
%
 
o
f c
o
n
tr
o
l)
-2 0 2 4 6 8
0
20
40
60
80
100
1 µM
3 µM
10 µM
prepulses
no prepulses
[cpd A]
time (min)
cu
rr
en
t (
%
 
o
f c
o
n
tr
o
l)
No prepulse
20 mV
-80 mV 1/12 s
3s prepulse
-80 mV
X mV
20 mV
1/12 s
E
0.1 1 10
1
10
100
E
D
C
B
A
FLIPR IC50 (µM)
Au
to
m
at
ed
EP
 
IC
50
 
(µ
M
)
D
 
Figure 3.15  Implementation of patch clamp recordings to support the discovery of 
novel P/Q-type calcium channel blockers. (A) Experimental flow scheme including the 
voltage protocol for analysis of P/Q-type calcium channel block on the automated system. 
Washing steps were included to exclude application artifacts. The prepulse potential X was 
set so that about 30-70% of the current was inactivated and only one concentration was 
applied per cell. (B) Run-down was only mildly but not significantly affected by increasing 
concentrations of DMSO and compound concentrations up to 30 µM could be used in this 
electrophysiological assay (□ 0.01% DMSO, ■ 0.1% DMSO, ■ 0.3% DMSO). (C) Functional 
single-dose validation of high throughput screen and hit-to-lead hits on the automated 
system. Active compounds decrease currents compared to control application. IC50 values 
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were determined for compounds A-D using automated patch clamp. (D) Evaluation of 
inhibition of one selected compound (cpd A) by manual patch-clamp. The concentration-
dependent block was normalized to time-matched vehicle controls of 0.1% DMSO 
(● inactivation and ○ resting state protocol). The protocol is shown on the right. In this 
manual patch clamp experiment holding potential was set to -80 mV (as described in the 
text). (E) Correlation of IC50 values from automated voltage clamp recordings with FLIPR 
data. The solid line represents the best linear fit to the selected compounds (slope = 0.8 ± 
0.2; r2 = 0.81). Letters correspond to the compound labels shown in C. (Mezler et al. (2012b)) 
Using this inactivating prepulse protocol, we investigated a set of 27 compounds on 
the Patchliner, which were either previously identified as blockers by primary high 
throughput screening, or were representatives from the subsequent optimization 
cycles (Figure 3.15C; n = 3-9 per compound). Most compounds which blocked 
calcium influx in the FLIPR assay were active in this functional secondary 
electrophysiological analysis, which suggests that the calcium FLIPR assay is 
appropriate for identifying novel P/Q-type calcium channel inhibitors. However, a few 
compounds (4 out of 27; compound 12, 13, 23, 26), initially identified by the FLIPR 
screen did not block ≥ 25% of the current amplitude on the Patchliner at 10 µM. Due 
to this (arbitrary) cut off, these were considered as false positives from the FLIPR 
and were excluded from further analysis. To control whether our incubation time 
would be sufficient for reaching steady-state inhibition, we followed the time course of 
two compounds by manual patch clamp analysis, which were subsequently chosen 
for characterization of state-dependent properties. One example (compound A) is 
shown in Figure 3.15D (n = 3 per group) illustrating that a compound incubation time 
of 2 min turned out to be largely sufficient for reaching steady state inhibition 
especially when using the inactivated protocol. 
In order to validate the relevance of IC50 determination in the FLIPR assay, we 
compared IC50 values of compounds detected by the primary FLIPR-based screen 
with electrophysiologically determined potencies by automated patch clamp. IC50 
values measured on the automated patch clamp system correlated with the FLIPR 
results (Figure 3.15E, r2 = 0.81) and thus validated the use of FLIPR for analyzing the 
large amount of analogues during the hit-to-lead phase. In addition, compounds were 
more potent in the FLIPR screen compared to automated electrophysiology, which 
might be caused by different levels of inactivation as described in the discussion. 
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3.3.4 Characterization of State-Dependency of Selected Compounds 
Lead candidates deriving from the chemical compound optimization process were 
subsequently analyzed for level of state-dependence by manual patch clamp 
analysis and advanced into the downstream screening cascade. Searching for state-
dependent channel blockers requires protocols with high throughput, reliable 
inactivation, and fast recovery. For characterization of candidate substances, we 
therefore used prepulses of 3 s duration. Based on the recombinant P/Q-type 
calcium channel inactivation properties shown previously, this value represents an 
optimal compromise between full inactivation as well as fast and complete recovery. 
For assessment of state-dependent properties, we therefore we applied the prepulse 
and resting protocol illustrated in Figure 3.16A using manual patch clamp.  
The prepulse potential was adjusted for individual cells to induce about 50% of 
current inactivation. Two substances were tested for state-dependent inhibitory 
potency. They are termed A-1048400 and compound A (denoted as compound 1 and 
2 in Figure 3.15C, p.84, respectively) and were originally identified by 
pharmacological drug discovery on recombinant N-type and P/Q-type calcium 
channels (Mezler et al., 2012b; Scott et al., 2012). In manual patch clamp 
experiments, currents of sufficient amplitude were recorded for up to 6 min in drug-
free control solution (Figure 3.16B+C). To adjust for run-down, all amplitudes were 
corrected for the corresponding time-matched vehicle controls (n = 3 for each group). 
In a FLIPR-based screen the compound A-1048400, was found to decrease calcium 
influx with an IC50 = 1.2 / 2.1 µM  for recombinant P/Q-type / N-type / T-type calcium 
channels and compound A with an IC50 = 2.1 / 1.8 / 49 µM for recombinant P/Q-type / 
N-type / T-type calcium channels (data not shown). 
In our electrophysiological assessment A-1048400 blocked P/Q-type currents in a 
state-dependent manner. In resting conditions (without prepulse) and (partially) 
inactivated conditions the IC50 was estimated at 13.1 / 2.7 µM (Figure 3.16B; n = 3 
each) yielding a 5-fold shift in potency. For compound A, the amount of current block 
was less dependent on the channel state, reaching half-inhibiting concentrations of 
IC50 = 9.8 / 5.3 µM (~ 2-fold difference) for the resting / inactivated state, respectively 
(Figure 3.16C, n = 3 each). For comparison, the clinically used drug verapamil is 
considered to be state-dependent. After induction of ~ 50% closed-state inactivation 
as in this study, the state-dependence of verapamil was reported as ~3-4 fold for T-
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type calcium channels (Freeze et al., 2006). Data from Nawrath and Wegener 
(1997), who examined the block of verapamil on the open state including closed-
state and open-state inactivation in parallel for the L-type calcium channel, suggests 
more pronounced state-dependent effects (although not explicitly quantified). Trox-1, 
a state-dependent calcium blocker currently in development for neuropathic pain, 
was described as about 6-fold state-dependent by electrophysiological experiments 
(Abbadie et al., 2010). 
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Figure 3.16  Characterization of state-dependent properties of two novel P/Q-type 
calcium channel blockers. (A) Experimental protocol including cumulative compound 
applications and pulse protocols. Pre-pulse voltage was adjusted to yield about 30-70% 
channel inactivation. For analysis of block at resting channel state, prepulses were omitted 
before stepping to the test potential at 20 mV. (B) The concentration-response curve 
obtained from manual patch clamp recordings on A-1048400 reveals a 5-fold difference in 
potency (○ resting / ● inactivation protocol: IC50 = 13 / 2.7 µM). The concentration dependent 
block was normalized to the corresponding time-matched vehicle control for both resting and 
inactivation conditions. (C) Concentration-response curve for compound A reveals a 
moderate 2-fold shift in potency between the protocols (○ resting / ● inactivation protocol: 
IC50 = 9.8 / 5.3 µM). (Hermann et al. (2013b)) 
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Our results indicate that this protocol is suitable to discriminate between P/Q-type 
calcium channel blockers with different state-dependent potencies. In addition, two 
state-dependent tool compounds were identified after primary and secondary 
screening efforts (Mezler et al., 2012b) which can be tested for their potential to 
reverse Aβ-induced synaptic deficits in hippocampal synaptic transmission. 
 
3.4 State-Dependent Block of Calcium Channels Prevents 
Oligomeric Aβ-induced Synaptic Deficits 
Due to automated secondary screening and subsequent manual patch clamp 
analysis we were able to identify and validate two novel P/Q-type calcium channel 
blockers and quantify their state-dependent properties. Subsequently, it was 
addressed whether these compounds could also rescue Aβ globulomer-induced 
deficits in synaptic transmission in a similar fashion as the state-independent peptide 
toxins tested previously.  
Considering our previous patch clamp results on recombinant channels (see chapter 
3.3.4, p.86ff), we applied concentrations of the compounds slightly below their IC50 
for inactivated channel states. Assuming that compound potencies are similar for 
native channels, a significant fraction of inactivated channels, but only a minor 
fraction of closed channels should be inhibited in organotypic slice cultures.  
We found that 1 µM of compound A-1048400 and 3 µM of compound A was sufficient 
to completely prevent Aβ-induced functional deficits, respectively (Figure 3.17A+C; n 
= 8-9 per group each). The observed synaptoprotective effect was similar to the 
specific state-independent peptide blockers shown in Figure 3.2 (p.57) and Figure 
3.3 (p.58). Neither LMW compounds modulated synaptic transmission when applied 
alone (Figure 3.17B+D; n = 8-9 per group).  
In conclusion, Aβ-induced functional deficits in synaptic transmission can be reversed 
with state-independent as well as state-dependent calcium channel blockers. Thus, 
introducing state-dependence, which may represent a more favorable side effect 
profile, does not impair the synaptoprotective effect of calcium blockers. While 
maintaining their therapeutic potential, this may reduce unwanted effects on 
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physiological basal synaptic transmission and might be beneficial for drug 
development of novel AD drugs, as described in the introduction. 
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Figure 3.17  State-dependent P/Q-type calcium channel block prevents Aβ globulomer-
induced functional synaptic deficits. (A) Application of 1 µM compound A-1048400, a 
LMW compound which was previously identified as 5-fold state-dependent, fully prevents 
Aβ globulomer-induced deficits in excitatory synaptic transmission of organotypic 
hippocampal slice cultures. (B) 1 µM Compound A-1048400 does not alter synaptic 
transmission when applied alone. (C) Likewise, 3 µM compound A, which is only 2-fold state-
dependent, also reverses Aβ globulomer-induced deficits. (D) No intrinsic effects on the 
input-output curve were detected after application of 3 µM Compound A. *p < 0.05, two-way 
RM ANOVA, Holm-Sidak post hoc. (Hermann et al. (2013a, submitted)) 
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4 Discussion 
This study investigated a novel molecular mechanism of AD pathology, namely 
facilitation of presynaptic calcium channel currents by oligomeric Aβ. It furthermore 
showed that functional synaptic deficits can be prevented in nervous tissue by 
blocking presynaptic ion channels including the P/Q-type calcium channel. As this 
channel is preferably expressed in the CNS (Luebke et al., 1993; Stea et al., 1994), it 
would be particularly attractive to target this channel with future therapeutics. We 
therefore suggest P/Q-type calcium channel blockers as a possible therapeutic 
strategy for the treatment of AD.  
Beyond AD, P/Q-type calcium channels have also been implicated in a number of 
neurological diseases including migraine (Tottene et al., 2002) and epilepsy 
(Pietrobon, 2005). Block of P/Q-type calcium channels was also found to decrease 
seizure activity in mice (Jackson and Scheideler, 1996). At least for AD no effective 
therapy is available. Thus, this study here describes an electrophysiological 
secondary screen for the identification of novel P/Q-type calcium channel inhibitors.  
State-dependence of modulators, which predominantly bind to inactivated channels, 
might aid to achieve functional selectivity. This is because they are hypothesized to 
preferentially bind to pathologically overactivated channels rather than to 
physiologically activated channels. Therefore this property is believed to enhance the 
therapeutic potential of a drug candidate (Winquist et al., 2005). In order to detect 
state-dependent compounds, an appropriate (screening) protocol needs to be 
applied. Ideally, this protocol should closely mimic the pathological condition which 
often includes channel inactivation. This can only be achieved if inactivation of the 
respective channel complex has been previously characterized under (screening) 
assay conditions. We found that inactivation may be reversible or irreversible, 
depending on the applied depolarization protocol. In addition, channel activation was 
identical for manual and automated patch clamp, whereas voltage-dependent 
inactivation varied between the systems. Based on these results, we were able to 
establish a robust inactivation protocol suitable for screening, which in the end 
proved to be capable of detecting novel state-dependent P/Q-type calcium channel 
blockers. This functional assay was implemented into the hit-to-lead phase of an 
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active drug discovery program for the development of P/Q-type calcium channel 
blockers. 
 
4.1 Overactivation of Presynaptic Calcium Channels as a Potential 
Molecular Mechanism in AD 
Following the first suggestions that oligomeric Aβ aggregates may cause synaptic 
deficits in AD, there has been an extensive search for the underlying molecular 
mechanism (Walsh and Selkoe, 2007). As discussed below, several proteins that are 
involved in synaptic transmission have been suggested to be modulated in their 
function. 
Oligomeric Aβ was found to alter presynaptic function by an impairment of vesicle 
release at axon terminals in hippocampal neurons through depletion of dynamin 1, a 
protein involved in vesicle recycling (Kelly et al., 2005; Kelly and Ferreira, 2007). This 
finding was supported by detection of dynamin cleavage in APP-overexpressing mice 
(Kelly et al., 2005) and AD patients (Yao et al., 2003). This cleavage may in turn be 
mediated by calpain (Kelly et al., 2005), a protease also associated with 
neurodegeneration (Nimmrich et al., 2008b).  
NMDA receptors may represent another target for Aβ oligomers, as impaired 
presynaptic vesicle release can be prevented by NMDA receptor blockers (Kelly and 
Ferreira, 2006). This may be explained by findings that NMDA receptors are also 
located presynaptically (Berretta and Jones, 1996; Charton et al., 1999) affecting 
vesicle release (Woodhall et al., 2001). Moreover, after application of Aβ oligomers, 
Shankar et al. (2007) demonstrated an NMDA-mediated decrease in calcium influx 
into dendritic spines and Lacor et al. (2007) observed a downregulation of NMDA 
receptors. Furthermore, studies on Xenopus oocytes suggest that Aβ induces 
calcium influx through NMDA receptors in the absence of glutamate (Texido et al., 
2011) but does not facilitate calcium influx when glutamate is present (Mezler et al., 
2012a). These effects on NMDA receptor currents may both increase and decrease 
vesicle release. On the one hand, this might possibly induce vesicle release by a 
calcium influx even under non-excited conditions (in the absence of glutamate). On 
the other hand, constantly elevated intracellular calcium levels may decrease the 
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dynamic range of changes in calcium concentration during arrival of an action 
potential, which in turn may result in decreased vesicle release. Taken together, Aβ 
oligomers may modulate NMDA receptor function, thereby altering presynaptic 
vesicle release. 
The involvement of HVA calcium channels in the pathology of AD was suggested by 
Sberna et al. (1997). They described that the peptide fragment Aβ25-35 increased 
activity of acetylcholineesterase by facilitating calcium influx through L-type, but not 
P/Q-type and N-type calcium channels in embryonal carcinoma cells. In contrast, 
Bobich et al. (2004) observed an increase in neurotransmitter release probability 
which they attributed to an Aβ-mediated increase in N-type rather than P/Q-type and 
L-type calcium channel currents. In line with this, presynaptic modulation by Aβ was 
also reported to increase the release probability at presynaptic terminals leading to 
an increased network activity and lowered synaptic plasticity (Abramov et al., 2009). 
In addition, several studies in the past suggested that acute and chronic application 
of Aβ peptide influences calcium channel conductance (He et al., 2002). Both 
presynaptic P/Q-type and N-type (MacManus et al., 2000; Ramsden et al., 2002) as 
well as postsynaptic L-type voltage-gated calcium channel currents (Ueda et al., 
1997; Kim and Rhim, 2011) were reported to be modulated. As noted in the 
introduction, some of these conflicting results may be caused by the use of different 
Aβ fragments and poorly defined Aβ preparations probably containing a mixture of 
Aβ species, which may or may not be relevant in the pathology of AD. We here 
further investigated the functional relevance of these findings on the network and the 
cellular level, using Aβ globulomer, a stable, well-defined, and pathologically relevant 
oligomeric Aβ preparation (Barghorn et al., 2005; Gellermann et al., 2008). 
 
4.1.1 Presynaptic Calcium Channel Block Reverses Oligomeric 
Aβ-induced Deficits in Synaptic Transmission 
On the network level we tested whether block of HVA calcium channels may protect 
from synaptic deficits induced by oligomeric Aβ in organotypic hippocampal slice 
cultures. Previously, Nimmrich et al. (2010) showed that overnight incubation of 
these slice cultures with Aβ globulomer causes synaptic decline, as observed by a 
decrease in evoked glutamatergic transmission. They proposed that such a 
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functional decline might be a consequence of several detrimental mechanisms 
including excitotoxicity, which was observed after Aβ application in vitro and in vivo 
(Harkany et al., 2000). Besides other mechanisms, this in turn may potentially be 
caused by overactivation of HVA calcium channels as observed by Mezler et al. 
(2012a). Therefore, an initial increase in calcium channel function can in the end lead 
to decreased excitatory synaptic transmission on the network level. If so, decreasing 
calcium influx through a specific silencing of overactivated (presynaptic) calcium 
channels might prevent these functional deficits. 
Here we found that specific block of either the presynaptic P/Q-type or N-type 
calcium channel could in fact prevent oligomeric Aβ-induced deficits in excitatory 
synaptic transmission in organotypic hippocampal slice cultures. This indicates that 
block of these calcium channels may compensate Aβ oligomer-mediated effects. 
These may either be specifically mediated via P/Q-type and N-type calcium 
channels, which are presynaptically expressed at the Schaffer collateral-CA1 
synapse (Westenbroek et al., 1992; Westenbroek et al., 1995), or via other 
(unrelated) mechanisms. The former hypothesis is supported by the observation that 
pre-application of a P/Q-type calcium channel antibody also prevented Aβ oligomeric 
deficits. This beneficial effect might have been mediated by direct channel inhibition 
or preoccupation of the possible Aβ globulomer binding site(s). These findings are in 
line with reports from other groups showing that block of presynaptic calcium 
channels can prevent functional deficits and neuronal decline. For example, 
neuroprotective effects of both peptidic and LMW calcium channel blockers have 
been demonstrated in several models, including neuronal ischemia in vitro (Small et 
al., 1995) and in vivo (Valentino et al., 1993) as well as brain injury (Verweij et al., 
1997; Berman et al., 2000). Moreover, a common downstream pathway for a wide 
variety of neurological disorders may be an increased release of excitatory amino 
acids (Lipton and Rosenberg, 1994), which can be inhibited by P/Q-type calcium 
channel blockers during neuronal overactivation in vivo (Wu et al., 1995). This may 
explain why P/Q-type calcium channel blockers also protect against several neuronal 
insults (Jackson and Scheideler, 1996; Asakura et al., 2000) and may also be 
relevant for AD. This is because diminishing neuronal spike activity by levetiracetam 
– which also decreases P/Q-type calcium currents – not only reverses synaptic 
deficits, but also ameliorates learning and memory impairment in APP-transgenic 
mice (Sanchez et al., 2012).  
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Next, we tested the effect of nimodipine (10 µM), which has shown limited efficacy in 
clinical trials regarding dementia (Birks and López-Arrieta, 2002). This LMW HVA 
calcium channel blocker was described both as specific (Furakawa et al., 1999) and 
non-specific (Diochot et al., 1995) for L-type calcium channels, which are 
predominantly located postsynaptically (Castillo et al., 1994; Wheeler et al., 1994). In 
contrast to the specific presynaptic calcium channel blockers, this compound did not 
prevent Aβ-induced functional deficits in slice cultures. The potency and selectivity of 
nimodipine greatly varies between previous reports. It has been claimed by 
Mansvelder et al. (1996) as up to eight orders of magnitude selective for L-type 
calcium channels in rat pituitary melanotropic cells (L-type IC50 = 3 pM; P/Q-type 
IC50 = 500 nM). Another study, which observed current block at 10 µM only for L-type 
but not other HVA calcium channels on recombinantly expressed channels in 
Xenopus oocytes, also reported nimodipine as selective (Furakawa et al., 1999). 
However nimodipine may be less selective, because Diochot et al. (1995) reported 
1 µM as IC50 for L-type calcium channels but also a 51% decrease in current 
amplitude at 10 µM from dorsal root ganglion neurons containing P/Q-type, N-type, 
and to a lesser extent L-type calcium channels. This may lead to two alternative 
interpretations, depending on the specificity of the compound at 10 µM in our system. 
Given that nimodipine preferentially blocked L-type calcium channels, this would 
imply that somato-dendritic intracellular calcium levels do not modulate or participate 
in the Aβ-mediated pathology of our in vitro model. Assuming that nimodipine 
unspecifically blocked all HVA calcium channels, this would suggest that additional 
postsynaptic L-type calcium channel block may dampen the beneficial effect of 
presynaptic calcium channel block. Testing another, more specific, L-type calcium 
channel blocker may address which hypothesis holds true in this in vitro model of AD. 
To conclude, based on this data it would be exciting to investigate whether more 
selective blockers may exceed the clinical efficacy of nimodipine, which could bring 
about a new generation of antidementive medicine. 
 
4.1.2 Oligomeric Aβ Augments Presynaptic Calcium Channel Currents 
After identification of presynaptic calcium channel block as a protective mechanism in 
oligomeric Aβ treated hippocampal slice cultures, this work attempted to elucidate the 
underlying molecular mechanism. It was recently shown that synthetic Aβ oligomers 
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(Aβ globulomer) increase P/Q-type calcium channel currents, which were expressed 
in Xenopus oocytes (Mezler et al., 2012a), suggesting that enhanced 
neurotransmitter release may underlie the decline of synaptic function following 
prolonged exposure to Aβ oligomers. We confirmed this finding in a stable 
recombinant expression system using a human-derived cell line (HEK293). We 
further found that Aβ oligomers modulate both presynaptic P/Q-type and N-type 
calcium channels. This implies that synaptic function can be altered in any brain 
region accessible to soluble oligomeric Aβ. Compared to the organotypic 
hippocampal slice culture experiments, significant effects on recombinant channels 
were only observed at a 10-fold higher concentration of Aβ (although a trend was 
observed already at similar concentrations (Figure 3.10, p.72)). The enhanced 
sensitivity of synaptic transmission to Aβ globulomer in the slice culture experiments 
may be, on the one hand, caused by the chronic and thereby longer incubation times. 
So it may be that already very subtle effects on presynaptic calcium influx will lead 
overnight to deficits in synaptic transmission. On the other hand, acute effects of Aβ 
globulomer might be more potent in native channels, as suggested by previous 
reports applying extracellular field (Barghorn et al., 2005) and patch clamp recordings 
(Nimmrich et al., 2008a). 
Before studying the effect of Aβ globulomer on calcium channel kinetics, functional 
recombinant channel expression was successfully characterized by manual whole 
cell patch clamp. The currents recorded from the α1A transfected HEK293 cell line 
after tetracycline-induction were similar to published recombinant P/Q-type calcium 
channel currents (Hans et al., 1999). Non-induced cells showed no appreciable 
current after depolarization, indicating that the current obtained in tetracycline-
induced cells was generated by charge movements through the recombinant 
P/Q-type calcium channel. Pharmacological modulation with ω-agatoxin IVA inhibited 
the depolarization-induced current within the range of published values (Bourinet et 
al., 1999; Hans et al., 1999). Roscovitine, a less specific channel modulator, slows 
deactivation kinetics thereby increasing tail currents (Buraei et al., 2007), which could 
also be reproduced using the α1A transfected cell line. This was taken as a further 
hint for the appropriate gating of the recombinant channels. Furthermore, the subtype 
specific blocker ω-conotoxin MVIIA did not block P/Q-type calcium channels but 
potently inhibited currents from the α1B transfected cell line, which compares well to 
previous findings on human N-type calcium channels (Kaneko et al., 2002). Taken 
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together, the currents generated by depolarization steps in our cell lines with 
inducible α1A and α1B expression are characteristic of P/Q-type and N-type calcium 
channels, respectively. We therefore considered these cell lines as suitable for 
analysis of potential effects of oligomeric Aβ on presynaptic calcium channels.  
After validation of proper channel expression, the effect of Aβ oligomers on 
presynaptic calcium channels was investigated. It was found that the current 
amplitude was increased at moderate depolarizations for both the P/Q-type and 
N-type calcium channels. This was attributed to a shift of the voltage at half-activation 
Vh to more hyperpolarized values. It needs to be noticed that in this study no 
evidence was collected that a similar mechanism is existent in patients with 
Alzheimer’s disease. However, this effect may be pathologically relevant as 
exemplified by P/Q-type calcium channel mutation-induced shifts in Vh which lower 
the threshold for cortical spreading depression, leading to migraine (Ayata et al., 
2000; Tottene et al., 2002). Here, the oligomeric Aβ-induced increase in P/Q-type 
calcium channel current amplitude (at depolarizations to -10 mV) was not modulated 
if part of the channels were previously inactivated. This suggests that the modulatory 
effect of oligomeric Aβ appeared to be independent of the previous channel state. 
Furthermore, it was found that application of oligomeric Aβ did not change Vinact, the 
voltage inducing half inactivation, for P/Q-type and N-type calcium channels. This 
implies that voltage-dependent inactivation kinetics are unaffected by application of 
oligomeric Aβ. Taken together, Aβ oligomers may specifically facilitate channel 
activation without altering other state transition kinetics, which would result in a tonic 
overactivation of the presynaptic calcium channels. 
As a result of this tonic modulation, oligomeric Aß will lead to faster activation of 
presynaptic calcium channels upon arrival of an action potential independent of 
previous synaptic activity. An overactivation of those channels by oligomeric Aβ may 
result in increased calcium levels and some form of synaptic “fatigue” without 
structural damage like e.g., loss of releasable vesicles (Kelly and Ferreira, 2007). 
Prolonged exposure to Aβ oligomers may also lead to retraction of spines and 
synaptic degradation (Shankar et al., 2007). Harkany et al. (2000) further reported 
that Aβ triggered extracellular accumulation of excitatory amino acids in vivo with 
subsequent neuronal loss, which may be a common final mechanism for neurological 
disorders (Lipton and Rosenberg, 1994). Recent in vitro studies by Nimmrich et al. 
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(2010) show that inhibition of calpain, a group of proteases which promote cell death, 
prevents NMDA-mediated excitotoxic cell death and restores oligomeric Aβ-induced 
functional deficits in synaptic transmission. The present data are compatible with 
these findings and suggest a possible molecular mechanism of Aβ-induced pathology 
in AD via overactivation of presynaptic calcium channels. 
 
Compared to this PhD study, Nimmrich et al. (2008a) observed different functional 
effects of synthetic oligomeric Aβ, namely a reduction in P/Q-type, but no effects on 
N-type calcium channel currents in cultured hippocampal neurons. In both studies the 
same oligomeric Aβ preparation and a similar methodology was used. As of today, 
there is no conclusive explanation concerning this discrepancy of data, but as noted 
in the introduction (see section 1.1.3.3), bidirectional effects have also been 
previously observed with other ion channel modulators (Koch et al., 2004). A 
bidirectional modulation of neuronal physiology has also been shown for Aβ 
oligomers. It has been shown that natural Aβ oligomers can both increase and 
decrease the frequency of miniature excitatory postsynaptic currents, which could be 
brought about by a reversal of ion channel regulation (Shankar et al., 2007; Abramov 
et al., 2009). Similarly, synthetic Aβ preparations can both increase and decrease 
LTP (Puzzo et al., 2008).  
Possible reasons for such effects may include concentration dependence, state-
dependence, or minor changes in the channel conformation. In our study we 
investigated concentrations ranging three fold in the order of magnitude but have not 
observed any hint for a possible concentration dependent effect on P/Q-type calcium 
channels. In addition, in the present study, the modulation of P/Q-type calcium 
channels by Aβ globulomer appeared to be tonic and therefore independent of 
channel state, which does not support the idea of a bidirectional modulation due to 
different states of the channel. Alternatively, oligomeric Aβ may have differential 
effects on native and recombinant channels. However, Rovira et al. (2002) reported 
that acute application of full length Aβ to acute hippocampal slices also increases 
P/Q-type and N-type calcium channel currents. Although this study used a poorly 
defined oligomeric Aβ preparation, this suggests that the bidirectional modulation of 
P/Q-type calcium channels between the studies is not solely caused by principal 
differences between native and recombinant channel expression. However, Mezler et 
al. (2012a) have shown that the effect of oligomeric Aβ on P/Q-type calcium channel 
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currents, expressed in Xenopus oocytes, is mediated by the auxiliary channel 
subunits. In the absence of these, only an increase in current amplitude, but no shift 
in channel activation was observed. Introducing the same auxiliary subunits, as used 
here, also led to a hyperpolarizing shift in channel activation, similarly as observed in 
this PhD study. This suggests that minor changes in the calcium channel complex, 
like a different pore forming splice variant or a different subunit composition, may 
modulate the effect of oligomeric Aβ. As P/Q-type calcium channels exist in a number 
of genetic variations (Soong et al., 2002; Tsunemi et al., 2002), the splice variant 
used in our recombinant systems may not need to be identical to the one(s) in 
hippocampal neurons. It remains to be shown whether this could actually lead to both 
a facilitation and depression of the calcium channel currents by Aβ oligomers and 
whether bidirectional modulatory effects, induced by a mixture of channel complexes 
expressed in a single cell, might potentially cancel each other out. A possible 
approach to address this would be to determine the splice variants and channel 
subunits of P/Q-type and N-type calcium channels (predominantly) expressed in the 
cultured hippocampal neurons. Subsequent comparison of the effect of oligomeric Aβ 
on these different calcium channel complexes within one study may test this 
hypothesis. 
The relevance of our findings of presynaptic calcium channels as a molecular target 
for Aβ oligomers is supported by the fact that oligomers are localized to presynaptic 
terminals in AD patients (Kokubo et al., 2005b; Noguchi et al., 2009). 
Immunocytochemical studies indicated that similar Aβ oligomer forms exist in AD 
brains. When antibodies were generated against a similar synthetic Aβ oligomer 
form, known as amyloid-derived diffusible ligands, oligomers were detected in 70-fold 
higher concentrations in Alzheimer’s disease than in control brains (Gong et al., 
2003). Also the Aβ1-42 globulomer epitope was detected in brain of AD patients 
(Barghorn et al., 2005). On a functional level, changes in calcium-dependent 
enzymes – which may be activated after excessive calcium entry – were reported in 
Aβ-overexpressing transgenic animals (Kelly et al., 2005) as well as in patients 
(Green et al., 2007). On a systemic level an increase of presynaptic calcium influx 
would result in enhanced neuronal excitability. Indeed, Palop et al. (2007) reported 
elevated neuronal activity and resulting seizure activity in transgenic mice with 
elevated Aβ levels. In line with this, increased seizure susceptibility was also 
detected in sporadic AD (Amatniek et al., 2006) and familiar AD patients (Cabrejo et 
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al., 2006). It has been recently shown in a mouse model of Alzheimer’s disease that 
prevention of seizure activity by levetiracetam reverses learning and memory deficits 
(Sanchez et al., 2012). Prolonged exposure to toxic Aβ inducing such functional 
effects may ultimately lead to the observed decrease in synaptic spine densities 
(Lacor et al., 2007; Shankar et al., 2007) and overall excitatory transmission 
(Hermann et al., 2009), which coincide with learning and memory impairments (Ashe, 
2001).  
 
4.2 Development of State-Dependent P/Q-type Calcium Channel 
Blockers  
The data presented in the previous section does not clarify whether blocking 
presynaptic calcium channels may indeed slow down the progression of synaptic 
degeneration in AD patients. Yet, from a drug development perspective it may 
suggest an exciting avenue for novel therapeutics that deserves further testing, e.g., 
in transgenic animal models. Unfortunately, all available selective presynaptic 
calcium channel blockers are of natural origin, i.e. toxins of marine snails or other 
invertebrates. The peptidic nature of these toxins limits drug development efforts, 
partly because of their limited bioavailability and CNS penetration. Thus, the 
necessity for improved pharmacokinetics requires the development of LMW ion 
channel blockers that are readily absorbed and reach sufficient brain levels for 
achieving the desired effect. Furthermore, under physiological membrane potentials 
most peptide toxins like ω-agatoxin IVA (McDonough et al., 1997) and ω-conotoxin 
MVIIA (Feng et al., 2003) do not preferentially bind to inactivated channels and 
equally or even preferentially bind to closed channels. However, it is now state-of-the 
art in ion channel drug discovery to develop state-dependent molecules (see 
introduction; section 1.3.3), which preferentially target inactivated channel states. 
These compounds are hypothesized to block tonically overactive sites without 
altering normal levels of synaptic activity (Winquist et al., 2005).  
Besides a possible relevance for the treatment of AD, P/Q-type calcium channels 
have been implicated in a number of neurological diseases including migraine and 
epilepsy. Moreover, some clinically used calcium channel blockers modulate HVA 
calcium channels, including the P/Q-type calcium channel (Uchitel et al., 2010), 
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indicating that modulation of this channel is tolerated in humans. For example, 
gabapentin inhibits channel activity by interacting with the α2δ1 and α2δ2 subunit 
(Catterall et al., 2005). Gapapentin might be effective for migraine prevention as 
suggested by an in vitro (Hoffmann et al., 2010) as well as a clinical phase III study 
(Mathew et al., 2001). Although, to my knowledge, there is no study on pro-cognitive 
effects in AD patients, gabapentin may increase cognition in non-demented elderly 
people (Martin et al., 2001). Thus, development of selective P/Q-type calcium 
channel blockers may find therapeutic application.  
It appears that the development of selective calcium channels blockers remains a 
challenge (reviewed by Yamamoto and Takahara, 2009; Nimmrich and Gross, 2012) 
due to the sparse information on structure-activity relationships of blockers and the 
close homology among the HVA calcium channels. Therefore, development of 
selective compounds may benefit from sophisticated screening (including high 
throughput electrophysiological methods) as well as counterscreening. Despite these 
difficulties, due to recent advances in assay development and automated 
electrophysiological techniques the development of selective calcium channel 
blockers may be more readily achieved as functional data can now be obtained at a 
higher throughput supporting investigation of the structure-activity relationship for 
LMW channel blockers.  
The following sections will discuss the generation and results of our 
electrophysiological secondary screen (following a FLIPR-based primary screen) for 
the identification of novel P/Q-type calcium channel inhibitors. Moreover, it is 
discussed that effective development of an electrophysiological secondary screening 
assay benefits from theoretical considerations of the targeted pathophysiology as 
well as from detailed analysis of inactivation kinetics. It is subsequently described 
that recombinant channel inactivation may be reversible or irreversible, depending on 
the applied depolarization protocol. In addition, despite identical channel activation, 
P/Q-type calcium channel inactivation varies between manual and automated patch 
clamp, so that a screening protocol for inactivated channels needs to be adjusted 
between systems. Based on these results a robust inactivation protocol suitable for 
screening was established, which allowed the detection of both state-independent 
and state-dependent novel P/Q-type calcium channel blockers, as validated by 
manual electrophysiology. This electrophysiological screen was implemented into the 
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hit-to-lead cycle of a drug development plan. The final part of this section discusses 
the effect of these novel LMW compounds on preventing Aβ oligomer-induced 
synaptic deficits. 
 
4.2.1 Appropriate Screening Protocol Selection Depends on Disease- 
and Channel-Specific Properties 
In recent years a number of different protocols have been suggested for the detection 
of state-dependent ion channel blockers (Dai et al., 2008; Belardetti et al., 2009; 
Finley et al., 2010). Ideally, the appropriate protocol should be designed to reflect the 
pathophysiology of the disease of interest as well as the physiological function and 
the inactivation kinetics of the therapeutic target.  
Pain is hypothesized to be mediated by excessive firing of dorsal root ganglion 
neurons (Nordin et al., 1984). For development of pain therapeutics it may therefore 
be beneficial that the respective screening protocol reflects the repetitive activity of 
neurons by implementation of a use-dependent protocol (Winquist et al., 2005). 
Indeed, previous and current drug discovery efforts for pain therapeutics have 
included high-frequency stimulation protocols, inducing rapid changes in channel 
states where the on- and off-kinetics of compounds can have a greater influence 
(Finley et al., 2010; Swensen et al., 2012). In contrast, several P/Q-type calcium 
channel-related diseases exhibit a pathophysiology that involves a more sustained 
depolarization of neurons. For example, the underlying mechanism of some familiar 
migraines is a gain-of-function of the P/Q-channel, leading to cortical spreading 
depression (Tottene et al., 2009). This phenomenon is marked by a tonic 
depolarization of neurons that propagates through the cortex. Furthermore, we 
suggest here that AD is marked by presynaptic accumulation of soluble Aβ oligomers 
that might also tonically enhance P/Q-type calcium currents, potentially leading to 
increased neurotransmitter release and excitotoxic cell death discussed in previous 
publications (Lipton and Rosenberg, 1994; Harkany et al., 2000; Nimmrich et al., 
2010). For the development of P/Q-type calcium channel blockers we therefore 
decided to use a sustained prepulse which may be more relevant to the 
pathophysiology of Aß-mediated effects than rapid changes in membrane potential 
as e.g., during seizure activity.  
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Moreover, the P/Q-type calcium channel is expressed preferably in the CNS, which is 
composed of multiple types of neurons. Some of these, like fast spiking interneurons, 
exhibit high-frequency firing. Their signaling might be silenced by use-dependent 
P/Q-type calcium channel block, leading to disinhibition at the network level. 
Similarly, synaptic plasticity in pyramidal neurons may involve spiking coupled to 
oscillations like theta rhythms (O'Keefe and Recce, 1993; Buzsáki, 2002). One may 
speculate that an interruption of such a process can disturb the delicate process of 
memory formation in the brain. To potentially avoid such adverse effects, we 
confirmed that our prepulse protocol did not induce any use-dependent accumulation 
of inactivation. It needs to be noted that these analogies are largely hypothetical, 
especially as the recombinant test system is not identical to native neuronal cells 
which express a variety of splicing variants and subunit compositions (Soong et al., 
2002; Liao et al., 2009). 
In any case, precise knowledge of the biophysical inactivation properties of the 
channel is necessary for the design of an appropriate prepulse paradigm. State-
dependent compounds can be detected with a variety of protocols since inactivation 
can be induced either by short prepulses or by sustained depolarizations, as applied 
in Dai et al. (2008). In order to obtain a sensitive, robust screening assay, possibly 
resembling a pathological AD-like channel state, we examined whether a sustained 
inactivation protocol was best applicable for identification of novel P/Q-type calcium 
channel blockers. Thus, we studied the properties of voltage-dependent inactivation 
of the recombinant P/Q-type calcium channel in detail using manual 
electrophysiology.  
Steady-state inactivation of the recombinant P/Q-type calcium channel was not 
achieved under any prepulse condition (up to 5 min). With increasing prepulse 
lengths channel inactivation progressively shifted to more hyperpolarized values. 
However, the decay in current amplitude could only be fitted with a two-exponential 
relationship suggesting the existence of more than one molecular mechanism of 
inactivation. It may be that additional slow inactivated states of the channels become 
effective with longer prepulse durations. Slow inactivation kinetics of recombinant 
calcium channels have also been observed in previous studies. Bezprozvanny et al. 
(1995) reported slow inactivation of recombinant N-type and Q-type calcium 
channels, especially in the presence of syntaxin, a membrane protein triggering 
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vesicle fusion. Here, probably in the absence of such intracellular modulators, we 
also observed that the current amplitude keeps decaying even for long prepulses 
hinting at a very slow transition rate. In line with our findings, several biophysical 
studies on voltage-gated calcium channels reported the presence of several 
inactivated states including fast and slow transition rates (Patil et al., 1998; Degtiar et 
al., 2000). Which of these are most relevant for drug discovery has not been 
elucidated yet, but this may depend on the pathology of interest (see above).  
Furthermore, we found that inactivation induced by depolarizations of several 
minutes was no longer reversible. This might be explained by extremely slowly 
reversing inactivated states or, alternatively, by inactivation-unrelated effects, e.g., 
channel desensitization, phosphorylation, or internalization. Vortherms et al. (2011) 
described an automated patch clamp assay for the N-type calcium channel using 
prolonged depolarizations to induce inactivation. Attempts were made to reproduce 
this protocol for our P/Q-type cell line but currents were less stable over time when 
prepulse duration significantly exceeded 3 s. Although prolonged depolarizations 
may be present in AD, a favorable screening protocol for state-dependent P/Q-type 
calcium channel blockers should also be designed to deliver reproducible, robust 
results at an acceptable throughput. Therefore, a protocol was established using 3 s 
prepulses inducing approximately 50% inactivation represented the best balance 
between strong, reversible inactivation and non-saturating slow inactivation or run 
down. Although this inactivation protocol probably increases the potency of state-
dependent compounds, state-independent blockers can also be detected. In fact, 
using this protocol for automated patch clamp and subsequent manual patch clamp 
analysis, both state-dependent and state-independent blockers were detected (see 
results section 3.3.3 and 3.3.4).  
It should be noted that assays using short to moderate (up to several seconds long) 
depolarization prepulses may underestimate compound potency. This is because 
channel inhibition would either need to occur within the allotted prepulse time or be 
maintained sufficiently between test pulses to allow for accumulation of block. The 
protocol used here might especially underestimate the potency of molecules with 
very slow binding kinetics to the inactivated state. Thus, protocols utilizing longer 
depolarizations could be more sensitive to slow-binding state-dependent molecules 
and potentially detect more, and for some pathological states (e.g., migraine) also 
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more relevant channel modulators. However, prepulses over several minutes or 
constant depolarizations might be less favorable for state-dependent screening of 
P/Q-type calcium channel blockers. As observed here, this may induce effects 
precluding the reversal of inactivation (e.g., run-down, channel internalization), and 
may thus be unspecific.  
To conclude, multiple aspects should be considered when designing 
electrophysiological assays for identification and validation of calcium channel 
blockers. The electrophysiological protocol should be chosen adequately for the 
disease area of interest as well as take into account the inactivation kinetics of the 
recombinant channel.  
 
4.2.2 Compound Screening Reveals Novel Channel Blockers 
For initial detection of novel channel blockers, the P/Q-type calcium channel cell line 
was applied to a FLIPR-based high-throughput screen as published in Mezler et al. 
(2012b). For this method cells are loaded with a calcium sensitive fluorescent dye, 
which can be stimulated with an argon laser. Thus, the emitted fluorescent signal 
detected by the system is proportional to the intracellular calcium concentration. The 
signal could be transiently increased upon addition of KCl to the media surrounding 
the tetracycline-induced P/Q-type calcium channel transfected cells. A subset of 
potential channel blockers, identified by the high throughput screen, was 
subsequently validated by secondary screening using automated patch clamp 
recordings. 
Validation of the FLIPR calcium assay was supported in this PhD study by 
perforated whole-cell analysis in current-clamp mode. Depolarized resting 
membrane potentials (approximately -30 mV) were observed, which corresponds to 
published values for HEK293 cells (Thomas and Smart, 2005). This implies that 
during FLIPR-based compound screening a large fraction of channels is inactivated 
as demonstrated by the electrophysiologically determined inactivation curves. This 
may facilitate the detection of state-dependent inhibitors. However, these results are 
only accurate for the specific solution applied to the patch pipette (here: 150 mM KCl 
and 10 mM HEPES). In order to obtain a more exact estimation of the resting 
potential, intracellular recordings applying sharp electrodes are necessary which do 
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not (or at most hardly) alter ionic concentrations of the cytosol. The current-clamp 
experiments further revealed that an extracellular increase in KCl concentration to 
60 mM (as applied in the FLIPR calcium assay) sufficiently depolarizes the cells to 
induce P/Q-type calcium channel opening. Taken together, this suggests that the 
resting membrane potential seemed to be depolarized enough to induce channel 
inactivation during compound incubation in the FLIPR assay. However, the 
membrane potential was still sufficiently hyperpolarized that upon depolarization 
enough channels were available for opening, as observed by a robust increase in 
intracellular calcium concentration during FLIPR measurements. As a consequence, 
additional methods for adjusting the membrane potential, like pharmacological 
modulation or co-transfection with an inward rectifier, were not necessary (Dai et al., 
2008). Indeed, in that study assessment of inactivated state block for HVA calcium 
channels was carried out at resting membrane potentials which were similar to our 
values. It should, however, be noted that other calcium channel assays might require 
adjusted methods, such as the use of gramicidin for better control of the membrane 
potential, to produce adequately robust calcium signals for analysis (Belardetti et al., 
2009).  
In turn, a chemically diverse subset of Abbott’s compound library was screened at 
AbbVie and a large number of hits identified (about 2% of the screening set, 
corresponding to 3,262 validated hits of 150,000 compounds - with an IC50 between 
8 nM and 10 µM), which is comparable to analogous ion channel programs. For 
instance, 115,320 compounds were screened in a N-type calcium channel high 
throughput screen, resulting in 3,600 confirmed hits with >60% inhibition at 5 µM 
(Lubin et al., 2006). 
Subsequently, in order to exclude unspecific effects on intracellular calcium levels 
(possibly detected by the FLIPR-based assay) and to show functional activity on the 
P/Q-type calcium channel, several confirmed hits were validated 
electrophysiologically in this PhD study. In order to obtain higher throughput 
automated planar patch clamp recordings from a 4-channel Patchliner system were 
established and compared to manual patch clamp data.  
Here, this Patchliner system increased the throughput by roughly 3- to 5-fold 
compared to manual patch clamp. This is because usually two to three automated 
experiments could be successfully run in parallel. Definition of a successful 
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experiment included cell capture at the hole of the planar chip and establishment of a 
whole-cell configuration (Rseal ≥ 200 MΩ; Cs > 2 pF; Rs ≤ 20 MΩ). The additional 
increase in throughput was obtained by shortened preparation times between 
experiments, as noted in the introduction (section 1.3.2). Characterization of 
recombinant P/Q-type calcium channel activation and pharmacological sensitivity to 
ω-agatoxin IVA yielded identical results between the manual and automated 
Patchliner set up. Our values also compared well to previous reports of recombinant 
(Hans et al., 1999) and native channels (Mintz et al., 1992). This indicates that our 
cell line in combination with automated patch clamp is well suited for pharmacological 
analysis.  
However, for the automated system a hyperpolarizing shift in channel inactivation 
was observed. This was dependent on the protease treatment by trypsin or Accutase 
prior to automated experiments, as this shift could be reproduced in manual patch 
clamp recordings if cells were freshly dissociated prior to the measurements. In the 
process of cell dissociation, channel function may be altered through partial digestion 
of channel proteins or even simply by the loss of cell adhesion.  
Since protease treatment with either accutase or trypsin might be causal to the 
observed shift in voltage-dependence, alternative cell dissociation methods could be 
evaluated. Ideally, such methods would allow achieving an identical voltage-
dependence of inactivation compared to manual patch clamp (lacking prior protease 
cell treatment). Combination formulations, like the proteolytic, collagenolytic, and 
DNAse enzyme combination FACSmax, Detachin, or similar preparations could be 
used. Further, it may be worth testing whether preparation of cell suspensions 
required for the automated setup might be done by ethylenediaminetetraacetic 
(EDTA) treatment alone or even by simple mechanical dislocation of the cells. As the 
cell line used here is HEK293, also these more gentle methods could be successful. 
If the shift in the inactivation curve is due to the suspension of the cells and their loss 
of cellular adhesion, then alternative enzymatic or mechanic treatment would not 
change the outcome of the electrophysiological measurements. Importantly however, 
since the difference in inactivation kinetics can be accounted for by adjusting the 
screening protocol, further exploration of these methods was not mandatory for this 
study. In our case this was obtained by shifting the holding and prepulse potential by 
-10 mV to more hyperpolarized values in the automated system. Taken together, it 
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can be concluded that automated patch clamp is a valuable option for higher 
throughput compound analysis, given that shifts in inactivation kinetics are corrected 
between the manual and automated patch clamp system. 
The automated electrophysiological secondary screen was performed at a single 
concentration (applying 3 s prepulses) to assess the functional activity of a larger 
number of structures in order to adequately support the throughput needed within the 
hit-to-lead drug discovery phase. This phase attempts to identify - from the numerous 
compounds after screening - chemical scaffolds, which may be suitable for further 
optimization by medicinal chemistry. Out of 27 compounds tested in this secondary 
screening assay, 23 compounds confirmed appreciable P/Q-type calcium channel 
inhibition.  
The reason for the lack of P/Q-type calcium channel inhibition of the four compounds 
was not further investigated, but may arise from non channel-related lowering of 
cytosolic calcium levels detected in the FLIPR-based assay. This might be caused by 
compound-dye interactions (Wolff et al., 2003), calcium uptake from intracellular 
organelles, or effects on e.g., calcium transporters (Tang et al., 2001; Terstappen, 
2005). Electrophysiologically validated hits were transferred back to medicinal 
chemistry hit-to-lead program and potential lead structure candidates were examined 
for their level of state-dependence by manual patch clamp analysis and advanced 
into the downstream screening cascade. This secondary analysis further confirmed 
the ability of the FLIPR-based high throughput screen to detect novel P/Q-type 
calcium channel inhibitors.  
The depolarized resting membrane potential of the HEK293 cells could, on the one 
hand, explain why most compounds blocked P/Q-type calcium channels also in the 
secondary screen. This suggests that these compounds (also) block inactivated 
calcium channels, although this was not explicitly tested (for this the channel block 
would also need to be assessed omitting the depolarizing prepulse). On the other 
hand, compounds tended to be more potent in the FLIPR assay as compared to the 
electrophysiological recordings. This could partially be caused by the fact that cells 
were constantly depolarized during the 3 min incubation time in the FLIPR compared 
to a transient 3 s depolarization (at a 12 s interval) during the 2 min incubation in the 
automated patch clamp assay. Therefore, channel inactivation was most likely more 
pronounced and sustained in the FLIPR assay. This could explain the increased 
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potency in the FLIPR assay especially for slow binding and state-dependent 
modulators. 
 
4.2.3 State-Dependent Calcium Channel Block Ameliorates Oligomeric 
Aβ-induced Deficits in Synaptic Transmission 
As noted in the introduction, state-dependent molecules are believed to have a 
beneficial safety profile by leaving physiological resting state activity largely 
unaltered. However, if this is the case only inactivated channels are fully blocked 
whereas channels in other states are blocked only to a lesser extent. Therefore, the 
overall block of channel currents decreases, which might compromise the therapeutic 
efficacy. Therefore, the synaptoprotective potential of the two previously 
characterized mixed P/Q-type and N-type calcium channel blockers was tested. One 
compound hardly distinguishes between resting and inactivated channels; the other 
preferentially blocks inactivated channels at 5-fold lower IC50 compared to the resting 
channels. 
Based on the potencies determined by electrophysiological and FLIPR 
measurements, compounds were applied to hippocampal slice cultures at 
concentrations below or close to the IC50 determined for inactivated P/Q-type calcium 
channels. For the 5-fold state-dependent compound this concentration is expected to 
induce little block at presynaptic P/Q-type and N-type channels at resting state and 
no block at L-type calcium channels (Scott et al., 2012). We were able to show that 
both (state-independent and state-dependent) LMW blockers completely reversed 
Aβ globulomer-induced deficits in synaptic transmission. Indeed, the effect of both 
compounds was comparable to the rather state-independent toxins, which were even 
applied at concentrations (slightly) above their IC50. It can therefore be concluded 
that state-dependence of compounds does not compromise the therapeutic effect in 
this in vitro model of AD. However, it might coincide with a lower side effect profile as 
observed for the sodium channel blocker like lamotrigine (Xie et al., 1995) compared 
to TTX (Zimmer, 2010), for example. 
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4.3 Conclusion and Outlook 
This study revealed that block of presynaptic calcium channels by selective peptides 
protects against oligomeric Aβ-induced functional decline in synaptic transmission in 
organotypic hippocampal slice cultures. This might be brought about by inhibiting 
excessive neurotransmitter release and possibly decreasing synapse loss (Shankar 
et al., 2007). We further report that oligomeric Aβ increases calcium currents from 
recombinant P/Q-type and N-type calcium channels by shifting voltage activation to 
more hyperpolarized values in a state-independent manner. This probably promotes 
facilitated neurotransmitter release and functional synaptic decline, which may 
potentially lead to excitotoxicity. 
Moreover, an automated electrophysiological secondary screen was established to 
identify novel calcium channel blockers, which has not been described previously for 
the P/Q-type calcium channel. Proper functional assay development requires the 
complex analysis of biophysical inactivation properties of the recombinant ion 
channel. The design and optimization of an inactivation protocol for routine 
automated patch clamp recordings is reported by this thesis, based on an intensive 
study of voltage-dependent inactivation of the recombinant P/Q-type calcium 
channel. This protocol is appropriate for the detection and validation of P/Q-type 
calcium channel blockers and was successfully implemented into the hit-to-lead 
phase of an electrophysiological secondary screen of a drug development program 
(Mezler et al., 2012b). One out of two validated calcium channel blockers, which 
were subsequently analyzed by manual patch clamp, was identified as 
state-dependent. The discovery and further optimization of state-dependent P/Q-type 
calcium channel blockers may also lead to the development of new medications for a 
range of neurological disease indications beyond AD, like migraine and epilepsy.  
Finally, both LMW calcium channel blockers were able to reverse oligomeric 
Aβ-induced deficits in synaptic transmission. Thus, state-dependent P/Q-type and 
N-type calcium channel block may antagonize functional synaptic deficits in in vitro 
models of AD. It is unclear whether this in vitro data can be extrapolated to patients 
suffering from AD. It now needs to be shown whether such calcium channel block 
may alleviate synaptic loss and neurodegeneration in animal models of AD. 
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